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Operational Definition of Terms 
 
Activity counts: Units of measurement of physical activity produced by the Actical 
accelerometer. Counts provide a quantitative measure of activity intensity and allow 
for classification of activity levels as well as monitoring of changes in activity levels. 
Activity counts are generated from the acceleration signals detected by the device, 
which are then amplified, filtered, digitized, and full wave rectified in order to be 
converted into activity counts (1). 
Black: Throughout this dissertation the term ‘Black’ has been capitalised as 
suggested by Bhopal in 2004 (2). The most widely used human racial1 categories are 
based on visible traits (especially skin colour, facial features and hair texture), genes, 
and self-identification (3). 
Light, moderate and vigorous activities: These are all activities that increase energy 
expenditure above resting levels and are classified into specific thresholds as 
calculated by the Actical software using the activity counts generated per minute 
epoch. Thus; light activity is defined as activity that generates counts between 100 
and 1535 (i.e.: 1.5-2.9 metabolic equivalent units (METs), where one MET is the 
energy cost of resting quietly and is defined in terms of an oxygen uptake of 
3.5mL.kg-1.min-1 (4)); moderate activity generates counts between 1535 and 3962 (3-6 
METs), and vigorous activity generates counts above 3962 (>6 METs). 
Physical activity: This refers to habitual activities that raise energy expenditure 
levels above that of resting, and can include leisure activities, ambulatory activity or 
conscious exercising. However, in the case of the patients with RA used in this study, 
it refers mostly to ambulatory, habitual activities. 
                                                        
1 The word ‘race’ does not refer to any biological attributes but rather to the compulsory classification 
of people into the Population Registration Act. Although the act has been repealed, these categories are 
still powerful and commonly used by South African government and statistical services. 
 vi 
Sedentary activity: This is any activity falling into the sedentary threshold as 
calculated by the Actical software using the activity counts generated per minute, and 
generally comprises of activities that do not increases energy expenditure above that 
of resting (such as sitting or lying down). Typically, this includes activities in which 
activity counts generated are less than or equal to 100 (i.e.: 1-1.5 METs).
 vii 
 
Abbreviations  
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Preface 
 
Don’t wish it were easier, wish you were better. Don’t wish for fewer problems, wish 
for more skills. Don’t wish for less challenges, wish for more wisdom.  
 
- Earl Shoaf 
When I started this journey I had very little understanding of what a diagnosis of 
rheumatoid arthritis actually meant. I was aware of the fact that patients with 
rheumatoid arthritis suffer from chronic pain and inflammation, and that they are 
therefore unable to function normally – the classic prelude to most research articles 
discussing rheumatoid arthritis. What I did not understand is what this means for the 
patient in reality. What does ‘chronic pain’ mean? What does the ‘inability to function 
normally’ mean? These terms are used so often that they almost become meaningless. 
It is difficult to understand or to explain what these terms mean for the patients who 
suffer them, but through my years of working with patients with rheumatoid arthritis 
on a very personal and involved basis, I started to get some idea. To not be able to get 
out of bed in the morning, to be unable to take a bath without assistance, to be unable 
to pick up your crying grandchild – these unthinkable situations are merely daily 
truths in the lives of patients suffering with rheumatoid arthritis. Without dramatising 
the stark reality of these lifestyles, I would just like to draw attention to the strength 
that these patients have. The ladies I worked with throughout my research greeted me 
everyday with a smile, through the cold winter months when their pain was 
“unbearable”, and truly taught me a lesson in appreciation of being healthy. I am so 
grateful for this experience. It is so easy, whilst pursuing a degree such as a PhD, to 
get caught up in the academia and necessity to publish your work and analyse your 
data, that one can often forget why the research is being conducted in the first place. I 
hope that what I have presented in the next few pages can be of some benefit to 
patients living with rheumatoid arthritis. It is so important that we as researchers, 
clinicians, specialists, or allied medical professionals, do whatever we can to 
enlighten each other with the knowledge we pursue and skills we develop. In doing 
so, we can work together to provide the best care to our patients and hopefully make 
their lives a little bit easier.  
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Abstract 
 
 
Rheumatoid arthritis (RA) is an autoimmune condition with a predilection for 
peripheral synovial joints. It affects 0.5 to 5% of the adult population worldwide. The 
chronic inflammation of RA results in destruction of the synovial joints, decreased 
mobility and chronic pain. Patients who have RA experience a poorer health related 
quality of life (HRQoL) in comparison to the general population. They are less 
habitually physically active than a healthy population, to the point of not meeting the 
required guidelines of physical activity to maintain a healthy wellbeing. Moreover, 
patients with RA are prone to developing osteoporosis as a consequence of systemic 
inflammation and a sedentary lifestyle.  
 
The aims of the research undertaken for this thesis were to: 1) objectively quantify 
habitual physical activity levels in RA patients in comparison to a healthy population, 
2) ascertain any associations between habitual activity levels and disease activity in 
patients with RA, 3) determine the changes in habitual physical activity levels in 
patients newly diagnosed with RA in response to commencement of DMARD 
therapy, 4) determine the predictive factors causing the changes seen in disease 
activity in response to commencement of DMARD therapy in patients with RA, 5) 
determine the associations between habitual physical activity levels and bone health 
in patients with RA, and 6) determine the effects of a WBV therapy intervention on 
functional ability, and bone health, as well as on disease activity and habitual physical 
activity levels in patients with RA. These aims were addressed by conducting three 
studies. 
 
 xvi 
In the first study habitual physical activity levels was assessed over a two week period 
in a cohort of 50 female RA patients in comparison to 22 healthy matched control 
participants, using an Actical accelerometer. Patients also completed various disease 
activity questionnaires, namely the Health assessment questionnaire (HAQ), and the 
Short Form-36 questionnaire (SF-36), and were assessed for rheumatoid disease 
activity by a physician using the simplified disease activity index (SDAI). All data are 
presented as mean (SD). The RA patients had a disease duration of 99(77) months, 
with moderate functional disability (HAQ score of 1.3(0.9)) and moderate disease 
activity (SDAI score of 18.38(11.76)). Patients had a poor HRQoL as assessed by the 
SF-36 with a score of 44(18). Accelerometry showed that the RA group spent 
significantly more time in sedentary behaviours than did the control group, spending 
71(11)% of their awake day in sedentary activities as opposed to 62(11)% in the 
control group (p<0.01). The RA group had significantly lower mean activity counts in 
the morning (p<0.01) and the late afternoon (p<0.01) than the control group. Within 
the RA group, patients who were more physically active scored significantly better in 
many components of the SF-36, indicating an association between better HRQoL and 
increased habitual physical activity levels. The HAQ scores, corrected for age and 
disease duration, correlated negatively with physical activity levels in the RA group 
(r2=0.12, p=0.03). 
 
In the second study habitual physical activity levels were observed longitudinally in 
18 RA patients before and three months after commencing DMARD therapy. The 
accelerometer was worn for two consecutive weeks before and after starting DMARD 
therapy. Patients also completed the same disease activity assessments as the patients 
in Study 1. The RA group was compared to a matched control group of 18 healthy 
participants. After three months of DMARD therapy, RA patients improved 
 xvii 
significantly on all measured indices of disease activity and accelerometry metrics. 
The activity counts in sedentary activities declined from  a mean (SD) of 995(283) to 
837(253) counts, p<0.01, whilst light activities increased from a mean (SD) of 
3461(1453) to 4451(92057) counts, p=0.04, indicating increased habitual physical 
activity levels after commencing DMARD therapy. Moreover, significant differences 
in mean activity counts observed between the control and RA groups in the morning 
(p=0.05) and afternoon (p=0.02) at baseline, were attenuated after three months of 
drug therapy, to the point where habitual physical activity levels were equivalent 
between the groups throughout the day. Multiple regression analysis showed that 
change in early morning stiffness was most strongly predicted by change in sedentary 
and moderate activity (β=0.69, p=0.04 and β=-0.93, p=0.02 respectively), while a fall 
in CRP levels was most strongly associated with change in moderate activity (β=-
0.92, p=0.03). Spearman’s correlation tests showed further positive associations 
between improvements in physical activity and improvements in disease activity. 
 
In the third study, the effects of 12 weeks of whole body vibration (WBV) therapy in 
stable and established RA was studied by randomising patients to either a WBV 
therapy group  (n=16) or a standard care control group (CON, n=15). All data are 
presented as mean (SD) or mean (SEM). Patients were fitted with an accelerometer 
for a one week period, completed the same questionnaires as done in the previous two 
studies, and had dual X-Ray absorptiometry (DXA) scans to measure BMD and body 
composition at baseline, end of therapy and 12 weeks post-therapy.  
 
Patients in the WBV and CON groups were well matched at baseline for all variables. 
During baseline analysis, all patients were divided into two subgroups – those with 
normal bone mass (n=21), and those with low bone mass (n=8). Compared to 
 xviii 
subgroup of patients with low bone mass (n=8), the subgroup of patients with normal 
bone mass (n=21) reported less functional disability (HAQ score (0.96(0.71) vs. 
1.57(0.74), p=0.05) and had a trend towards lower RA disease activity as assessed by 
CDAI (7.7(6.1) vs. 13.8(10.8), p=0.07). The normal bone mass subgroup also had 
higher overall habitual physical activity (p<0.01). They spent on average two hours 
less per day in sedentary activity (65(4) vs. 73(2) % time per day, p<0.01), over 70 
minutes more time in light activity (23(1) vs. 18(2) % time per day, p<0.01), and over 
50 minutes more in moderate activity per day (12(3) vs. 8(2) % time per day, p<0.01), 
than the low bone mass subgroup. The normal bone mass subgroup broke up their 
sedentary time more frequently per day than low bone mass subgroup (72(21) vs. 
53(18) times per day, p=0.03). Patients who met the minimum recommended physical 
activity guidelines for a rheumatic population had significantly better Z scores at the 
hip than those who failed to meet the minimum guidelines (p=0.03).  
 
Thereafter, at the end of the 12 week intervention, the patients who underwent WBV 
therapy experienced significant improvements in HAQ scores (1.22(0.19) to 
0.92(0.19), p=0.02), fatigue levels assessed by a self-report Lickert scale (4.4(0.63) to 
1.1(0.65), p<0.01), and whole body BMD (1.09(0.03) to 1.10 (0.03) g.cm-2, p=0.05).  
By contrast, in the CON group there was no significant change in HAQ scores or 
fatigue levels, and whole body BMD declined significantly (1.07(0.03) to 1.05(0.03) 
g.cm-2, p<0.01), while a significant increase was seen in the WBV group (1.09(0.03) 
to 1.10(0.03) g.cm-2). Rheumatoid disease activity remained stable in both groups 
throughout the intervention period. Ten minute bouts of light and moderate physical 
activity were significantly reduced in the CON group over the intervention period 
(2.8(0.61) to 1.8(0,64) bouts/day, p=0.01), but were preserved in the WBV group 
(3.1(0.59) to 3.0(0.61) bouts/day, p=0.70). Twelve weeks post therapy, fat mass was 
 xix 
decreased (37(3) to 35(3) kg) in the WBV but increased in the CON group (31(3) to 
35(3) kg, p<0.01), while lean mass decreased in the CON group (42(2) to 40(2) kg), 
and was increased in the WBV group (46(2) to 45(2) kg, p<0.01). In summary this 
study showed that intermittent WBV results in sustained improvements in functional 
ability, attenuation of bone mass loss at the hip, and improvement in fatigue levels in 
established RA.  
 
Altogether, these studies demonstrate that RA patients are indeed more sedentary in 
comparison to a healthy, matched control group, and that habitual physical activity 
levels measured by accelerometry correlate with patient-reported functional ability. 
Accelerometry measures were found to be responsive to change in relation to disease 
activity. Besides improving RA disease activity indices, DMARD therapy increased 
habitual physical activity levels and patterns of daily physical activity in RA patients 
started to resemble those of the control group. The research also showed that BMD is 
positively associated with increased habitual physical activity in RA patients and, 
lastly that WBV therapy improved functional ability and fatigue levels, and attenuated 
bone loss at the hip, without significant impact on rheumatoid disease. Hence, 
increased habitual activity needs to be encouraged, and WBV therapy is a feasible, 
safe and simple intervention for improving functional ability, HRQoL, and BMD in 
patients with established RA.  
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Chapter 1: Literature Review 
 
1.1. Introduction: 
 
This chapter will examine rheumatoid arthritis (RA) as a disease, bone health in RA, 
medical treatments for the disease, and traditional outcome measures used in RA. The 
use of accelerometry as an objective measure of physical activity will be reviewed. 
Exercise interventions for the treatment of RA will be explored, including the role of 
whole body vibration (WBV) therapy in chronic musculoskeletal diseases. This 
chapter will conclude with an introduction to the problem that this thesis aimed to 
address. 
1.2. Rheumatoid Arthritis: 
 
Rheumatoid arthritis (RA) is an autoimmune condition with a predilection for 
peripheral synovial joints. The disease affects 0,5 to 5% of the adult population 
worldwide, with the prevalence being at least two times higher in women than in men 
(5). RA is the most common immune-mediated inflammatory arthritis (6-7).   
 
Immunologically, the destruction of joints and swelling resulting from RA is due to 
the synovial inflammation and proliferation, known as pannus, which histologically 
shows infiltration of CD4+ T cells, B cells, and macrophages which organise into 
lymphoid aggregations with germinal centres (6). Local proteolytic enzymes are 
induced that degrade surrounding cartilage and subchondral bone. Pannus produces 
many pro-inflammatory interleukins (IL), such as IL-6, IL-1, IL-15, IL-18, tumour 
necrosis factor alpha (TNF-), and an array of chemokines (6).  
 
The exact aetiology of RA is largely unknown (7), but there is evidence that 
 2 
hereditary factors and environmental factors such as smoking, and certain infectious 
agents predispose to the disease (8). Rheumatoid arthritis is also strongly associated 
with class II human leukocyte antigens, HLA-DR4 and DR1, indicating a genetic 
association (6). However, like all autoimmune conditions, a combination of events 
needs to take place for the disease to develop, namely: having a genetic background, 
the activation of the innate immune system due to an unknown environmental trigger, 
and the adaptive immune responses that ensue. Several genes have been shown to 
play a part in susceptibility to RA, yet twin studies have shown that genes are 
responsible for only 50% of the risk for RA; with the other 50% being attributed to 
environmental factors, as well as stochastic, or chance factors (8). Infectious agents 
such as Epstein-Barr Virus (EBV), mycobacteria and parvoviruses have been known 
to trigger RA in genetically predisposed individuals (9). Eighty percent of patients 
with RA have antibodies directed against EBV, and RA perpetuates the response 
against EBV (10) 
 
The cardinal clinical features of RA are prolonged early morning stiffness of the 
joints, lasting for more than 30 minutes (11), and swelling and tenderness of the small 
joints of the hands and feet (pain in these areas is usually among the first noticeable 
symptoms) (6). The chronic inflammation of RA results in destruction of the synovial 
joints, decreased mobility and chronic pain (12). The presence of constant pain limits 
the ability of patients with RA to function normally, and as a result, physical activity 
levels are lowered. Rheumatoid arthritis is thus characterised by synovial swelling and 
inflammation, autoantibody production, and deformity due to cartilage and bone 
destruction. Systemic inflammation further results in comorbidities affecting the 
heart, lungs, bone, central nervous system, and host immunity to infections and 
cancers (13).  
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Diagnosis of RA is not always easy, and hence classification criteria for RA have 
been developed mainly for research purposes but also as guide to the practicing 
clinician. These classification criteria have undergone a number of revisions. The 
1987 American College of Rheumatology (ACR) criteria being applied in this work 
are shown below in Table 1.1 modified from Braun & Sieper, 2009 (11), yet more 
recent 2010 ACR/European League Against Rheumatism (EULAR) revised criteria 
have been developed in order to increase detection of early disease2.   
 
Table 1.1 The 1987 ACR classification criteria for rheumatoid arthritis 
 
1 Morning stiffness in and around joints lasting at least 1 hour before maximal 
improvement 
2 Soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician 
3 Swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or 
wrist joints 
4 Symmetric swelling (arthritis) 
5 Rheumatoid nodules 
6 The presence of rheumatoid factor 
7 Radiographic erosions and/or periarticular osteopenia in hand and/or wrist 
joints 
 Criteria 1 to 4 must have been present for at least 6 weeks. RA is defined 
by the presence of 4 or more criteria, and no further qualifications 
(classic, definite, or probable) or list of exclusions are required.  
 
                                                        
2 The ACR together with EULAR have developed the new 2010 RA classification criteria (176). These 
criteria were developed specifically to facilitate the classification of RA patients with early disease, 
rather than to diagnose established RA disease. These criteria are therefore more sensitive and are 
aimed at preventing patients from reaching a chronic, erosive disease state (as defined by the 1987 
criteria). The 2010 criteria assess level of joint involvement, serology, acute-phase reactants, and 
duration of symptoms.  
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Diagnosis of RA is made on the basis of phenotypic features rather than the 
underlying pathogenic mechanisms causing these features (14).  
 
Laboratory features of RA include inflammatory markers such as elevated C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) in active disease, and 
autoantibodies such as rheumatoid factor (RF) and anti-citrullinated peptide 
antibodies (ACPAs) (9). Rheumatoid factor is an antibody directed at the fragment 
crystallisable (Fc) region of immunoglobulin G (IgG), (typically involved in the 
secondary immune response). It was first discovered by Waaler in 1939, and only 
later further characterized as an antibody by Kunkel in 1957 (15). The discovery and 
classification of RF was the first evidence classifying RA as an autoimmune 
condition. Eighty percent of RA patients are RF positive, and the presence of RF 
normally indicates more severe disease progression (6), yet RF is also seen in other 
inflammatory diseases and sometimes in healthy individuals (9).  The more recent 
discovery of ACPAs, which are thought be more specific than RF, are also found in 
about 80% of cases (16). 
 
Rheumatoid inflammation can result in extra articular manifestations affecting organs 
such as the eyes (sicca syndrome, scleritis), lungs, heart, brain, and skin (vasculitis) 
(8). In addition, a multitude of comorbidities have been associated with RA as a result 
of the chronic inflammatory process inherent to the disease. The increased mortality 
in patients with RA is largely attributed to cardiovascular events. Of these, ischemic 
heart disease is the most common, including heart attacks and sudden cardiac death 
(8). Cardiovascular disease present in patients with RA is often not explained solely 
by the traditional risk factors, but also by the chronic inflammatory process (13). 
Patients with RA are also at increased risk of developing osteoporosis, infections such 
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as tuberculosis, and non-Hodgkins lymphoma (13). Metabolic syndrome, fatigue, and 
depression also frequently occur. Furthermore, the musculoskeletal system is most 
severely affected, as will be explored in subsequent sections.  
 
1.3. Outcome Measures in Rheumatoid Arthritis: 
1.3.1 Disease Activity: 
 
Measuring disease activity is important for several reasons: 1) measuring disease 
activity helps the clinician to adjust medical therapy and ‘treat-to-target’, 2) ongoing 
poorly controlled disease activity is associated not only more with permanent physical 
disability, but also with increased risk of premature death, and 3) ongoing disease 
activity increases the risk of extra articular diseases such as rheumatoid vasculitis 
(17). 
 
There are many individual measures of disease activity in RA, such as the acute phase 
reactants (CRP), pain, and joint swelling; yet no single clinical parameter measures 
the total burden of inflammation in RA. Over the last 20 years, EULAR, along with 
the WHO and the International League Against Rheumatism (ILAR), have therefore 
developed a core set of variables that should be assessed, namely: swollen joint counts 
(SJC) and tender joint counts (TJC), both of which are calculated by palpation of 28 
upper and lower limb joints; patient global self assessment (PGA); physician global 
assessment of patient (MDGA); patient pain assessment (PPA) and the concentration 
of an acute phase reactant (18). Composite scores have been developed to assist with 
consistency of diagnosis and to guide therapy decisions, improve patients 
understanding of their disease, and to attempt to improve outcomes through the use of 
a more consistent evaluation, specifically for use in clinical trials. The original 
composite score used was the 44 Joint Disease Activity Score (DAS-44), followed by 
the 28 Joint Disease Activity Score (DAS-28), and more recently the Simplified 
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Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI), which 
are essentially based on the DAS-28. Three such composite measures have been 
validated for South African populations: the CDAI, the SDAI, and the DAS-28 (19). 
The SDAI and CDAI were used in this research and are calculated as shown below in 
Equation 1 and Equation 2 respectively: 
 
SDAI=TJC+SJC+MDGA+PGA+(CRP/10) 
……………………………………………………Equation 1. 
CDAI=TJC+SJC+MDGA+PGA 
……………………………………………………Equation 2. 
 
These simple numerical calculations allow for a quick and easy assessment of disease 
activity, far simpler than the calculation of the DAS-28. Furthermore, the inclusion of 
the physician global assessment in the CDAI and SDAI makes these scores somewhat 
more objective than the DAS-28 (which only includes the patient global assessment). 
CDAI is even simpler and quicker to calculate due to the lack of an acute phase 
reactant such as CRP, which requires analysis of blood results that take time, and are 
often missing from patient files leading to inconsistency. However, the inclusion of 
CRP in SDAI does confer some benefit in terms of validity as an outcome measure, as 
it has been shown to be the most reliable acute phase reactant, and is responsive to 
change in disease activity (18)). Both CDAI and SDAI are well validated, and have 
been shown to correlate very well with each other, as well as with the DAS-28 (18). 
The calculation of these scores also allows for patients with RA to be categorized 
according to severity of disease activity using the following cut offs: 
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Table 1.2. Cut-offs for rheumatoid disease activity and outcome assessments 
 
This scoring system allows for comparisons to be made between RA patients, as well 
as for the individual RA patient before and after therapy; and the quantifiable score 
makes for an easier understanding of disease activity. Scoring also allows for 
decisions to be made with regards to drug therapy, as well as allowing for a ‘treat to 
target approach’, such as treating to achieve low disease activity or remission (as 
discussed further in Section 1.4.).  
 
Rheumatoid arthritis has a disease progression typical of an autoimmune disease that 
consists of day to day fluctuations in symptoms, as well as flare ups and periods of 
remission. It is important to measure the status of the joints by assessing 
inflammation, structural damage and general physical status (20). Direct palpation of 
the joints is the easiest measure of joint inflammation, yet is unquantifiable. Magnetic 
resonance imaging and ultrasound provide a more quantifiable measure of joint status, 
yet are not always available and are expensive (20). These measures are therefore not 
used routinely in clinical trials or in clinical practice. Composite measures of disease 
activity give a better idea of overall disease status. 
 
HAQ Score  SDAI Score  CDAI Score  SF-36 Score  
Low impairment 
Moderate impairment 
High impairment 
<0.75 
<1.75 
>1.75 
Remission 
Low disease activity 
Moderate disease activity 
High disease activity 
<3.3 
<11 
<26 
>26 
Remission 
Low disease activity 
Moderate disease activity 
High disease activity 
<2.8 
<10 
<22 
>22 
Poor outcome 
Good outcome 
<66 
>66 
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1.3.2 Functional Disability and Health Related Quality of Life: 
 
Patients with RA have long been shown to have a decreased health related quality of 
life (HRQoL) compared to the general population (21). This is largely due to the 
presence of chronic pain and joint deformities. Health related quality of life, defined 
as the physical, emotional and social aspects of life which are affected by a patient’s 
disease or their treatment, is a relevant measure of disease activity according to the 
WHO (22), and studies have shown that “feeling well” is an important patient 
outcome, along with the management of pain, sleep, fatigue, emotional- and physical 
wellbeing (21). Short term outcomes such as pain and fatigue are becoming more 
important to treat, as well as to understand, due to the importance of “feeling well”. 
Fatigue in RA is caused by to the systemic effects of inflammation on the brain and 
disturbed sleep patterns, and is measured as an outcome of RA disease activity (8). 
The ability to positively affect fatigue levels is one of the most prominent benefits of 
current cytokine antagonist drugs (8).  
 
Decreased functionality is another important aspect of RA, and once again, functional 
ability is used to measure treatment effects in RA as a means to assess how patients 
feel and function in normal daily life (8). Pain has been correlated with decreased 
physical activity in other chronic diseases, such as fibromyalgia (23) and osteoarthritis 
(24). Furthermore, habitual participation in vigorous activities has been shown to 
decrease pain sensitivity in healthy females (25). In RA, swollen and tender joints 
force patients into a sedentary lifestyle (22). This decrease in physical activity is 
worsened by the joint and muscle damage occurring during severe disease, which 
results in disability and muscular atrophy (25), further decreasing physical activity 
(Figure 1.1). Some patients with RA lose their ability to work due to their disease, 
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resulting in an economic burden on society, as well as increasing the patient’s 
financial stress, a common problem in developing countries such as South Africa (26).  
 
 Joint inflammation      Joint damage 
 
 
    Physical disability 
Figure 1.1. Relationship between joint inflammation, damage, and disability in RA 
 
 
The concurrent effects of persistent pain and decreased physical activity and 
functional ability lead to disturbances in sleep patterns, which worsens daily 
functioning and further perpetuates pain. Pain is the leading cause of insomnia, yet at 
the same time, sleep can alter pain thresholds (27). The disease process of RA, as well 
as the medication taken for it, disturbs sleep patterns in more than half of RA patients, 
which can lead to increased stiffness, and hence pain the next day (27). Increased pain 
leads to a decreased ability to be active and therefore decreased physical activity (23), 
which in turn contributes to disturbed sleep patterns (27).  
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Figure 1.2. Relationship between factors that affect health related quality of life in rheumatoid arthritis 
on pain and habitual physical activity levels. 
 
In addition, patients living with a chronic pain condition such as RA have been shown 
to have a 13 to 20% prevalence of depression, which is two to three times greater than 
the prevalence in the general population (22). Depression has been associated with 
decreased functionality and physical activity (22). There is a strong association 
between sleep, pain, depression and decreased physical activity and functionality, and 
it is probable that these factors have a bidirectional causal relationship with each other 
and RA disease activity (Figure 1.2), and all of these factors should be considered 
when treating patients with RA.  
 
There has therefore been a shift towards measuring outcomes that are important to 
patients with chronic diseases, and specifically with RA. The Health Assessment 
Questionnaire (HAQ) was developed originally by Jim Fries at Stanford when his 
group popularised the concept of the 5 Ds of RA, i.e.: death, discomfort, disability, 
drug (therapeutic) toxicity, and dollar cost (28). The modified, shortened version of 
this questionnaire, the mHAQ (referred to from here on as the ‘HAQ’) is most 
commonly used and is as sensitive as the original version, and comprises of three out 
of the six ACR outcome measures (29). The questionnaire is self-administered and 
takes approximately five minutes to complete and one minute to score. It assesses fine 
movements of the upper and lower extremities, as well as locomotor movement of 
both the upper and lower limbs. The questionnaire is comprised of 20 items assessed 
in eight domains, namely: rising, dressing, walking, hygiene, eating, reach, grip, and 
usual activities. Patients score each item in terms of difficulty on a scale of 0-3 (0=no 
difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do) and a total score is 
then calculated (the outcome of which is assessed using the cut-offs shown in Table 
1.2). The HAQ is a well validated assessment of functional capacity in patients with 
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RA (29), and accurately reflects joint inflammation and disease activity (19). The 
HAQ has been validated in Black RA populations in South Africa (30), and is 
therefore recommended for the assessment of disability in South Africa (19).  
 
While the HAQ can predict both long- and short-term outcome with regards to disease 
progression of RA (31), it is still important to measure HRQoL as a measure of the 
success of treatments for these patients. The Short Form-36 (SF-36) is a general 
health status questionnaire which describes the impact of disease on patient outcomes, 
and has been well validated for use in patients with RA, correlating well with HAQ 
scores (31). While HAQ is specific to RA disease, SF-36 can compare HRQoL across 
various diseases. The SF-36 consists of questions in eight domains of health, namely: 
physical function, role physical, body pain, general health, vitality, social functioning, 
role emotional, mental health and reported health; all of which are separated into 
either composite physical health or composite mental health scores, and combined to 
give a total SF-36 score from 0-100, where a higher score indicates a better outcome 
(as shown in Table 1.2). The SF-36 has been successfully used for assessment of 
HRQoL in Black, South Africans with RA (32). Outcome factors such as pain and 
fatigue are often measured independently using self-reported measures such as Lickert 
scales, due to their importance in patient perceived well being (8). 
 
Although functional ability has been shown to be one of the most important outcomes 
for patients with RA, as well as the most commonly assessed RA outcome (33-34), 
the current methods of assessing functional ability (HAQ, and certain domains of the 
SF-36 questionnaire) are subjective, and no routine objective assessment of physical 
functional ability exists for patients with RA. In fact, objective physical activity levels 
are not routinely measured in RA patients in clinical practice.  
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1.3.3 Damage (Irreversible) 
 
Joint destruction and bone erosion are also routinely measured in clinical practice, 
using radiographs, as well as quantitative assessments of bone damage such as X-
Rays (8), and scores such as the rheumatoid arthritis articular damage score (RAAD) 
(35), and the Sharp scoring method (36). Eroded bone and articular damage in RA is 
largely irreversible (8), and while it is important to measure the extent of this damage; 
it is imperative to measure and understand reversible disease activity factors such as 
those mentioned above, as a means to monitor response to therapy and treatments.  
1.4. Principles of Management of Rheumatoid Arthritis: 
1.4.1 Medical Treatment: 
 
Since there is no definite cure for RA, treatments aim to decrease the symptoms of 
pain and disability. Physical disability negatively affects social lives, employment and 
personal care (19). Drugs used in the treatment of RA are designed to limit pain and 
decrease inflammation (thereby limiting damage), and should therefore improve 
ability to function normally in daily life. South African recommendations for 
management of RA, like those of EULAR and ACR, recommend that drug treatment 
regimes should be designed to achieve low disease activity or remission (See Section 
1.3). Decreasing disease activity allows for better physical function, as well as 
decreased structural damage (19). 
 
The most widely prescribed class of drugs used to treat RA are synthetic or traditional 
disease modifying antirheumatic drugs (DMARDs). These drugs inhibit or halt the 
process of RA disease progression (37). The most commonly prescribed drug within 
this class of drugs is methotrexate (19, 38) Methotrexate has an excellent safety 
profile, and is either used as monotherapy, or as combination therapy with other 
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DMARDs depending on disease severity (19). Other drugs used for symptomatic 
treatment of RA include non-steroidal anti-inflammatory drugs (NSAIDs) and 
analgesics that are used to decrease the pain and stiffness experienced, and are usually 
prescribed ‘as needed’. Glucocorticoids such as prednisone are used to treat 
inflammation, either orally in conjunction with DMARDs, or injected locally into 
joints during acute flares. These drugs work rapidly in reducing symptoms and 
erosions, yet the side effects limit long term use (19). Lastly, biologic DMARDs, 
which are proteins designed to target specific cytokines or their cell receptors (such as 
TNF- antagonists) are excellent in reducing symptoms and work well for patients 
who have failed DMARD therapy. Biologics are very expensive, and although a wide 
range of biologics are now available in South Africa, their use may be limited in 
developing countries such as South Africa.  
 
There are many approaches to the treatment of RA, yet the best success is seen from 
using an aggressive approach (triple DMARDs, usually using methotrexate as an 
‘anchor drug’ in combination with prednisone, with gradual reduction in DMARDs 
and withdrawal of prednisone until remission is achieved) following early diagnosis 
(9). Current treatment strategies aim to achieve remission (a disease free state). This 
requires the use of a treat to target approach, whereby absolute indices of disease 
activity (such as those derived from the SDAI, CDAI, DAS-28) are used to quantify 
remission (8). Thus, treatment plans should focus on early, aggressive treatment, a 
treat to target approach using one of the abovementioned indices in order to target 
remission or normal functional status, defining the extent of joint damage, followed 
by optimisation of the therapy for the individual (8).  
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1.4.2 Non-pharmacological Treatment and Surgery: 
Treatment of RA requires a multidisciplinary approach. Patients may be offered joint 
protection education, physical therapy and nutritional advice, as well as 
physiotherapy, occupational therapy and podiatry treatment as a means to control their 
symptoms.  
 
Physical activity has been used as a treatment strategy for RA since the 1950’s (39), 
yet there is still conflicting evidence with regards to the types of activity that should 
be undertaken, as well as the effects of these activities on RA disease progression. 
Furthermore, clinicians do not often prescribe physical activity as a means of 
treatment to their patients. The types of exercises prescribed are generally range of 
motion and stretching exercises that aim to improve joint mobility; as well as 
strengthening exercises to improve muscle strength and counteract muscle atrophy. 
This concept will be expanded on in Section 1.8 and Section 1.10. 
 
Surgery is usually reserved for severe joint damage (9), and as a means to decrease 
severe pain and to improve functional ability of joints that have severe irreversible 
damage and deformities. In these cases, joint arthroplasty is usually indicated (9). The 
incidence of surgery for RA in South Africa has been declining since the introduction 
of the above mentioned aggressive therapy approach following an early diagnosis 
(19).  
 
1.5. The Burden of Rheumatoid Arthritis in South Africa: 
 
South Africa is a unique setting for the study of RA as it is a developing, upper 
middle income country with a prevalence of RA as high as the rest of the world (40), 
juxtaposed with an underdeveloped health care system and a high rate of poverty, as 
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well as a high prevalence of many infectious diseases that generally take priority over 
non life-threatening diseases such as RA. 
 
Epidemiological studies conducted in the 1970s in a Black urban Johannesburg 
community revealed the prevalence of RA to be unexpectedly high at 0.9% (40), 
whilst prevalence in rural Black South Africans is lower; between 0.12-0.67% (26). 
Although the prevalence of RA is relatively low in rural Black South African 
populations, the prevalence in urban Black South Africans is similar to that of 
Caucasian populations (40), and European and American Black populations (41). 
Furthermore, RA disease in urban Black South African populations was found to be 
similar to the polyinflammatory arthritis found in Caucasian populations, rather than 
the mild RA often seen in rural South African populations (40). Some studies have 
however shown that severe RA disease cases are not uncommon in rural Black South 
Africans (42). While the incidence of RA seems to be decreasing in the United States 
and Western Europe, the incidence of RA is rising in Africa (43). Black populations 
have been shown to have a greater excess of females with RA, and a younger age of 
peak onset when compared to White populations (43). Urban Black South Africans 
were also found to have a very high prevalence of erosive disease, defined as the 
presence of an erosion or cortical break “in at least three separate joints at any of the 
following sites: the proximal interphalangeal, the metacarpalphalangeal, the wrist, and 
the metatarsalphalangeal joints…” (44), specifically present in the hands and feet 
(40). 
 
All patients with RA are at increased risk for developing tuberculosis (TB), and the 
incidence of TB in South Africa is amongst the highest in the world (19). Drugs taken 
to control RA disease further increase risk of development of TB (19). Human 
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Immuno-deficiency Virus (HIV) prevalence in South Africa, similarly, is amongst the 
highest in the world with 33% of females between the ages of 25-29 being infected in 
2010 (19). Drug therapy for RA is often immunosuppressive, complicating the 
management of RA patients who are HIV+. Additionally, little is known with regards 
to the effects of anti-retro viral therapies (ARTs) on RA disease process, or the effects 
of RA drug therapy on ARTs. Many South African patients with RA are 
immunocompromised, resulting in a need for specialised care and personalised drug 
therapy that most patients will not receive when diagnosed with RA in a developing 
country (26).  
 
These complications, coupled with the high rate of poverty and underdeveloped health 
care system mentioned earlier, make the management of RA in South Africa even 
more complicated than it is in more developed countries, and special attention needs 
to be paid to these factors when designing disease management interventions within 
these populations. 
1.6. Rheumatoid Arthritis and Bone Health: 
 
The involvement of bone in RA has been described in much detail since the first 
description thereof by Barwell in 1865 (45). Currently, it is understood that RA 
patients are predisposed to developing osteoporosis, which is a systemic skeletal 
disease resulting in low bone mass (46), and are therefore at increased risk of fracture. 
Fracture risk can be estimated using dual X-Ray absorptiometry scans (DXA), which 
calculate areal density of bones and then classify values as either normal, osteopaenic, 
or osteoporotic, based on criteria established by the WHO (46), by comparing values 
obtained to those of a healthy index population. The hip and spine are the preferred 
sites for these measurements due to the high predictive value of hip bone mineral 
density (BMD) for fracture risk.  
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Osteoporosis in RA can be generalised, (affecting the axial skeleton such as the hip 
and lumbar spine), or peri-articular (affecting local areas of inflammation such as the 
hand joints) in nature. The increased risk of developing osteoporosis is attributed to 
multiple factors: namely the presence of circulating pro-inflammatory cytokines, the 
decreased mobility of these patients, resulting in a sedentary lifestyle, as well as 
certain medications taken to treat the disease such as corticosteroids. There are 
multiple factors that affect the degree of loss of bone density in patients with RA (see 
Figure 1.3). Studies have shown that the majority of bone density loss in RA occurs in 
the first six months of disease (47). Furthermore, patients with higher disease activity 
have been shown to exhibit greater loss in BMD, and higher indices of bone turnover. 
Also, levels of mobility and function have been correlated with BMD, as have age, 
stature, and sex (48-49). 
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Figure 1.3. Factors that have been documented to affect the degree of bone loss in rheumatoid arthritis 
in the literature. 
 
It is natural for bone to model and remodel throughout life according to the stresses 
and strains placed on the bone. Modeling, which refers to the change in shape and 
structure of a bone, occurs from childhood up to early adulthood, whereas remodeling 
occurs continuously throughout life. Bone remodeling is dependant on the coupled 
interaction between bone deposition by osteoblasts and bone resorption by 
osteoclasts. These cells are highly sensitive to strains and stresses within the bone 
matrix, and are activated and stimulated to proliferate or apoptose accordingly in 
response. This process is controlled by receptor activator of nuclear factor- ligand 
(RANKL) and its permissive factor macrophage colony stimulating factor (M-CSF) 
which is secreted by local osteoblasts (Figure 1.4).  Receptor activator of nuclear 
factor- ligand binds to its receptor – RANK, on the surface of osteoclast precursor 
cells in order to stimulate their differentiation into mature osteoclasts, known as 
osteoclastogenesis. Conversely, osteoblasts secrete osteoprotegerin (OPG), a decoy 
receptor that binds to RANK and prevents binding of RANKL, therefore inhibiting 
osteoclast formation and promoting osteoclast apoptosis. Osteoblasts, on the other 
hand, are highly sensitive to shear stresses and strains within the fluid matrix of bone, 
and are activated and stimulated to proliferate in response (50). 
 
 19 
Figure 1.4. Schematic overview of the RANKL/RANK/OPG system that mediates bone modeling. 
Taken from Coetzee and Kruger in 2004 (51) 
 
The mechanism whereby RA results in bone loss is dependant largely on these 
systems. Inflammation causes bone loss through the upregulation of RANKL and 
RANK via pro-inflammatory cytokines, like IL-1, IL-6 and TNF, as well as through 
regulation of osteoclastogenesis via the modulation of M-CSF. Synovial tissue 
contains fibroblasts that produce protein for RANKL, and the T lymphocytes within 
synovial tissue express RANKL on their surface. The rheumatological synovium and 
inflammatory cytokines present therefore sustains an osteoclastogenic environment. 
Furthermore, TNF-, which is elevated in RA, both promotes osteoclastogenesis and 
inhibits osteoclast apoptosis (50).  
 
This increase in osteoclastogenesis and consequent bone loss evident in RA is further 
amplified by the decreased mobility and sedentary behaviour that these patients 
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exhibit. Wolff’s law, which has been described over a century ago, states that the 
skeleton transforms it’s mass and morphology according to individual activity levels 
and forces placed upon the bone (52). Furthermore, Frost’s mecahnostat theory, 
derived in 1964, states that each bone has a specific strain threshold, and that in order 
for that bone to be remodeled, the minimum effective strain must be placed upon it 
(53). A sedentary individual does not place sufficient strain on the skeleton, and bones 
are thus remodelled in a direction that promotes bone loss. Patients with RA are 
therefore at increased risk of osteoporosis due to inflammatory processes inherent to 
their disease, and the consequent effect of a sedentary lifestyle (50). 
 
The additional factor contributing to osteoporosis in RA is the drug therapy used to 
treat the disease. Glucocorticoids are commonly used to treat inflammatory diseases 
such as RA, yet are associated with the development of osteoporosis and fractures 
(54).  Glucocorticoids affect the function and replication of osteoblasts, as well as 
increase apoptosis of mature osteoblasts, and inhibit apoptosis of osteoclasts. 
Glucocorticoids also increase expression of M-CSF and RANKL, as well as decrease 
expression of OPG, and inhibit calcium uptake, therefore promoting bone resorption 
(50).  
 
These factors predispose patients with RA to developing osteoporosis and therefore to 
increased risk of fracture. A study conducted on a cohort of female patients with RA 
in Oslo, has shown that overall risk of osteoporosis was two-fold higher in these 
patients than in the general population, and that this risk was higher in patients who 
were older, had a longer disease duration, were post menopausal, had higher levels of 
disability, had a positive RF, and had a low body weight (55). Fracture risk is greater 
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with osteoporosis of the hip and the spine, and incidence of osteoporosis at these sites 
is between 15-20% in patients with RA (50).  
 
Bone health in RA can be modified using treatments designed to increase bone mass 
(such as bisphosphonates, vitamin D and calcium, TNF inhibitors and biologic 
DMARDs), treatments to decrease RA disease activity (as are discussed in Section 
1.4.), or by increasing physical activity sufficiently to increase bone loading and 
remodeling. Regular exercise can increase bone strength by increasing bone size, 
shape, and density (56) This concept will be explored in more detail in Sections 1.8 
and 1.10 
1.7. Rheumatoid Cachexia and Sarcopenia: 
 
Rheumatoid cachexia is a term used to describe the concurrent decreased body mass, 
increased resting energy expenditure and increased whole body catabolism that often 
occurs with RA (57). The end result of cachexia is skeletal muscle wasting, and 
increased fat mass. The term ‘cachexia’ was first described by Sir James Paget in 
1873, and was derived from the Greek term meaning ‘bad condition’ (58-59). Recent 
definitions of cachexia explain the condition as a metabolic syndrome that is 
characterised by loss of muscle (sarcopenia) with or without loss of fat mass (58). 
Rheumatoid cachexia, unlike classic cachexia, which is observed in only 1-13% of 
RA patients, usually presents with preserved or increased fat mass (60). Rheumatoid 
cachexia occurs in 10-20% of patients with well controlled disease, and around 38% 
of patients with active disease (60), and is associated with increased mortality and 
morbidity (59). The hypermetabolism and protein catabolism seen is associated with 
the increased pro-inflammatory cytokines such as IL-1 and TNF-α, as well as with 
decreased peripheral insulin activity, and decreased physical activity levels (59).  
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Figure 1.5. Relationship between rheumatoid disease process and cachexia in rheumatoid arthritis. 
Taken from da Rocha et al in 2009 (61) 
 
The decreased body cell mass (BCM)- consisting of muscle mass, visceral mass such 
as serum proteins, erythrocytes, granulocytes, lymphocytes, liver, kidney, pancreas 
and heart, and immune cell mass- which occurs in cachexia can result in death due to 
decreased muscle strength and altered metabolism. Cachexia also increases 
susceptibility to infection, which is already 2-5 times greater in patients with RA 
compared to the general populace (59). Roubenhoff et al (62) showed that RA patients 
have a 15% decrease in BCM, which is more than one third of the maximal survivable 
loss of BCM (58). Sarcopenia in RA is a manifestation of cachexia, yet still carries 
adverse outcomes of its own such as disability, lower HRQoL and death (63), Three 
effective treatments of rheumatoid cachexia and sarcopenia exist: exercise-, dietary- 
and pharmacological interventions. Regular, progressive resistance training has been 
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shown to be the most effective, nonpharmocological intervention to treat cachexia in 
RA (59).  
 
Resistance training of sufficient intensity, duration and dose can increase fat free mass 
in patients with RA (64) and has been shown to be able to normalize the accelerated 
protein catabolism seen in RA due to increased TNF-α (57). Sharif et al in 2011 (65) 
showed that resistance exercise 3 times per week for 16 weeks, was able to increase 
resting energy expenditure, endurance, strength, and muscle fiber cross sectional area, 
as well as decrease pain, and disease activity scores in a case study of one female 
patient,  aged 46. The authors found, however, that resistance exercise was not able to 
decrease fat mass in this individual, and recommend that some form of aerobic 
exercise be included in order to maximise the beneficial effects seen. 
 
Increased fat mass often leads to obesity, which is considered a pro-inflammatory 
state (66), and in order to counteract this; adipocytes secrete adiponectin, which is an 
anti-inflammatory adipokine (67). Patients with RA have more circulating adipocytes 
than healthy individuals (57), indicating that obesity in RA may have a protective role 
in terms of inflammation and disease activity. Indeed, having a low body weight is 
one of the most predictive indicators of developing more active disease, and poor 
radiological outcome in RA (58). However, increased fat mass combined with 
decreased lean body mass and a sedentary lifestyle is a major risk factor for 
developing cardiovascular and metabolic diseases, as well as osteoarthritis (57). 
Aerobic exercise can decrease the risk of cardiovascular disease (67), and as such, 
after twelve weeks of aerobic exercise training female South African RA patients 
have been shown to have significant improvements in cardiac autonomic function 
(68). Exercise interventions, including resistance as well as aerobic exercise, would 
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therefore be beneficial in reversing or slowing down the progression of rheumatoid 
cachexia and sarcopenia, as well as their associated complications.  
 
1.8. Physical Activity and Rheumatoid Arthritis: 
 
Pain control in RA is important in itself, but also to improve quality of life and 
increase functional ability. Physical activity as a term is often used broadly, and it is 
important to define the term in the context of this thesis. Physical activity involves all 
body movements, and includes structured, planned exercise, as well as leisure 
activities, household chores, occupational activities and ambulatory movements (69). 
Physical activity interventions generally involve increasing structured exercise via an 
exercise programme. Habitual physical activity, as used in this thesis, refers to 
ambulatory movement (simply moving around) and day-to-day activities such as 
household chores and possibly occupational activities, as well as travel. Habitual 
physical activity can include structured exercise; however in the case of patients with 
RA, it often does not.  
 
Physical activity has been promoted as a form of treatment for RA since the 1950’s 
(39), and randomised controlled trials studying the effects of physical activity 
interventions in RA have been conducted since the 1970’s (70). Habitual physical 
activity, on the other hand, has been shown to be lower in patients with RA in 
comparison to healthy controls when measured subjectively, yet there is a lack of 
definitive, objectively measured evidence to prove this relationship (69). Furthermore, 
there has been little research into the effects of increasing habitual physical activity 
levels on disease activity in RA. Much of the research in this field has focused on 
exercise interventions within the RA population, and here most authors have found 
physical activity to either have no effect on pain levels or joint scores (71), or to 
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slightly improve joint counts over time (72), increase muscle strength, functional 
status, balance, flexibility of joints, and to decrease pain (73). The most recent 
reviews of all the randomised controlled trials using a physical activity intervention in 
patients with RA are considered in Section 1.10. Included in these reviews are trials 
that were conducted from as early as 1975 using aerobic (cycling, dance, aquatic and 
walking and running), as well as resistance training interventions. These studies 
revealed that exercise is generally effective in reversing joint damage, and in 
improving functional capacity, strength, aerobic capacity, and sometimes pain. 
Resistance training has been shown to improve strength, muscle mass, and 
functionality (74), to improve certain measures of cardiac health, HRQoL, disease 
activity and functional capacity (68, 75). 
 
Although physical activity interventions are evidently beneficial in RA, it is unclear 
how increased habitual physical activity affects disease activity, and whether it can 
improve functional ability (69). Roubenhoff et al (2002) are of the opinion that there 
is no evidence that controlling inflammation and joint pain will reverse the sedentary 
habits of patients with RA (57). Henchoz et al (2012) later showed that patients with 
RA who had greater habitual physical activity levels, as assessed via physical activity 
questionnaires, exhibited better disease activity scores (76).  
 
Habitual physical activity is difficult to assess as an outcome measure of disease 
activity due to the lack of objective measurement tools available. Questionnaires and 
recall diaries are commonly used in research, but are subjective (77). Furthermore, it 
is often difficult for patients to recall their activity levels accurately, especially for 
light to moderate activities (78). Accuracy in these subjective measures relies on 
patient fluency in the English language as well as compliance, and as such 
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questionnaires cannot necessarily be used reliably in all population groups 
(particularly in South Africa). Nevertheless, physical activity questionnaires are 
currently being used as a subjective means to ‘quantify’ physical activity levels in 
patients with RA (76, 79), and these studies consistently report that habitual activity 
levels are significantly lower in patients with RA as compared to healthy populations. 
The lack of an objective assessment tool to measure physical activity in RA (or any 
other chronic disease), however needs to be addressed in order enable an empirical 
comparison of these physical activity levels.  
 
1.9. Accelerometry: 
 
Accelerometry is an objective means of measuring physical activity. Accelerometers 
measure the acceleration of the limb to which they are attached by detecting low 
frequency (0.5-3.2 Hz) gravitational forces (0.05-2.0g) (80). Acceleration is thought 
to be directly proportional to muscle forces generated, and therefore to energy 
expenditure (78). This theory along with an inbuilt algorithm allows for the 
conversion of energy expenditure into activity counts, which are generated every 
minute, or in specific time intervals as specified by the user. These counts can be 
classified into thresholds indicating sedentary, light, moderate or vigorous intensity 
levels (78). Sedentary activity is defined as any activity which does not increase 
energy expenditure above that of resting (4); while light, moderate and vigorous 
activities raise energy expenditure to various degrees above resting levels. These 
terms are further defined in the Operational Definition of Terms. 
 
Actical accelerometers (Respironics Inc, Murrysville, USA) are small, unobtrusive 
and comfortable. The accelerometer device has been shown to be most accurate when 
placed on the part of the body where the motion occurs, and studies have shown the 
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hip to be the only place able to predict free living activities at all intensity levels, with 
the wrist and ankle being second and third best respectively (80). Figure 1.6 shows a 
typical graphical output from an Actical accelerometer. 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Accelerometer data from an Actical worn on the hip over seven days. Data on the right 
shows total energy expenditure per day in kcal. Spikes in data indicate peaks in activity counts during 
the day, while the blocks indicate energy expenditure during the day. The circle highlights a period of 
particularly high activity for this participant, where activity counts are high as is the energy 
expenditure. The rectangle highlights an area of very low activity with low activity counts and energy 
expenditure as basal level only. 
 
Accelerometry has potential advantages over self-reported measures of physical 
activity, such as being able to track intensity, duration and frequency of an activity 
without relying on patient recall (81). Omnidirectional accelerometers such as the 
Actical, although being able to more accurately predict low level activity levels that 
unidirectional accelerometers, still have certain limitations, such as slightly 
underpredicting light activity and not being able to accurately predict energy 
expenditure not associated with acceleration (in which case a heart rate monitor is 
better advised) (82).  Despite these limitations, accelerometers can detect varying 
levels of activity, being able to detect activities of a low intensity and movement in 
multiple planes better than other accelerometers (80), and showing better inter- and 
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intra-device reliability than other accelerometers (83). Accelerometers would, as such, 
be ideal for measuring ambulatory physical activity levels in patients with RA, who 
are generally sedentary and where most movement is functional and of low frequency 
and intensity, and therefore unlikely to be reported accurately using self report 
measures. Accelerometers could also be ideal for measuring physical activity levels in 
South African populations where not all patients are fluent enough in English to be 
able to complete extensive activity questionnaires accurately. The accuracy of 
accelerometers is not dependent on language, making it ideal for use in a developing 
country such as South Africa.  
 
Few studies have been done using accelerometers to measure physical activity levels 
in patients with chronic disabling conditions such as RA (80), and none have been 
done in Black South African women with RA, even though these patients may not be 
able to accurately report their activity levels subjectively using questionnaires. Of the 
few studies that have been done, one used a Dynaport monitor to quantify the amount 
and intensity of physical activity in patients with RA, and the ambulatory monitor 
measurements were correlated with physical activity, functional status and disease 
activity in these patients (78). In another study, an ActiGraph accelerometer worn on 
the hip of RA patients for a week was able to measure physical activity in these 
patients, although this study did not examine the associations between habitual 
physical activity and disease activity, and the authors suggest that it is important to 
have accurate thresholds for activity levels in chronic pain patients such as these (84). 
Accelerometers have been used in RA in order to determine the effects of ‘activity 
pacing’ on habitual physical activity levels (85). The authors of this study found that 
activity pacing was associated with decreased habitual activity levels in these patients. 
They also found that physical activity levels were over-estimated when using 
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questionnaires, in comparison to the objectively acquired accelerometer data. Lastly, 
Acticals were used in a cross-sectional study in order to determine which factors pre-
dispose RA patients to being inactive (86). The authors found that 42% of patients 
were inactive, and that the strongest predictors of inactivity were lack of motivation 
and belief related to physical activity. There has, however, been no work done 
comparing habitual activity levels in RA patients to healthy subjects, or assessing the 
relationship between habitual physical activity levels and disease activity in RA.  
 
The Actical accelerometer has also been used to measure physical activity levels in 
patients with other painful conditions such as primary dysmenorrhoea and 
fibromyalgia. In women with primary dysmenorrhoea, who subjectively report similar 
symptoms to patients with RA, such as decreased physical activity and functional 
ability, the Actical was able to detect decreases in physical activity in response to 
changes in pain levels (77). Patients with fibromyalgia and chronic fatigue syndrome 
have some symptoms similar to RA, such as pain, fatigue, depression, tender joints 
and subjectively reported decreases in physical activity (23). In these patients, 
accelerometry detected reduced levels of peak activity in comparison to healthy, age-
matched controls, and these measurements were also correlated with subjective 
measures of physical activity (23). Lavie et al (1992) studied patients with 
fibromyalgia using the Actical accelerometer to measure not only daily physical 
activity and habitual behavior, but also sleep patterns, and found accelerometry data 
to correlate well with sleep logs and polysomnography, the gold standard for sleep 
measures (87). Similarly, Pruitt et al (2008) conducted a study in RA using actigraphy 
to measure their sleep quality, and found that movements detected during sleep using 
actigraphy were well correlated with poor sleep quality defined using 
polysomnography (78).  
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Accelerometers offer a potential method of objectively and unobtrusively measuring 
physical activity, whether functional or recreational. Patients with RA are generally 
sedentary, and most activity undertaken is functional, and thus of low intensity. 
Accelerometers could potentially be a tool for measuring these low intensity activities 
accurately by overcoming the inaccuracies present in evaluations done by means of 
subjective questionnaires, thus providing a means for clinicians to determine daily 
physical activity levels and functionality in RA patients.  
1.10. Exercise Interventions for Rheumatoid Arthritis: 
 
Exercise interventions of various modalities have repeatedly been shown to have 
beneficial effects on most outcomes in RA (88). That being said, there is still a lack of 
definitive guidelines for physical activity interventions in RA. Meta-analyses have 
been conducted to assess the effects of various exercise interventions on RA, yet due 
to the vast differences in intervention types, duration, intensity, population samples, 
and outcomes measured; the most effective means of delivering an intervention to this 
population remains to be established. It is likely that interventions will need to be 
tailored specifically for age, disease duration, functional disability and radiographic 
joint progression, amongst other things. In spite of these limitations, exercise 
interventions show promising results in improving many facets of RA. Table 1.3 
below, (modified from those of Cairns et al in 2009 (89), Metsios et al in 2008 (90), 
and Baillet et al in 2010 (91)), summarises the current literature on exercise 
interventions in RA. Although not exhaustive, this table includes all the randomised 
controlled trials (RCTs) conducted between 1975 and 2013, as well as some pertinent 
cross sectional and non-randomised longitudinal trials which have assessed the effects 
of various types of exercise interventions (aerobic, strength, or combinations thereof) 
in patients with RA, in comparison to a control group (either standard care, routine 
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exercise therapy, standardised range of motion (ROM) exercises, or habitual daily 
activities). From this table it is evident that, although exercise has been used in RA for 
many years, definitive guidelines are not yet available.
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Table 1.3. Exercise interventions for the treatment of rheumatoid arthritis 
Study 
(Author, year) 
Participants 
(Exercise vs. 
Control) 
Exercise Intervention 
 
Control group 
activities 
Duration Outcomes measured Results 
(Significant improvement in 
exercise group vs. control group) 
Ekblom et al, 
1975 
23 vs. 11 Cycling 
50-70% HR max 
5 days per week twice 
daily 
 
Rehabilitation 
programme 
6 months Aerobic capacity, pain, 
muscle strength 
Increased aerobic capacity (chronic 
and acute) 
Nordemar et al, 
1981 
23 vs. 23 Home based 
cardiorespiratory  
70% HR max 
30-60 min 
Pharmaceutical 
therapy 
4-8 years Joint damage, walking 
time, quad torque, CVS 
fitness 
Less joint progression, increased 
walking ability, and quad torque 
Harkom et al, 
1985 
11 vs. 6 Cycling 
70% HR max 
3 days per week 
Routine 
activities 
12 weeks V02 max, muscle 
strength, joint count, 
functional status 
Increased V02 max and decreased 
joint count 
Stenstrom et al, 
1991 
30 vs. 30 Aquatic programme 
1 day per week 
30-40 min  
Standard 
medical 
treatment 
4 years Activity, grip strength, 
functional status 
Increased activity and grip strength, 
less admittance for hospital care 
Baslund et al, 
1993 
12 vs. 12 Cycling 
80% HR max 
2 days per week 
45 min 
Current 
activities 
3 months Functional capacity, 
strength, ESR, joint 
counts, morning 
stiffness 
Functional capacity and strength 
increased 
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Hansen et al, 
1993 
45 vs. 15 Aquatic programme 
3 days per week 
45-90 min 
Normal 
treatment 
2 years Disease activity and 
joint damage 
No effect 
Hansen et al, 
1993 
60 vs. 15 Home based 
cardiorespiratory  
70% HR max 
3 days per week 
90 min 
Usual care 104 weeks Morning stiffness, pain, 
joint count, health 
assessment, ESR, Hb, 
x-ray 
No effect 
Lyngberg et al, 
1994 
12 vs. 12 Cycling and dynamic 
strength 
50-70% HR max 
2 days per week 
45 min 
Usual care 12 weeks Joint count, walk time, 
muscle strength, V02 
max, ESR 
Left ankle strength increased, 
functional capacity increased 
Stenstrom et al, 
1994  
42  Dynamic aerobic and 
strength home exercises 
5 days per week 
None 12 weeks Self efficacy, functional 
capacity, pain, mobility, 
Ritchie index 
Improved pain, self efficacy, 
mobility, functional capacity and 
Ritchie index 
Noreau et al, 
1995 
19 vs. 10 Supervised 
cardiorespiratory dancing 
50-70%HR max 
2 days per week 
15-30 min 
 
Usual care 
12 weeks 50 foot walk, aerobic 
capacity, strength, 
mood, pain, depression 
and anxiety 
Improved 50 foot walk, strength, 
endurance, and decreased pain, 
depression and anxiety. 
Hall et al, 1996 69 vs. 70 Aquatic programme or 
land exercise 
2 days per week 
30 min 
Seated 
immersion or 
relaxation 
3 months Quality of life Physical and psychological benefits  
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Rintala et al, 
1996 
18 vs. 16 Aquatic programme 
2 days per week 
45-60 min 
Normal 
activities 
24 sessions Muscle strength, 
mobility, aerobic 
capacity 
Increased muscle strength and 
mobility 
Van den ende et 
al, 1996 
25 (in each of 
3 exercise 
groups) vs. 25 
High intensity exercise 
Low intensity group 
exercise 
Low intensity individual 
exercise 
3 days per week 
60 min 
ROM exercise 
at home 
12 weeks V02 max, muscle 
strength, HAQ, joint 
count, pain, ESR/CRP 
V02 max, joint mobility, muscle 
strength, swollen joint count (more 
in high intensity) 
Komatireddy et 
al, 1997 
25 vs. 24 Circuit training 
3 days per week 
20-27 min 
Habitual 
activities 
12 weeks Muscle strength, V02 
max, functional status, 
joint counts 
Decreased self reported joint count, 
night pain, increased strength and 
anaerobic capacity 
Sanford-Smith 
et al, 1998 
24 total Aquatic programme 
70% HR max 
3 days per week 
25-30 min 
ROM and 
isometric 
exercise 
10 weeks Grip strength, fitness, 
ESR, HAQ 
Increased grip strength and exercise 
tolerance, decreased ESR 
McMeeken et 
al, 1999  
17 vs. 18 Quadriceps and 
hamstring training 
 
Normal 
activities and 
weekly contact 
6 weeks Muscle strength, HAQ, 
pain, TUG 
Peak muscle torque, pain, HAQ, 
TUG 
Hakkinen et al, 
1999, 2001, 
2003, 2004 
(multiple) 
35 vs. 35 Home based dynamic 
strength 
2 days/week 
45 min 
 
ROM and 
stretching 
24 months Muscle strength, 
BMD, DAS28, HAQ, 
Larsen score,  
Increased strength, improved 
DAS28, HAQ, ESR, Pain and 
increased hip BMD 
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Westby et al, 
2000 
23 vs. 30 Aerobic dance and 
strength 
3 days per week 
45-60 min 
Habitual 
activities and 
therapy 
12 months Joint count, ESR, 
BMD, HAQ, fitness 
Fitness (questionnaire) 
Functional capacity 
Van den ende et 
al, 2000 
34 vs. 30 Supervised isometric and 
isokinetic and cycling 
60% HR max 
3 days per week 
15 min 
ROM exercise 
and isometric 
30 days Swollen joint count, 
muscle strength 
Muscle strength, decreases disease 
activity (both groups) 
De jong et al 
2003, 2004 
(multiple) 
151 vs. 158 Cycling, circuits, games 
70-90% HR max 
2 time/week 
75 min 
Usual care 104 weeks BMD 
Larsen score 
Muscle strength, 
DAS28, HAQ 
Increased functional ability, slowing 
of loss of BMD at hip, 
No radiographic progression of hand 
and feet 
Bilberg et al, 
2005 
22 vs. 27 Moderate pool exercises 
2 time/week 
45 minute 
70% HR max 
Normal 
activities 
12 weeks V02 max, SF-36,  
Physical function 
Increased muscle function and 
endurance 
 
Munneke et al, 
2005 
151 vs. 158 Cycling, circuit, games 
70-90% HR max 
2 days per week 
90 min 
Habitual 
activity 
24 months Radiographic joint 
change 
Accelerated joint damage 
progression in those with existing 
damage 
Meligoklou et 
al, 2006 
20 vs. 20 Treadmill 
60% HR max 
2 times per week 
20 min 
 
ROM exercise 2 weeks IGF-1, IGFBP-3, pain, 
HAQ, ESR, CRP 
IGF-1 concentration improved 
 36 
Van den berg et 
al, 2006 
82 vs. 78 Home based 
cardiorespiratory exercise 
60=80% HR max 
5 times per week 
10-30 min 
Education 52 weeks Physical activity, 
quality of life, 
functional ability, 
disease activity 
No effects 
Eversden et al, 
2007 
57 vs. 58 Hydrotherapy 
Once per week 
30 min 
Land exercises 6 weeks Global impression of 
change, HRQoL, Health 
status, HAQ, 10m walk 
test 
Increased impression of change 
Neuberger et al, 
2007 
173 vs. 75 Supervised and home 
based cardiorespiratory 
60-80%HR max 
3 days per week 
60 min 
Usual care 12 weeks Pain, fatigue, 
depression, walk time, 
grip strength 
Pain, fatigue and depression 
decreased in class exercise, walk 
time and grip strength improved in 
both groups vs. control 
Baillet et al, 
2009 
25 vs. 23 Supervised 
cardiorespiratory and 
conditioning 
60-80%HR max 
5 days per week 
45 min 
Education 4 weeks HAQ, health, HRQoL, 
joint progression, 
DAS28, fitness, 
dexterity 
HAQ, health and fitness improved 
Lemmey et al, 
2009 
13 vs. 15 Progressive resistance 
training 
80% 1 Rep max 
2 times per week 
 
ROM exercise 24 weeks Lean body mass, 
Appendicular lean 
mass, fat mass, 
function, disease 
activity, muscle 
strength, IGF 
Increased lean body mass and 
appendicular lean mass, and protein, 
decreased fat mass and trunk fat in 
both groups, increased strength and 
50 foot walk, increased IGF-1, 
IGFBP-3, decreased cachexia and 
obesity. 
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HRmax – Heart rate maximum, VO2 Max – Maximum volume O2, SF-36 – Short form-36, BMD – Bone mineral density, DAS28 – 28 joint disease activity score, HAQ -
Health assessment questionnaire, ROM – Range of motion, ESR – Erythrocyte sedimentation rate, TUG –Timed up-and-go test, CRP – C-reactive protein, IGF – 
Immunoglobulin factor, CVS – cardiovascular, Hb – Haemoglobin, HRQoL – Health related quality of life, 1 Rep max – 1 repetition maximum.
Janse Van 
Rensberg et al, 
2010 
19 vs. 8 45 minutes aerobic 
exercise as well as 
stretching and 
strengthening exercises 
3 times per week 
Usual care 12 weeks  DAS28, HAQ, pain, 
strength, flexibility and 
fitness 
Increased flexibility, strength, fitness 
and disease activity in exercise 
group. Increase in strength and HAQ, 
and decrease in fitness in control 
group. 
Janse Van 
Rensberg et al, 
2012 
19 vs. 18 45 minutes stretching, 
strength and aerobic 
exercise 
3 times per week 
Usual care 12 weeks Heart rate variability, 
DAS28 
Improved cardiac health (as 
measured by heart rate variability) in 
exercise group vs. control group. 
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The meta-analysis conducted by Baillet et al (91) provides cumulative results from 
RCTs comparing aerobic exercise to either non-aerobic exercise, education or 
standard care for RA. They conclude that aerobic exercise of various modalities has 
beneficial effects on HRQoL, functional ability, pain levels, tender and swollen joint 
counts, and radiographic damage. Certain patient characteristics at baseline were 
found to influence the outcome; shorter disease duration resulted in increased 
improvement of pain levels and HRQoL, and lower HAQ scores at baseline resulted 
in significantly greater improvements in functional ability following an exercise 
intervention. The design of the exercise intervention also altered the outcomes; 
HRQoL was only improved following interventions that lasted less than three weeks, 
and sessions lasting longer than 60 minutes. Supervised exercise influenced HRQoL 
more so than unsupervised exercise. Lastly, pain scores were only improved 
following interventions lasting less than three months.  
 
Similarly, based on meta-analysis, Cairns et al (89) concluded that aerobic exercise 
was able to improve muscle strength, physical function, aerobic capacity, disease 
activity, and, in one study, hip BMD. Higher intensity exercise imparted greater 
benefits than lower intensity exercise; and it was evident that a combination of 
aerobic and strength exercises was needed in order to achieve both increased aerobic 
capacity, as well as increased strength. Only one study, conducted by Munneke et al 
in 2005 (92), reported negative effects of aerobic exercise. They observed a 
worsening of some of the joints of the shoulder and the subtalar joints. Although their 
study was a retrospective analysis, they cautioned against prescribing aerobic 
exercises in patients with high baseline radiographic damage.  
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There is clear evidence for the benefits of exercise for RA. What remains to be 
determined is how best to refine these interventions for specific subgroups of patients, 
based on factors like disease duration and extent of erosive damage, whilst still 
ensuring the feasibility of these interventions within these populations. Specifically, 
long term aerobic and resistance exercises may not be feasible in our South African 
RA population for various reasons. Lack of financial resources, which may result in 
difficulties obtaining standard drug therapy, make implementing supervised 
alternative or complementary therapy such as exercise improbable. Furthermore, 
patients may not have the resources to travel to exercise centres frequently, nor are 
there an abundance of community centres that could be used for these purposes (as is 
often the case in more developed countries). What is also evident from the literature is 
the lack of exercise interventions in RA that focus specifically on improving bone 
health. The risk of osteoporosis, and later development of a fracture in patients with 
RA is greater than in healthy populations. Devising an exercise intervention that is 
focussed on increasing bone mass (or even slowing down bone loss or preserving 
bone density); whilst also improving muscle strength, lowering disease activity and 
pain, and improving quality of life; would have widespread beneficial effects for 
patients with RA.  
1.11. Whole Body Vibration Therapy in Chronic Disease: 
 
Whole body vibration (WBV) therapy is a mechanism whereby a mechanical 
vibration platform produces energy via forced oscillation. The vibratory waves are 
then transferred to an individual via propagation through the feet, legs, trunk and 
finally, the head (93). Vibration platforms can either be oscillating (moving from side 
to side, whereby opposite legs are elevated and lowered repetitively), or synchronous 
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(moving up and down parallel to the ground, thereby creating less movement around 
the axis). Synchronous plates have been shown to create less movement around the 
hip and spine (94), as well as to exert greater osteogenic effects on the trunk. These 
plates are therefore potentially safer in patients with joint, muscle, or nerve disorders. 
An erect posture while standing on the plate further increases transmissibility through 
the hip and spine (94). Vibration plates can vary in the force generated through 
alteration of the frequency (measured in Hz and defined as the number of complete 
up-and-down cycles per second) and amplitude (measured in mm and defined as peak 
to peak displacement of each cycle) of the vibration (95). Although certain amplitudes 
and frequencies have been shown to impart deleterious effects on humans, specifically 
through occupational exposure; low magnitude (1-10mm and 15-60Hz) vibration has 
been shown to be a safe and effective means to exercise musculoskeletal structures 
(96). 
 
Whole body vibration therapy is increasingly gaining popularity as a means to 
increase bone mineral density in healthy subjects, as well as patients with physical 
diabilities. For the purposes of this thesis, the literature review will focus on WBV 
therapy as an exercise intervention in chronic musculoskeletal diseases. Whole body 
vibration therapy has been used in a multitude of musculoskeletal diseases, with 
varying objectives. These objectives primarily include attempting to improve balance, 
bone mass, muscle strength, neuromuscular performance, flexibility, pain, stiffness, 
depression, mobility, and gait; and WBV protocols vary depending on the desired 
outcome. Table 1.4 below (modified from Wysocki et al (93), Pang et al (97), and 
Chanou et al (98)), summarises some of the most recent and pertinent RCTs on the 
use of WBV therapy in any chronic musculoskeletal disease. Excluded from this table 
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are studies where WBV has been used in healthy populations or children; or where 
WBV therapy has been used to treat other diseases or outcomes not relevant for the 
purposes of this thesis. 
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Table 1.4. Whole Body Vibration therapy in the treatment of chronic musculoskeletal disease: protocols and results 
 
 
Study 
(Author, 
year) 
Condition 
treated 
Sample 
size 
Frequency 
(Hz) 
Amplitude 
(mm) 
Duration 
(min/day) 
Days 
(per week) 
Protocol Outcome 
measured 
Results 
Iwamoto et 
al, 2005 
Osteoporosis 50 20 Not reported 4  1 12 months 
WBV therapy 
plus drug 
therapy vs. 
only drug 
therapy 
Hormonal 
secretion, bone 
density, pain 
Decreased pain 
in WBV groups 
vs. control group 
Gilsanz et 
al, 2006 
Osteopaenia 
(young 
individuals with 
spinal fracture) 
48 30 Not reported 10 7 48 weeks 
WBV 
training vs. 
control group 
BMD, body 
composition 
Increased 
cancellous and 
cortical bone, 
increased 
paraspinous 
muscle mass in 
WBV group vs. 
control group 
Alenthorn-
Geli et al, 
2008 
Fibromyalgia 36 30 2 18  2 6 weeks 
static and 
dynamic 
exercise on 
WBV plate 
vs. sham 
protocol vs. 
control 
Pain, fatigue, 
stiffness, 
depression 
WBV group 
decreased pain 
and fatigue more 
than other two 
groups 
Moezy et al, Anterior 23 30-50 2.5-5 4-16  3 4 weeks Proprioception, Increased 
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2008 cruciate 
ligament 
surgery 
WBV 
exercises vs. 
no exercise in 
conjunction 
with standard 
physical 
therapy  
balance stability in WBV 
group vs. control 
group 
Ruan et al, 
2008 
Osteoporosis 116 30 5 10 5 24 weeks 
WBV therapy 
vs. control 
group 
BMD, BMI, 
back pain,  
Increased hip and 
spine BMD and 
decreased back 
pain in WBV 
group vs. control 
group 
Alenthorn-
Geli et al, 
2009 
Fibromyalgia 24 30 2 18  2 6 weeks 
static and 
dynamic 
exercise on 
WBV plate 
vs. sham 
protocol  
Hormonal 
secretion 
Insulin-like 
growth factor 
No changes 
evident in either 
group 
Trans et al, 
2009 
Osteoarthritis 52 24-30 Not reported 3-5 2 8 weeks 
stable 
platform 
WBV vs. 
balance board 
WBV vs. 
control 
Isokinetic knee 
extension, 
isometric 
flexion torque, 
proprioception 
Stable platform 
increased 
isokinetic knee 
extension and 
flexion torque 
more than 
controls. Balance 
board increased 
knee 
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proprioception 
more than 
controls. 
Gusi et al, 
2010 
Fibromyalgia 36 12.5 3 3 3-6  12 weeks 
WBV therapy 
vs. control 
Balance, 
HRQoL,  
HRQoL 
preserved in 
WBV group yet 
decreased in 
control group 
Johnson et 
al, 2010 
Total knee 
arthroplasty 
16 35 2-5 2-18  3 4 weeks 
static and 
dynamic 
exercises on 
WBV plate 
vs. standard 
resistance 
exercise all in 
conjunction 
with physical 
therapy 
Strength, 
mobility, pain, 
range of 
motion 
No differences 
between two 
groups 
Prioreschi 
et al, 2012 
Exercise 
induced 
osteopaenia and 
osteoporosis 
15 30 3 15 3 10 week 
intermittent 
WBV vs. 
control group 
BMD Increased hip 
BMD and 
maintained spine 
BMD in WBV 
group vs. control 
group. 
 
 
WBV- Whole body vibration, BMD – bone mineral density, HRQoL – Health related quality of life, BMI – Body mass index.
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The ability of WBV therapy to improve the above-mentioned outcomes is of great interest; 
particularly the ability of WBV to increase or maintain BMD.  Studies conducted in 
postmenopausal women (99), as well as healthy populations (96), and athletes with low BMD 
(100), have shown WBV therapy to improve BMD, particularly at the hip and spine (101-
102). Although the exact mechanisms whereby WBV therapy increases BMD are not entirely 
clear, it is likely that there are multiple mechanisms at play. Whole body vibration has been 
shown to activate fluid flow in the canaliculi and lacunae of bone matrix in rats (103), in a 
manner proportional to loading frequency. This fluid flow creates shear stress on the plasma 
membrane of osteocytes, bone lining cells, and osteoblasts, which therefore respond 
accordingly (56). WBV thus activates mechanostransduction in bone, which stimulates 
osteogenesis (99). Frost’s mechanostat theory (104) states that each bone has a specific strain 
threshold, and that in order for that bone to be remodeled, the minimum effective strain needs 
to be placed upon it. Anything above this strain will cause new bone deposition, while 
anything below it with cause resorption of existing bone. Therefore, vibration stimulus must 
sufficiently load bones in order to increase deposition. Furthermore, muscle forces have been 
shown to exert the greatest osteogenic stimulus on bone, and the generation of these forces 
through vibration stimulus is likely a contributor to the skeletal adaptations that occur (94).  
 
The direction of vibration, the frequency and magnitude of load, acceleration, duration of 
protocol, and body posture on the plate all play a role in the effectiveness of WBV for bone 
health. Studies have shown that the most effective WBV therapy sessions are 2-20 minutes in 
duration, and that shorter sessions that incorporate rest periods are the most effective for 
promoting musculoskeletal adaptations (103). Turner in 1998 stated three ‘rules’ for bone 
adaptation, namely: 1) bones respond to dynamic rather than static loading, 2) loading 
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duration should be short, and 3) that bone cells adapt to regular loading, making them less 
responsive (53). Hert et al demonstrated in 1971 that bone responds to dynamic loading, due 
to the increased rate of deformation and fluid flow in the bone matrix. Further, bone cells 
become desensitized to repetitive loading, losing up to 95% of their mechanosensitivity 
(105). However, incorporating rest periods between loading periods can return this 
sensitivity. Vibration set at low amplitudes and higher frequencies (up to 60Hz) have been 
shown to be anabolic to trabecular bone (106), however protocols in the current literature are 
varied with regards to exact frequencies and amplitudes used.  
 
Since patients with RA are already at risk for developing osteoporosis, and are therefore at 
greater risk of fracture; WBV could potentially be a means to treat low BMD, or at least to 
attenuate the progressive loss of BMD, without the need for a vigorous exercise programme. 
Exercise interventions in RA are not always feasible, specifically bone loading exercises 
which need to be dynamic in order to increase bone mass (56). WBV therapy is safe, requires 
minimal effort and movement, yet still exhibits muscle strengthening effects and stimulates 
bone loading in a controlled environment.  
1.12. The Problem: 
 
The best outcome measures of RA that provide the most definitive assessment of disease 
activity remain to be elucidated. There is a clear link between physical activity and RA 
disease activity, yet there are no outcome measures which incorporate objective measurement 
of physical activity levels, nor is there an understanding of the mechanisms underlying this 
association. There is also a lack of data regarding the habitual physical activity levels of 
patients with RA, especially using objectively measured physical activity levels, and there are 
few comparative studies between healthy control participants and RA patients with regards to 
physical activity levels. Little is known with regards to the factors that result in changes in 
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habitual physical activity levels over time, including whether drug therapy affects habitual 
physical activity levels in any way. 
 
Furthermore, although exercise is prescribed for RA, there is no consensus on the most 
effective type of exercise for the disease, and many exercise interventions described in the 
literature are not necessarily feasible in a South African context. Very few interventions 
focus on increasing bone density as a primary aim, despite the very real risk of fracture in 
these patients, and the associated implications thereof (social, economical and health related).  
 
The clear link between disease activity and physical activity, compounded by the paucity of 
knowledge in this area, forms the premise of this research. The objectives of the studies 
conducted for this thesis were, broadly: 
 
 To assess the potential clinical utility of accelerometry in quantifying habitual 
physical activity levels and patterns in patients with RA 
 To quantify habitual physical activity levels in patients with RA and to determine 
those factors which affect habitual physical activity and those which are affected by 
levels of habitual physical activity 
 To determine whether WBV therapy would have beneficial effects on functional 
ability and bone health in patients with RA 
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1.13 Thesis Framework: 
 
In order to address the broad objectives stated in Section 1.13 above, three main studies were 
conducted. These studies addressed more specific aims, as follows: 
 
Study 1: 
 
 To objectively quantify habitual physical activity levels in RA patients in comparison 
to a healthy population 
 To ascertain any associations between habitual activity levels and disease activity in 
patients with RA 
Study 2: 
 To determine the changes in habitual physical activity levels in patients newly 
diagnosed with RA in response to commencement of DMARD therapy 
 To determine the predictive factors causing the changes seen in disease activity in 
response to commencement of DMARD therapy in patients with RA 
Study 3: 
 To determine the associations between habitual physical activity levels and bone 
health in patients with RA 
 To determine the effects of a WBV therapy intervention on functional ability, and 
bone health, as well as on disease activity and habitual physical activity levels in 
patients with RA  
 
The results (Chapter 2) of these studies will be presented in the form of the publications that 
emanated from each specific study, or in the form of the submitted manuscripts in the cases 
where manuscripts have not yet been accepted for publication. Author contributions and 
acquiescence forms have been included (Appendix 14). The methodology used in this thesis 
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will be described in detail within each results section. These publications/manuscripts are as 
follows: 
1. Prioreschi A, Hodkinson B, Avidon I, Tikly M, McVeigh JA. The clinical utility of 
accelerometry in patients with rheumatoid arthritis. Rheumatology. 
2013;52(9):1721-1727. (Appendix 11). 
2. Prioreschi A, Hodkinson B, Tikly M, McVeigh JA. Changes in physical activity 
measured by accelerometry following initiation of DMARD therapy in rheumatoid 
arthritis. Rheumatology. 2014:53(5);923-6. (Appendix 12). 
3. Prioreschi A, Makda MA, Tikly M, McVeigh JA. Higher habitual activity levels are 
protective of bone health in patients with rheumatoid arthritis. Under review at BMC 
Musculoskeletal Disorders. 
4. Prioreschi A, Makda MA, Tikly M, McVeigh JA. Positive Effects of a 12 week WBV 
Intervention on Bone Mineral Density and Fatigue are Sustained in a Population 
with RA. Submitted to International Journal of Bone and Mineral Research. 
 
As well as manuscript describing the protocol used for Study 3 (Appendix 13): 
 
5. Prioreschi A, Tikly M, McVeigh JA. A three month controlled intervention of 
intermittent whole body vibration designed to improve functional ability and attenuate 
bone loss in patients with rheumatoid arthritis. Under review at BMC Musculoskeletal 
Disorders. 
 
The discussion and conclusions section (Chapter 3) that follows these 
publications/manuscripts will summarise all the results obtained, and integrate the findings in 
light of the current literature.  
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1.14. Conclusion: 
 
This chapter has examined the literature with regards to RA, patients with RA in South 
Africa, bone health in RA, treatments of RA, outcome measures of RA, physical activity in 
RA and accelerometry, as well as WBV therapy in chronic disease. This chapter concluded 
by highlighting the gap in the knowledge that I wish to address, and by broadly introducing 
the objectives of the studies conducted in this thesis. 
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Chapter 2: Results 
 52 
2.1. Study 1 – The Clinical Utility of Accelerometry in Patients with 
Rheumatoid Arthritis1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Prioreschi A, Avidon I, Hodkinson B, Tikly M, McVeigh JA. The clinical utility of 
accelerometry in patients with rheumatoid arthritis. Rheumatology. 2013; 52(9):1721-1727 
 
Please note that Table and Figure numbers, as well as citations have been modified from the published version 
in order to align with the numbering of the thesis.
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Abstract: 
Objectives: To objectively assess habitual physical activity levels in patients with 
rheumatoid arthritis (RA) compared to healthy control participants, and to compare these 
measures to health related quality of life and disease activity in the RA patients. Methods: 
Fifty RA patients (age 48(13) years) and 22 body mass index-, sex- and geographically-
matched control participants were recruited. Habitual physical activity was measured using 
an Actical accelerometer worn on the hip for two consecutive weeks. Patients completed the 
Short Form-36 (SF-36) and modified Health Assessment Questionnaires (HAQ-DI). Disease 
activity was assessed using the Simplified Disease Activity Index (SDAI). RA patients were 
further categorized as more physically active (n=25) and less physically active (n=25) 
according to their average activity counts. Results: The RA group spent more time in 
sedentary activity than the control group (71% vs. 62% of day respectively, p=0.002), and 
had bimodal decreases in diurnal physical activity compared to the control group in the 
morning (p<0.001) and late afternoon (p<0.001). HAQ-DI, when adjusted for age and disease 
duration, was negatively correlated with physical activity in the RA group (r=-0.343, 
p=0.026). The more physically active patients scored better than the less physically active 
patients on every component of the SF-36. Conclusion: Patients with RA lead a significantly 
more sedentary lifestyle than healthy controls, and show diurnal differences in physical 
activity due to morning stiffness and fatigue. Higher levels of habitual physical activity may 
be protective of functional capacity and are highly associated with improved health related 
quality of life in RA patients. 
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Introduction: 
Patients with RA have been shown to have a decreased health related quality of life (HRQoL) 
in comparison to the general population (1). HRQoL (which is defined as the physical, 
emotional and social aspects of life which are affected by a patient’s disease or their 
treatment) is a relevant measure of disease activity according to the WHO (2) and “feeling 
well” is an important patient outcome, along with management of pain, sleep, fatigue, 
emotional- and physical wellbeing (1).  
 
The presence of pain limits the ability of patients with rheumatoid arthritis (RA) to function 
normally, and as a result everyday habitual physical activity levels are reduced (3). Exercise 
interventions in patients with RA have been shown to improve sense of wellbeing, decrease 
morning stiffness, improve sleep patterns, and decrease swollen joint counts over time (4), as 
well as to reduce pain and improve functional ability (5). Increasing levels of physical 
activity have been shown to be beneficial for patients with RA without having any adverse 
effects on disease activity (6). Most studies have examined the effects of enforced exercise 
interventions on RA disease activity, yet surprisingly little is known about the effects of 
everyday, spontaneous habitual physical activity levels in patients with RA, and whether 
patients with increased habitual physical activity levels have better disease activity profiles or 
“feel better”. One large study by Sokka et al (2008) did examine self-reported physical 
activity levels in over 5000 outpatients with RA in over 20 countries around the world and 
found that over 70% of these patients did not engage in regular physical activity at all. 
Furthermore, physical inactivity was more prevalent in patients with lower functionality as 
assessed by the Health Assessment Questionnaire (HAQ) (110). These findings remain to be 
elucidated using objective measures of physical activity. 
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Physical activity, as a functional assessment of quality of life is difficult to assess. 
Questionnaires and recall diaries are commonly used but are subjective (8), and it is difficult 
for patients to recall their activity levels accurately, especially for light to moderate intensity 
activities (9). Few studies have been performed on RA patients assessing habitual, daily 
physical activity levels (10). Two studies have compared energy expenditure levels between 
patients with RA and controls, (average energy expenditure was found to be lower in RA 
patients than in controls in both these studies) although both made use of subjective measures 
of physical activity only (76,79). 
 
Accelerometers are growing in popularity as an objective way to measure physical activity, 
especially in healthy populations (13), and have been validated using calorimetry and doubly 
labeled water methods (14). Actical accelerometers are small, unobtrusive and comfortable, 
and measure acceleration of the limb to which they are attached by detecting low frequency 
(0.5-3.2 Hz) forces (0.05-2.0g) (13). Acceleration is thought to be directly proportional to 
muscle forces generated, and therefore to energy expenditure (9). This theory along with an 
inbuilt algorithm allows for the conversion of energy expenditure into activity counts, which 
are generated every minute. These counts can be classified into thresholds, indicating 
sedentary, light, moderate or vigorous intensity levels (9). Accelerometers have advantages 
over self-reported measures, such as being able to objectively track intensity, duration and 
frequency of an activity without relying on patient recall (15). Acticals in particular can 
detect varying levels of activity and movement in multiple planes (10), making them 
potentially ideal for measuring physical activity in patients with RA, who are generally 
sedentary and where most movement is functional and of low frequency and intensity, and 
therefore unlikely to be reported accurately using self report measures.  
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Accelerometry has already been used to quantify physical activity levels in other rheumatic 
diseases, such as osteoarthritis (112), and to study knee biomechanics in spondyloarthropathy 
and RA patients (113). The aims of this study were to assess the potential clinical utility of 
accelerometry in quantifying habitual physical activity levels and patterns in a group of 
patients with RA by assessing whether varying levels of habitual physical activity are 
associated with disease activity and HRQoL; and to compare their physical activity levels to 
those of a healthy group of control participants. 
 
Participants and Methods: 
Participants: 
Fifty female patients fulfilling the 1987 ACR classification criteria for RA (18) with a mean 
age of 48(13) were recruited from the Chris Hani Baragwanath Rheumatology Clinic in 
Soweto, South Africa (RA group). Participants were excluded if they had any co-morbidities 
including cardiac, muscle or neurological disorders, that could potentially impact on physical 
activity, were using any assistive walking devices, or were pregnant. The RA group were 
compared to 22 control participants (control group) who were matched for mean body mass 
index (BMI- calculated as weight (kg)/(height(m))2), race, and sex, and were recruited from 
the same geographical living area as the RA patients so as to closely match the two groups 
for socioeconomic circumstances. Ethical approval was obtained from the human research 
ethics committee of the University of the Witwatersrand (M110430 and M110236), and 
complies with the Helsinki Declaration. All participants signed written informed consent and 
were free to withdraw from the study at any time.  
 
Outcome Assessments: 
Physical Activity: 
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Actical accelerometers (Respironics Inc, Murrysville, USA) were worn on a velcro belt on 
the hip of the dominant leg during the day for two consecutive weeks (the Actical device has 
been shown to be most accurate when placed on the part of the body where the motion 
occurs, and studies have shown the hip to be the only place able to predict free living, 
habitual activities at all intensity levels (13)). Acticals were removed only when the 
participants were bathing/showering or participating in any water-based activities. Actical 
data were recorded in one minute epochs and data were reduced by removing only full days 
of non-wear time (as observed in the counts or as reported by the participants), as well as 
sleeping time as reported by participants. The remaining data (which included daily activities 
as well as rest periods throughout the day) are referred to as the “wear period” which was 
calculated in a similar manner to that described by Semanik et al in 2010 (5). Data for the 
wear period were divided into thresholds, namely sedentary, light, moderate or vigorous 
activity according to the activity counts recorded and the inbuilt algorithm calculated by the 
Actical software (Respironics Inc, Murrysville, USA). Since the participants were found to be 
extremely sedentary, these data were then expressed as percentage of time spent in sedentary 
activities on average per day as recommended by Pate et al in 2008 (19). The 95th percentile 
of the activity counts recorded over the period for each participant was also noted in order to 
eliminate any outliers in maximal activity counts. Activity counts for each participant were 
also divided into time intervals throughout the day in order to assess daily habitual physical 
activity patterns in RA patients (early morning:6am-9am, late morning:9am-12pm, 
afternoon:12pm-3pm, late afternoon:3pm-6pm, and evening:6pm-9pm), and the average 
activity counts in each time interval throughout the day were compared between the control 
group and patients with RA. Participants also completed a physical activity questionnaire 
after the two weeks stating the type of activities undertaken over the study period, which was 
used to assess any water based activities that were not recorded by the Actical.  
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Actical Calibration: 
It has been recommended that accelerometers be calibrated according to the types of 
activities they would be recording (20). All Acticals were calibrated for light ambulatory 
activity typical of patients with RA by being worn by the same person on the hip of the 
dominant leg while walking on a treadmill (StarTrac S, Toronto, USA) for five minutes at a 
standard speed (5km/hour) and with no inclination. The marker button on the Actical was 
pressed at the start and end of the five minute period and data were recorded as average 
activity counts per minute over the period. The average activity counts recorded for each 
person over the two week period was then divided by the calibrated value that was 
determined for the respective Actical that the participant wore and this new value was used to 
classify the participants into ‘more physically active’ and ‘less physically active’ groups. 
 
Functional Ability, HRQoL and RA Disease Activity: 
Before being fitted with an Actical, RA patients completed the Short Form-36 (SF-36) 
questionnaire, a general assessment of HRQoL comprising of eight categories of health 
namely; physical function, role physical (the role that health plays on physical function), 
body pain, general health, vitality, social functioning, role emotional (the role that health 
plays on emotional function), mental health and reported health, all of which are separated 
into either composite physical health or composite mental health, and combined to give a 
total SF-36 score where a higher score indicates a better outcome (21). RA patients also 
completed a patient global assessment  score (PGA), and a modified Health Assessment 
Questionnaire (HAQ-DI) (22) which is a well validated RA specific assessment of functional 
capacity where the total score ranges from the best possible result (score of 0) to the worst 
possible result (score of 3). Patients were all assessed by the same physician (BH) before 
commencing the study with a tender joint count (TJC), swollen joint count (SJC), and 
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physician global assessment (MDGA). These, in combination with the C-reactive protein 
concentration in mg/dL (CRP) and PGA, were used to calculate the composite Simplified 
Disease Activity Index (SDAI), with cut-offs of <11, >11 and <26, and >26 for low, 
moderate and severe disease activity respectively (21).  
 
Statistical Analysis: 
Unpaired students t-tests were used to compare all continuous variables between groups. 
Pearson’s and Spearman’s correlations (for parametric and non-parametric data respectively) 
were used to determine correlations between the objective physical activity counts (which 
were first log transformed to normalise the data) and subjective questionnaire data as well as 
disease activity scores within the RA group. A one-way ANOVA was used to assess 
differences between average activity counts within each category of SDAI. Health 
assessment questionnaire scores were adjusted for age, as well as disease duration in order to 
eliminate any confounding variables, and this adjusted mean was correlated with activity 
counts. The RA group was divided into a “more” physically active group and a “less” 
physically active group according to the median average activity count value for all the 
patients over the two week period in order to assess the SF-36 scores using unpaired students 
t-tests to compare the two groups. All statistical analyses were done using STATISTICA 
v10.0 (Tulsa, OK) and a p-value of <0.05 was considered significant. 
 
Results: 
The characteristics of the groups are summarised in Table 2.1. There were no differences 
between the two groups for any of the variables measured except for age, which was 
significantly greater in the RA group than in the control group (p=0.018). The mean BMI of 
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both the RA and control group was greater than 30, categorising participants as obese 
according to the WHO (23).  
 
Table 2.1. Characteristics of the RA participants and control participants.  
 
 
 
 
 
 
 
 
 
 
 
All values are mean(SD). 
HAQ (Health assessment questionnaire), SDAI (Simplified disease activity index), BMI (Body mass index)  
* p<0.05 
 
The percentage wear time during the day (mean (SD) of 15(3) hour awake day) spent in 
sedentary activity is shown in Figure 2.1. Overall, RA patients spent a significantly greater 
percentage of their day in sedentary activity than the control participants (71(11)% vs. 
62(11)%, p=0.002), and had a significantly lower value than the control group for the 95th 
percentile of activity counts recorded (mean (SD) of 22612(12255) counts vs. 37091(17650) 
counts, p<0.001). None of the participants took part in any water based activities. 
 RA group  
(n=50) 
Control group 
(n=22) 
p Value 
Age (years) 48(13)  41(8) 0.018 * 
Height (m) 1.58(0.05) 1.59(0.11) 0.586 
Weight (kg) 80.20(24.67) 77.30(15.61) 0.615 
BMI (kg.m-2) 32(9) 31(8) 0.639 
Disease Duration (months) 99(77)   
SDAI 16(11)   
Tender joint count 4(5)   
Swollen joint count 3(3)   
Physician global 
assessment 
4(3)   
Patient global assessment 5(3)   
C-Reactive protein (mg/dl) 19.68(31.26)   
HAQ index 1.3(0.9)   
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Figure 2.1. Histogram showing the percentage of time spent in sedentary activity between the RA group (black 
bars) and the control group (white bars).  
 
We assessed how time of day affects physical activity by examining three hourly intervals 
throughout the day (morning, late morning, midday, afternoon and evening). The average 
activity counts per three hourly intervals were significantly lower in the RA group compared 
to the control group for each time category (except for in the evening where there was no 
difference between the two groups (p=0.589)), as shown in Figure 2.2. These differences 
between the RA patients and controls were greater in the morning (p<0.001) and the 
afternoon (p<0.001) than in the late morning (p=0.033) and at midday (p=0.037). 
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Figure 2.2. Average activity counts per three hourly interval for the RA group (solid line) and control group 
(hatched line) throughout the day. Morning was calculated from 6am-9am, late morning from 9am-12pm, 
midday from 12pm-3pm, afternoon from 3pm-6pm, and evening from 6pm-9pm. The control group had 
significantly higher activity counts than the RA group at all time points except for in the evening. 
* p<0.050 
** p<0.001 
 
Table 2.2 shows a correlation matrix between physical activity counts and various outcome 
measures. Activity counts were negatively correlated with age, BMI and disease duration, 
and positively correlated with the composite physical health score of the SF-36. There was no 
correlation between SDAI and physical activity, and there was no difference in the average 
activity counts of participants who fell into the respective disease classification categories 
(low to high) of SDAI (p=0.976). Rheumatoid arthritis participants had a moderate functional 
disability according to the HAQ-DI scores shown in Table 2.1 (22). Health assessment 
questionnaire scores, when corrected for age and disease duration was negatively correlated 
with physical activity (r2=0.117, p=0.026) in the group of RA patients as shown in Figure 2.3. 
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Table 2.2. Correlation matrix comparing various outcomes to average activity counts 
per day (when log transformed for normality) within the RA group (n=50) 
 
 Spearman R or r value p Value 
Age  -0.441 0.005 * 
BMI -0.361 0.023 * 
SDAI 0.172 0.295 
ESR  -0.133 0.419 
CRP -0.028 0.852 
Disease Duration -0.406 0.010 * 
SF-36   
Total 0.269 0.097  
Composite Mental 
Health 
0.189 0.247 
Composite Physical 
Health 
0.326 0.043 * 
Physical Function 0.289 0.074 
Role Physical 0.173 0.235 
Body Pain 0.221 0.177 
General Health 0.207 0.207 
Vitality 0.187 0.255 
Social Functioning 0.117 0.477 
Role Emotional 0.100 0.492 
Mental Health 0.031 0.853 
Reported Health 0.061 0.712 
 
ESR (Erythrocyte sedimentation rate), CRP (C-reactive protein)  
Correlations were Spearman’s correlations for non parametric data and Pearson’s correlations for parametric 
data as applicable. 
* p<0.05 
 
Figure 2.3. Correlation between the average activity counts per day in the patients with 
RA and HAQ-DI adjusted for age and disease duration (r=-0.343, p=0.026). 
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There was a wide range of activity counts within the RA group. In order to assess whether 
SF-36 scores would be different between an ‘more active’ RA group and a ‘less active’ RA 
group, we arbitrarily divided the RA group into a more physically active group and a less 
physically active group based on the median physical activity count of 1885. The results for 
the SF-36 between the RA patients (once divided into a more physically active and a less 
physically active group) are shown in Figure 2.4. Both groups scored poorly (<66), yet the 
more physically active group scored higher than the less physically active group on every 
component of the SF-36, and significantly higher for the vitality component (54(17) vs. 
45(17), p=0.04), the composite mental health component (53(17) vs. 44(16), p=0.05), the 
composite physical health component (47(19) vs. 37(18), p=0.05), and the total SF-36 score 
(49(18) vs. 39(17), p=0.03). The vitality component of the SF-36 was positively correlated 
with physical activity in the RA patients, and the total SF-36 score trended towards a 
significant positive correlation with physical activity (r=0.269, p=0.097) as shown in Table 
2.2.  
 
Figure 2.4. Spydergram showing the components of the SF-36 questionnaire for the RA group divided into a 
more physically active group (solid line) and a less physically active group (hatched line) according to the 
median activity count value of the whole group. The more physically active group scored significantly higher 
than the less physically active group for vitality (p=0.034), overall physical health (p=0.05), overall mental 
health (p=0.05) and total SF-36 score (p=0.03). 
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Discussion: 
We have used accelerometry to quantify habitual physical activity in patients with RA 
compared to healthy, matched controls. Our data supports the clinical utility of accelerometry 
as an outcome measure of habitual physical activity in patients with RA as demonstrated by 
its association with SF-36 and HAQ-DI. In addition, we have shown quantifiable differences 
in physical activity levels over the course of a day between a group of patients with RA and 
healthy, matched controls. Patients with RA in the present study were more sedentary and 
less habitually physically active than healthy, matched controls. An average American adult 
spends 60% of their day in sedentary activities (24). Our control group spent a similar 
percentage of their day in sedentary activities, yet our RA group spent almost two hours more 
each day in sedentary activities than their healthy matched controls.  
 
Daily habitual physical activity patterns for patients with RA were markedly different to that 
of healthy controls. RA patients were significantly more sedentary than control participants 
throughout the day except for in the evening, when the two groups converged to a similar 
average level of activity. Interestingly, the control participants had two peaks in habitual 
physical activity levels that were not present in the RA group. These occurred in the early 
morning and late afternoon. The absence of these peaks in activity levels in the patients with 
RA are likely to be related to two known symptoms of the RA disease, namely morning 
stiffness of the joints (118) and fatigue, which tends to peak in the afternoon (119). Fatigue is 
an important barrier to physical activity in patients with RA, and was shown to be negatively 
associated with subjectively measured physical activity levels in patients with RA (76). The 
ability of the accelerometer to detect the presence of these symptoms, as well as to 
differentiate between the two groups through measurement of physical activity, makes it a 
promising tool in the measurement of RA disease outcomes. 
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Similar to Sokka et al, we have reported decreased functional ability in patients with RA in 
association with decreased physical activity levels, but have extended and further unpacked 
this finding with the use of an objective measure of physical activity. The clinical utility of 
accelerometry devices could minimise the difficulties associated with language and 
questionnaire limitations. Functional capacity (as assessed by the HAQ-DI) was shown in the 
current study to be negatively correlated with objectively measured physical activity in 
patients with RA. Higher levels of habitual physically activity may have a protective role on 
functional disability in patients with RA. de Jong et al in 2003 found HAQ scores to decrease 
(although not significantly) in a group of patients with RA who underwent dynamic exercise 
training for two years (27). Also, Walker et al in 1999 found HAQ scores to be negatively 
correlated with ambulatory activity in patients with RA as measured by a Numact activity 
monitor, which only assesses energy expenditure, calculated from number and vigour of steps 
taken (28). Henchoz et al in 2012 found that HAQ was not associated with physical activity, 
yet their study did not assess physical activity objectively. Despite this, all disease-related 
scores were found to be significantly poorer in sedentary compared with physically active 
patients (76). We show an association between increased levels of objectively assessed 
habitual physical activity (using a calibrated activity monitor capable of quantifying intensity 
and frequency of activity within certain thresholds) and functional ability in patients with 
RA, supporting the utility of the accelerometer as a complementary outcome measure for RA. 
 
Within our RA group, more physically active patients scored better in almost every domain 
of SF-36 than less physically active patients, and therefore patients with greater habitual 
physical activity levels reported feeling better than less physically active patients. This is in 
keeping with a previous study that showed exercise to improve the sense of well being in a 
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group of females with RA of a similar age range to our participants (4). These findings imply 
that, although not necessarily having an effect on disease activity, higher levels of habitual, 
ambulatory physical activity are associated with improved quality of life and sense of well 
being, potentially making the disease easier to cope with.  
 
Despite our RA group not nearly meeting the current recommended guidelines for physical 
activity (30 minutes in moderate to vigorous activities every day of the week (19)), those that 
simply had higher habitual physical activity level fared better on assessments of functional 
status and well being despite the lack of association with disease activity. It is important to 
develop healthy, feasible guidelines for patients with chronic limitations of movement, 
potentially focusing more on increasing light activity and decreasing sedentary activity as an 
adjunct to increasing moderate to vigorous activity where possible. Patients with RA may 
need frequent rest breaks depending on their severity of their disease (5), and it might be 
necessary to develop different Actical cut-off points for activity levels in people with chronic 
pain conditions in order to allow for the increased periods of non-movement time to be 
considered. The Actical was able to quantify ambulatory habitual physical activity levels in 
this group of patients with RA, which is the first step in developing guidelines for this 
population.  
 
SDAI was not significantly correlated with physical activity. We attribute the absence of a 
relationship between physical activity and SDAI to the fact that SDAI is comprised largely of 
tender and swollen joint counts, 26 out 28 of which, are upper limb joints. An activity 
monitor placed on the hip would measure only ambulatory, lower limb activity and not upper 
limb activity. It may be necessary to look at the associations between physical activity and 
deformity of the joints (especially lower limb joints) as assessed by an X-ray or a clinical 
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measure of joint deformity such as the rheumatoid arthritis articular damage score (RAAD 
score) (35).  
 
The limitations of this study include the cross sectional design, which limits the causality 
conclusions we can draw. While increased habitual physical activity levels were associated 
with improved well being and better functional status, it is not clear if this is the cause or the 
effect. Also we focused only on females, and these results cannot necessarily be extrapolated 
to males, although the incidence of RA is much higher in females (26). We also excluded 
patients who were using assistive walking devices, which limits the extrapolations we can 
make to RA patients needing to make use of such devices. Lastly, we did not manage to 
successfully match the ages of the control group with the RA group, and although this was 
controlled for in the analysis, it is still a limitation to the study.  
 
In conclusion, RA patients have decreased habitual physical activity levels in comparison to 
healthy, matched controls. The daily physical activity patterns of the patients with RA do not 
show the same bimodal peaks seen in healthy control participants and are likely to be related 
to periods of morning stiffness and fatigue. The activity counts recorded by the Actical 
accelerometer correlate well with the HAQ-DI, giving the Actical construct validity as a 
novel outcome measure in RA. Furthermore, patients with higher physical activity levels 
scored better with regards to the SF-36 in both physical and mental domains. A longitudinal 
study is needed to assess the responsiveness of physical activity to changes in disease 
activity.  
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Key Messages: 
1. Actigraphy counts are negatively correlated with HAQ scores in patients with RA. 
2. More physically active RA patients scored better than the less physically active 
patients on many components of the SF-36. 
3. RA patients demonstrated quantifiable bimodal decreases in daily physical activity in 
the morning and late afternoon. 
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2.2. Study 2 – Changes in Physical Activity Measured by Accelerometry 
Following initiation of DMARD therapy in rheumatoid arthritis1 
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Abstract: 
Introduction: This study aimed to assess changes in disease activity, as well as 
corresponding changes in objectively measured physical activity levels in response to 
commencement of DMARD therapy in drug-naïve patients with rheumatoid arthritis (RA). 
Methods: Eighteen RA patients completed this study as did 18 age, sex and body mass index 
matched healthy control participants. At baseline, and again after three months, Actical 
accelerometers were fitted on the dominant hip of each participant for two weeks; and RA 
patients completed disease activity and functionality questionnaires. Results: After three 
months of drug therapy, patients had significant improvements in disease activity as assessed 
by CDAI (p<0.001) and functional ability as assessed by HAQ (p<0.001). In parallel with 
these changes, the average activity counts in sedentary thresholds decreased (p=0.010), while 
average activity counts within higher intensity thresholds increased. At baseline, RA patients 
were less physically active than control participants in the morning (p=0.048), and in the late 
afternoon (p=0.016), yet these diurnal differences were no longer evident after the DMARD 
intervention. Multiple regression analysis showed that the change in moderate activity was 
associated with a decrease in C-reactive protein (β=-0.922, p=0.026), and the decrease in 
sedentary activity and increase in moderate activity were associated with decreased morning 
stiffness of the joints (β=0.694, p=0.035 and β=-0.927, p=0.024 respectively). Conclusion: 
DMARD therapy significantly improved disease activity in patients with RA, and these 
improvements were paralleled by subsequent improvements in physical activity levels. 
Changes in physical activity levels were significantly correlated with changes in disease 
activity measures.  
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Introduction: 
Patients with rheumatoid arthritis (RA) are generally more sedentary than their healthy 
counterparts. RA is associated with physical disability as a consequence of a combination of 
active synovitis and joint deformities, as well as chronic pain (123), all of which force 
patients into a sedentary lifestyle. There is growing interest in the use of patient reported 
outcomes measures in the assessment of RA, along with standard clinical and physician 
assessments. Of these patient reported outcomes; physical functionality has been shown to be 
one of the most important outcomes, as well as the most commonly assessed outcome (33), 
(34). The current methods of assessing physical functionality are, however, subjective, and to 
date no objective measures of physical functionality for patients with RA have been routinely 
included in clinical practice or in clinical trials. 
 
Accelerometry has been used previously in patients with RA with varying objectives (85), 
(86, 124). There is, however, still a paucity of knowledge regarding the habitual physical 
activity levels (this refers to activities of daily living such as locomotion, leisure activities 
and conscious exercising) of patients with RA, or the effects of their sedentary lifestyle on 
their disease activity. Although it is likely that the chronic pain patients with RA experience 
on a daily basis makes an active lifestyle difficult to accomplish, it is unclear whether RA 
patients would spontaneously become more habitually physically active if their symptoms 
were controlled, or whether disease activity and habitual physical activity levels are indeed 
associated with each other.  
 
In our study we aimed to explore the changes that may occur in physical activity levels in 
patients with RA in response to commencement of drug therapy, as well as the use of 
accelerometry as an outcome assessment of physical functionality in RA. This was achieved 
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by objectively measuring habitual physical activity levels in newly diagnosed, drug-naïve 
patients with RA using a well validated Actical accelerometer (81), and then re-evaluating 
their habitual physical activity levels after three months of being treated with standard RA 
drug therapy. Secondly, we aimed to determine whether there were any associations between 
changes in disease activity levels and changes in habitual physical activity levels at the end of 
a three month drug intervention.  
 
Patients and methods: 
Inclusion and Exclusion Criteria: 
Of the 22 patients initially enrolled in this study, 18 patients completed the study and were 
included in the results. The remaining four participants were lost to follow up. Patients were 
included if they were female, with newly diagnosed RA fulfilling the 1987 ACR criteria 
(114), were naïve to disease modifying anti rheumatic drug (DMARD) therapy, and if they 
were attending the Chris Hani Baragwanath Academic Hospital Rheumatology Clinic (South 
Africa). Exclusion criteria were co-morbidities that could affect physical activity such as 
previous history of a stroke, cardiac complications or physical disability, use of assistive 
walking devices, pregnancy, or patients who had been previously treated for RA.  These 
patients were matched with 18 healthy control participants for age, sex, and body mass index 
(BMI) from the same geographical area. Ethical approval was obtained from the human 
research ethics committee of the University of the Witwatersrand (M110430 and M110236), 
and complied with the Declaration of Helsinki. All participants signed written informed 
consent, and were free to withdraw from the study at any time. 
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Study Design: 
Patients were assessed at baseline and again after three months. Upon enrollment, patients 
completed various health related quality of life (HRQoL) and functionality questionnaires (as 
described below), and were assessed for disease activity by their physician. Anthropometric 
measurements were also taken. Participants were immediately fitted with an Actical 
accelerometer (Respironics Inc, Murrysville, USA), which was worn on a Velcro belt on the 
hip of the dominant leg for two consecutive weeks. Acticals were removed only when the 
participants were bathing/showering or participating in any other water-based activities. No 
medication was given for the initial two weeks following diagnosis, while the Actical was 
being worn with the exception of intra-articular steroid injections (methylprednisolone 
acetate) in severe cases and only if the affected joint was on the upper limb so as not to affect 
Actical readings. After the two week period, patients returned to the clinic and were started 
on medication as prescribed by their physician (BH) in order to achieve a low disease activity 
(methotrexate 15mg/week which was escalated by 5mg/week every month until low disease 
activity was achieved, and prednisone 7.5mg/day). This drug treatment plan was consistent 
between patients for the three month period. Patients then continued taking their medications 
for three months, where after they returned to the clinic for their follow up assessment where 
all measurements were repeated including wearing the Actical for two weeks. Control 
participants were fitted with an Actical on the dominant hip for two weeks at baseline only.  
 
Physical Activity and Anthropometry Measurements: 
Actical data were recorded in one minute epochs and data were reduced by removing only 
full days of non-wear time as assessed either by observation of the data where a full day of 
consistent zero activity counts was recorded, or as indicated by the participant if a day of 
wearing the Actical was missed. The remaining data are referred to as the “wear period” in a 
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similar manner to that described by Semanik et al in 2010 (84). Data for the wear period were 
divided into thresholds, namely sedentary, light, moderate or vigorous activity according to 
the activity counts recorded and the inbuilt algorithm calculated by the Actical software 
(Respironics Inc, Murrysville, USA). Activity data for the patients were represented as 
average activity counts during the ‘awake’ period (patients had an average 16.0(2.3) hour 
awake day at baseline and 15.7(1.3) hours at follow up, p=0.614) per hour over the two week 
period. These data were then expressed as average activity counts within each threshold per 
day as recommended by Pate et al in 2008 (4). The 95th percentile of the activity counts 
recorded over the period for each participant was also noted in order to eliminate any outliers 
in maximal activity counts. Patients were fitted with the same Actical at baseline and at the 
three month follow up so as to avoid any inter-device differences in recording of data. Height 
(to the nearest cm) and weight (to the nearest kg) were taken using a standard stadiometer 
and scale (Holtaine, USA), with participants barefoot and not wearing excess clothing. 
Equipment was routinely calibrated throughout the study. 
 
Measures of Disease activity, Functional Disability, and HRQoL: 
Disease activity was assessed using Clinical Disease Activity Index (CDAI), and was done 
throughout the study by the same physician (BH) (18). C-reactive protein (CRP) in mg/dL 
was documented, however data were missing for six patients and thus CRP data is reported 
for 12 patients only. RA patients were also questioned on their pain levels using a self-
assessment scale where possible scores range from 0 to 5, with a score of 5 indicating 
unbearable pain and 0 indicating no pain, as well as on the duration of the stiffness of their 
joints on the morning of their assessment. Patients also completed the modified HAQ; a well 
validated RA specific assessment of functionality (29) where the total score ranges from the 
best possible result (score of 0) to the worst possible result (score of 3). Patients completed 
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the SF-36, a generic instrument to measure HRQoL comprising of eight categories of health 
(125) where a higher score indicates a better outcome.  
 
Statistical Analysis: 
Sample size calculation was based on a Priori power analysis (β=0.8) showed that at a 10% 
level, a sample size of 17 patients would be needed to detect a difference in sedentary activity 
with a power of 82% (126). Paired Student’s t-tests were used to compare changes from 
baseline in continuous variables in order to assess any changes in these data over the three 
month period for parametric data, and Wilcoxon matched pairs tests were used for non 
parametric data. Unpaired students t-tests were used to compare patient and control 
characteristics at baseline. Spearman’s correlations were run to determine any correlations 
between activity data and clinical data. For categorical variables, a Chi-squared contingency 
test and a Fishers exact test were used to determine differences in distribution of patients 
within categories before and after drug therapy. A backwards stepwise multiple regression 
was run to determine predictors of various changes in disease activity outcomes. All 
statistical analyses were done using STATISTICA v10.0 (Tulsa, OK) and a p-value of <0.05 
was considered significant. 
 
Results: 
RA group compared to control group at baseline: 
There were no significant differences at baseline between patients and controls with respect 
to age, (50(14) vs. 44(7) years, p=0.103), height, (1.59(0.06) vs. 1.60(0.11) m, p=0.629), 
weight, (76(22) vs. 73(11) kg, p=0.677) or BMI, (30(8) vs. 29(5) kg/m2, p=0.613). The mean 
BMI was in the obese range in both groups according to the WHO classification criteria.  The 
symptom duration of the RA patients at baseline was 43(55) months.  
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Disease activity changes in the RA group following DMARD therapy: 
As shown in Table 2.3, there was a significant improvement in disease activity, HAQ scores, 
and in a number of domains of the SF-36 over the three month period. Similarly, height 
increased significantly by 1cm after three months of drug therapy. The majority of patients at 
baseline (78%) had severe functional disability, defined as a HAQ score 1.5, yet only a 
minority (17%) remained in this category at follow up (p<0.001). Furthermore, morning 
stiffness improved significantly over the three month period, from 101(64) to 46(56) minutes 
at follow up (p=0.048). Patient pain scores also improved over the three month period from 
2.6(0.8) to 1.5(0.8) (p<0.001). Clinical disease activity index decreased significantly, as can 
be seen in Table 2.3, as did each individual component of CDAI: namely tender joint count 
(11(6) to 3(4), p<0.0001), swollen joint count (9(6) to 2(3), p<0.0001), physician global 
assessment (7(3) to 3(2) out of 10, p=0.003) and patient global assessment (8(3) to 4(2) out of 
10, p=0.003). The percentage of participants in each category of CDAI: namely remission 
(≤2.8), low disease activity (≤10), moderate disease activity (≤22), and severe disease activity 
(>22); was significantly improved following the three month drug intervention (X2=21.57, 
p<0.0001) as can be seen in Table 2.3. 
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Table 2.3. RA patient characteristics of demographic and clinical features at baseline 
and three months after commencing drug therapy.  
 
* p<0.05 
# CRP values (n=12) 
BMI: Body mass index; CDAI: Compound Disease Activity Index; HAQ-DI: Health Assessment Questionnaire 
Index; SF-36: Short Form-36. 
 
 
Physical activity changes in the RA group following DMARD therapy: 
Table 2.4 shows the baseline and follow up data of the accelerometry measures. At the three 
month follow up there were significant decreases in sedentary activity measures, and 
significant increases in light activity measures compared to baseline. The average activity 
counts in sedentary activity at the follow up decreased significantly from baseline, and the 
same was true for the activity counts at the 95th percentile within sedentary activities. A trend 
was seen for increased average activity counts in light activity at the follow up from baseline, 
while the activity counts in the 95th percentile of light activity increased significantly. There 
were no significant changes measured in moderate or vigorous activity thresholds. 
 Baseline (n=18) 
Mean(SD) 
Follow up (n=18) 
Mean(SD) 
p-value 
Height (m) 1.59(0.06) 1.60(0.06) 0.021 * 
Body mass (kg) 76(22) 76(21) 0.171 
BMI (kg/m2) 30(8) 30(7) 0.850 
CDAI 41(11) 14(8) <0.001 * 
Remission  1 3  
Low Disease Activity  0 3  
Moderate Disease Activity  2 10  
Severe Disease Activity  15 2  
HAQ (/3) 1.94(0.87) 0.98(0.76) <0.001 * 
C-reactive protein (mg/dL) # 32.59(35.84) 23.90(38.04) 0.060 
SF-36    
Physical Function 41(25) 49(26) 0.252 
Role Physical 10(17) 28(39) 0.061 
Body Pain 26(21) 48(17) <0.001 * 
General Health 53(19) 54(29) 0.868 
Vitality 38(14) 55(22) 0.002 * 
Social Functioning 55(21) 60(24) 0.488 
Role Emotional 22(38) 50(45) 0.047 * 
Mental Health 60(18) 63(16) 0.470 
Composite Physical Health 34(14) 47(19) 0.003 * 
Composite Mental Health 46(15) 56(20) 0.038 * 
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Table 2.4. Physical activity measures at baseline and at the three month follow up in the 
RA group 
 
* Activity data significantly improved at follow up as compared to baseline (p<0.05) 
 
We further divided the activity counts into three hourly intervals throughout the day as shown 
in Figure 2.5. We compared these data to those obtained from a control group of healthy 
participants. Although there were no significant differences between the average activity 
counts spent in each time period at baseline and at the three month follow up within the RA 
group; at baseline the RA patients were significantly less active than the matched control 
group in the morning (p=0.048) and the late afternoon (p=0.016). Importantly, at the three 
month follow up, these differences were no longer evident between the RA patients and the 
control group in the morning (p=0.624) or the late afternoon (p=0.402), or at any other time 
interval.  
 Baseline (n=18) 
Mean(SD) 
Follow up (n=18) 
Mean(SD) 
p-value 
Average activity (counts/day) 110908(42942) 112502(61190) 0.286 
Sedentary activity  
Average counts 
95th percentile counts 
Light activity  
 
428(124) 
995(283) 
 
 
354(158) 
837(253) 
 
 
0.012 * 
0.004 * 
 
Average counts 
95th percentile counts 
Moderate activity  
1208(665) 
3461(1453) 
1496(810) 
4451(2057) 
0.094 
0.039 * 
Average counts 
95th percentile counts 
Vigorous activity  
Average counts 
5431(3062) 
22087(12292) 
 
50(135) 
5615(4266) 
24271(16074) 
 
44(120) 
0.983 
0.948 
 
0.612 
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Figure 2.5. Average activity counts spent in three hourly time intervals throughout the day at baseline (solid 
circle) and again at the three month follow up visit (clear circle). Data are also compared with the control group 
(solid square). 
* p<0.05 between the patients at baseline and the control group. 
 
Multiple regression analysis: 
The change from baseline in the patient’s disease activity measures (CDAI, HAQ, CRP, SF-
36 components, morning stiffness and patient’s pain assessment) and the change from 
baseline in their activity data (95th percentile of activity counts in each threshold) were 
correlated using Spearman’s correlations. Change in vitality score was positively correlated 
with change in average daily activity count (R=0.646, p=0.005), change in HAQ was 
negatively correlated with change in vigorous activity (R=-0.536, p=0.022), and change in 
CRP was negatively correlated with change in moderate activity (R=-0.577, p=0.039). 
Furthermore, since height changed significantly from baseline, change in height was also 
correlated with the change in all disease activity and physical activity measures and was 
found to be significantly positively correlated with change in tender knee joint count 
(R=0.528, p=0.043). Change in height was not correlated with any other variables. 
Significant correlations were then entered into a multiple regression analysis and the results 
are shown in Table 2.5. 
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Table 2.5. Multiple regression analysis showing change in disease activity indices vs. 
change in physical activity data. 
 
# CRP values (n=12) 
C-reactive protein (CRP).  
All represented correlations were significant; regression was run as a backward step-wise analysis. 
 
Discussion: 
In this study we report novel data on objectively measured habitual physical activity levels in 
patients with RA before and after starting DMARD therapy. Following three months of 
DMARD therapy there was a significant improvement in disease activity, functional ability 
and HRQOL as measured by CDAI, HAQ, and the SF-36 respectively. Patients reported 
having less pain after three months of drug therapy, which was likely a contributing factor to 
their improved physical activity levels, along with their significantly lower tender and 
swollen joint counts as assessed by their physician.  
 
In parallel with these improvements, objective measures of habitual physical activity also 
improved significantly. Following the DMARD therapy intervention there was a significant 
reallocation of activity counts from participation in sedentary activity (activities requiring 
minimal energy expenditure over and above resting metabolic rate such as lying down and 
sitting) to increased participation in light activity (activities such as standing up and light 
walking) of activity. The decreased mean activity counts in the sedentary activity threshold in 
Independent variable 
(change from baseline) 
Predictor variable  
(change from baseline) 
β value   p-value 
Morning stiffness Sedentary activity 0.694 0.035  
 Moderate activity -0.927 0.024 
CRP#  Moderate activity -0.922 0.026 
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conjunction with the increased mean activity counts within the light activity threshold, is 
indicative of patients breaking up their sedentary activities with light activities more 
frequently than before the DMARD therapy intervention. These observed increases in 
habitual physical activity show the effectiveness of the Actical accelerometer in measuring 
the response of physical activity to change in disease activity.  
 
We also assessed the average activity counts in three hourly intervals throughout the day in 
order to observe daily fluctuations in habitual daily activity levels. Compared to control 
participants at baseline, RA patients had significantly lower activity levels in the morning and 
in the late afternoon. These differences were no longer evident after the DMARD therapy 
intervention. The lower activity levels observed at baseline in the early morning and late 
afternoon are likely to be related to two common symptoms of RA, namely early morning 
stiffness and late afternoon fatigue. After the DMARD therapy intervention, the length of 
morning stiffness time was significantly shorter, and this change was significantly associated 
with an increase in moderate activity counts. Although we did not assess afternoon fatigue 
levels subjectively, the vitality component of the SF-36 has been shown to be a relevant 
measure of overall fatigue in RA (127), and these scores increased significantly over the three 
month period. Furthermore, this improvement in vitality score was positively associated with 
the increase in average activity counts measured. Our results indicate that the drug therapy 
attenuated differences in habitual physical activity levels between healthy control participants 
and RA. In our study, DMARD therapy improved the common symptoms of RA over three 
months, and the Actical accelerometer was sensitive enough to detect changes in habitual 
physical activity in response to drug therapy.  
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Apart from a decrease in disease activity and a concurrent increase in habitual physical 
activity levels in our patients, there were also strong associations between these outcomes 
measures. All of these correlations indicated that improvements in disease activity were 
associated either with increased physical activity (at either light, moderate or vigorous 
intensities), or with decreased sedentary activity. The Actical data were significantly 
correlated with every one of the well-validated, standard outcome measures of RA that were 
assessed in this study. 
 
An unexpected finding was the significant increase in height observed in our patients (by 
1cm), after three months of DMARD therapy. Possibly, the significant positive correlation 
between change in tender knee joint count and change in height could account for this. It is 
likely that the increase in height is due to a minor flexion deformity of the knee that improved 
following DMARD therapy, allowing patients to stand more upright. The fact that we did not 
measure flexion angles limits the conclusions we can draw from this finding. Patients also 
reported being in significantly less overall pain after three months, which could further 
explain their ability to stand taller. An alternative explanation to the increase in height could 
be related to bone loss associated with RA (128). Improved bone status (after a whole body 
vibration intervention) in cyclists with low bone mass has been shown to be associated with 
an increase in height (129). Although this result should be interpreted with caution, stature is 
an important variable to monitor in patients with low bone mass (130). Decreases in height 
are observed with worsening bone loss, as well as with aging, due to narrowing of 
intervertebral disks and loss of vertebral height (131). An increase in height, such as those 
seen in our RA patients after three months of DMARD therapy, could be also be indicative of 
improvements in bone health due to the improvements in disease activity, although we did 
not measure bone mineral density in this study. 
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The placement of the Actical on the hip only can be considered a limitation of our study. The 
hip placement means that only lower limb movement could be measured. The exclusion of 
male participants (although the majority of patients with RA are female (118)), as well as the 
fact that the participants in this study were obese means that our results cannot necessarily be 
extrapolated to male RA patients and those within the normal BMI range. The exclusion of 
patients using assistive walking devices further limits the conclusions we can draw with 
regards to patients who are more severely disabled. Future studies should aim to build on the 
novel work presented here, by using study designs with larger sample numbers and a longer 
duration of study, or by including some form of activity intervention in these patients and 
monitoring changes in disease activity. 
 
Conclusion: 
The results of this study indicate that patients treated with DMARD therapy became less 
sedentary and started undertaking more light physical activity, and following patterns of daily 
activity levels similar to those of healthy individuals. Changes in disease activity were 
correlated with changes in physical activity, further clarifying the associations between 
disease activity and physical activity levels in RA. The results of this study also present 
accelerometry as a tool for assessing changes in physical activity in response to DMARD 
therapy, and support the use of accelerometry as a concurrent measure of disease activity and 
physical function in patients with RA. 
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Key Messages: 
 
1. Objectively measured physical activity levels improve in response to DMARD 
therapy in patients with RA. 
2. Following DMARD therapy, patients start to undertake less sedentary, and more light 
activity. 
3. Daily patterns of physical activity start to resemble those of a healthy population 
following DMARD therapy. 
4. Improvements in physical activity levels are correlated with improvements in disease 
activity. 
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2.3. Study 3 (Baseline) – Higher Habitual Activity Levels Are Protective of 
Bone Mass in Patients with Rheumatoid Arthritis1 
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Abstract: 
Background: Prolonged periods of time spent in sedentary behaviour by patients with 
rheumatoid arthritis (RA) may increase the likelihood of the development of osteoporosis. 
We aimed to determine the associations between habitual physical activity levels and bone 
health in patients with RA. Methods: Twenty nine female patients with RA, recruited from 
Soweto, South Africa, were assessed for site-specific bone mineral density (BMD) using dual 
x-ray absorptiometry (DXA), and were classified as having low or normal bone mass 
according to peak reference values at the hip. Habitual physical activity levels were measured 
objectively using an Actical accelerometer over a two-week period. Patients were assessed 
for RA disease activity using the Compound Disease Activity Index (CDAI), and functional 
disability using the Health Assessment Questionnaire (HAQ). Results: Twenty-one patients 
were classified as having normal bone mass, and eight had low bone mass. There was no 
difference in the age of the two groups of patients (51(8) in the normal bone mass group vs. 
57(12) years in the low bone mass group, p=0.19). Patients with normal bone mass reported 
less functional disability (0.96(0.71) vs. 1.57(0.74), p=0.05), and had a trend towards lower 
RA disease activity than patients with low bone mass (7.7(6.1) vs. 13.8(10.8), p=0.07). 
Further, habitual physical activity levels were greater in the normal bone mass group 
(p<0.01). Patients with normal bone mass spent on average two hours less per day in 
sedentary activity (65(4)% vs. 73(2)%, p<0.01), over 70 minutes more time in light activity 
(23(1)% vs. 18(2)%, p<0.01), and over 50 minutes more in moderate activity per day 
(12(3)% vs. 8(2)%, p<0.01) than did patients with low bone mass. Patients with normal bone 
mass also broke up their sedentary time more frequently per day than those with normal bone 
mass (72(21) vs. 53(18) times per day, p=0.03), and those patients who met the 
recommended physical activity guidelines for a rheumatic population had significantly lower 
Z scores than patients who did not meet the guidelines (p=0.03). Conclusions: The results of 
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this study indicate that higher habitual activity levels may be protective of bone health in 
patients with RA, and should be encouraged as an affordable, sustainable therapeutic option. 
 
Introduction: 
Rheumatoid arthritis (RA) (the most common autoimmune condition), results in systemic and 
local inflammation, disability, joint erosion and musculoskeletal deterioration. Osteoporosis, 
-a skeletal disease resulting in low bone mass (46) which manifests clinically as fractures 
(132), is a major source of morbidity for people with RA (133). The presence of circulating 
inflammatory cytokines, decreased mobility of patients with RA (resulting in a sedentary 
lifestyle), as well as certain medications taken to treat the disease such as corticosteroids and 
methotrexate, all contribute towards an increased incidence of osteoporosis in patients with 
RA (50). The incidence of osteoporosis in patients with RA has been reported to be almost 
double (18%) of that in non-RA patients (10%) (134-136). 
 
Studies have shown that the majority of bone density loss in RA occurs in the first six months 
of acquiring disease (47). Furthermore, patients with higher disease activity have been shown 
to exhibit greater loss in bone mineral density (BMD), as well as higher indices of bone 
metabolism (137). One third of women with osteoporosis will incur a fracture in their lifetime 
(138); and the decreased muscle mass present (sarcopenia) in patients with RA predisposes 
these patients to falling, further increasing fracture risk (139). Patients with RA often present 
with sarcopenia and either preserved, or increased fat mass (sarcopenic obesity) (63).  
 
Physical activity is an important, non-pharmacological method to increase (or preserve) 
BMD (140), and the most efficient means to increase lean muscle mass and therefore reduce 
sarcopenia in RA (61). Furthermore, it is an inexpensive treatment option. Numerous exercise 
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interventions have been implemented in healthy participants with low BMD with successful 
results (140), however fewer studies exist examining the effects of exercise on BMD in 
patients with RA. Haakkinnen et al in 2001 reported that low intensity strength training over 
a period of two years in a group of RA patients increased BMD significantly more so than 
stretching exercises did in a control group of RA patients (who experienced a decreased 
BMD) (141).  
 
To the best of our knowledge, the association between objectively measured habitual physical 
activity levels and BMD in patients with RA has not been studied.  Kroot et al (2001), found 
that BMD loss was significantly attenuated in postmenopausal RA patients who had a higher 
activity load (as assessed by a questionnaire that quantified time spent walking and multiplied 
it by body mass in order to obtain ‘activity load’ at the hip), than those with a lower activity 
load, and experienced a greater loss in BMD over a six year period (142).  
 
Other cross sectional studies report lower levels of subjectively measured physical activity to 
be correlated with lower BMD values in patients with RA (48); and although these studies are 
important, there is still a lack of evidence linking objectively measured habitual physical 
activity levels to bone status in patients with RA. We have recently used accelerometry as a 
means to quantify habitual activity levels in patients with RA (143). The current study aimed 
to determine the association between objectively measured habitual physical activity levels 
(using an Actical accelerometer) and bone health in a group of patients with RA.  
 
Methods: 
 
Participants and Study Design: 
Thirty one Black, female patients with established RA participated in this study. Patients 
were recruited from the Rheumatology Clinic at the Chris Hani Baragwanath Academic 
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Hospital, Soweto, South Africa between April 2013 and September 2013. Consenting 
patients were included if they were older than 18 years, had been diagnosed with RA 
(according to the 1987 ACR criteria (123)) at least three years previously, were on stable 
drug therapy (prednisone <10mg/day), and had been for at least three months previously. 
Patients were excluded if they were HIV+, were using bisphosphonates or corticosteroid 
injections, had any co-morbidities that could potentially impact on physical activity levels, 
were using assistive walking devices, had previously had hip or knee joint replacement 
surgery, and if they were pregnant. Ethical approval was obtained from the Human Research 
Ethics Committee of the University of the Witwatersrand (M130113), and all participating 
patients gave written informed consent.  
 
All patients were assessed at two separate visits. At the first visit patients were assessed for 
disease activity using the Compound Disease Activity Index (CDAI) by the same physician, 
and were asked to complete the modified Health Assessment Questionnaire (mHAQ), the 
Short Form-36 questionnaire (SF-36), as well as a demographics questionnaire. At the second 
visit, patients underwent a Dual X-Ray Absorptiometry (DXA) scan to assess Bone Mineral 
Density (BMD) and body composition. Anthropometric measurements were taken and 
included height (measured to the nearest mm using a stadiometer (Holtaine, UK)), and body 
mass (measured to the nearest 100g using a standard digital scale (Dismed, USA), as well as 
waist and hip circumference, and leg girth (measured to the nearest cm using a standard tape 
measure). From these measurements Body Mass Index (BMI) was calculated, as was 
waist:hip ratio.  
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Physical Activity: 
Patients were fitted with an Actical (Respironics Inc., Murrysville, PA, USA) accelerometer 
(for the assessment of habitual physical activity) that was worn on a Velcro belt on the hip of 
the dominant leg for a two week period. Patients were instructed to wear the accelerometer 
all day, and to remove the device only while sleeping, bathing or showering. Patients then 
returned the accelerometer to the clinic two weeks later. Actical data were recorded in one 
minute epochs and data were reduced by removing only full days of non-wear time as 
observed by a full day of zero activity counts. Sleep time was removed by direct observation 
of the data, and only the remaining data were considered as wear time.  
 
Data Reduction: 
Data were reduced according to standard criteria (25) where non-wear time was considered as 
more than 60 minutes of consecutive zero activity counts. A valid day was considered to have 
at least 10 hours wear time. Non-valid days were removed, and patients were excluded if they 
had less than four valid days of data. Two patients were consequently excluded, and data 
analysis was conducted on the remaining 29 patients. 
 
Activity Data: 
 The Actical accelerometer records activity counts, which (based on the number of counts per 
epoch), are then classified by the inbuilt Actical software into thresholds of intensity; namely 
sedentary (0-100 counts), light activity (100-1485 counts), moderate activity (1486-5557 
counts), and vigorous activity (5558 counts). Data were thus considered “active” data if a 
minute epoch had an activity count that was greater than 100 (i.e.: light to moderate/vigorous 
activity). Activity bouts were then calculated as the number of times per day that at least 10 
consecutive minutes of “active data” were recorded. We defined compliance with physical 
activity guidelines as ≥30 min of “active” time performed in bouts of 10 minutes at least 
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three times per week according to guidelines for rheumatic and healthy populations (4, 88). 
The number of times that sedentary activity was “broken up” was calculated as the number of 
times per day that a sedentary minute epoch (<100 counts) was followed by an active minute 
epoch (>100 counts); and these data were thus considered as a break in sedentary time (144). 
Data were thus reported as average activity counts per day; percentage of time spent in 
sedentary, light, moderate and vigorous activity thresholds; average number of activity bouts 
per day, as well as average number of sedentary breaks per day.  
 
BMD assessment: 
All patients were assessed for site specific areal BMD at the left hip, lumbar spine (L1-L4), 
and whole body. All scans were performed by the same qualified technician on the same 
machine (Hologic QDR 4500A, Hologic, Boston, USA). The machine was routinely 
calibrated throughout the study, and a phantom spine was scanned daily to determine 
coefficients of variation of the machine. Coefficients of variation during the course of the 
study for spine BMD were 0.31%. 
 
In order to classify patients’ bone status, T and Z scores were calculated based on the total 
hip BMD, and according to the reference values in the NHANES database (145). T scores 
were calculated using reference values for Caucasian women at peak bone mass 
(BMD=0.971 with a SD of 0.114), and Z scores were calculated using reference values for 
age, sex and ethnicity- matched women. According to the WHO classification criteria, a T 
score >-1 SD above the mean reference value is considered normal, while a T score -1 SD 
and >-2.5 SD the reference value is considered osteopaenic (low bone mass), and a T score -
2.5 SD the reference value is considered osteoporotic. Therefore, in the current study, we 
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classified patients with a T score -1 at the hip into a low bone mass group and those with a 
T score>-1 into a normal bone mass group. 
 
Total lean body mass (LBM) was obtained from the body composition component of the 
whole body DXA scan, and appendicular lean mass (ALM) was calculated by adding left and 
right- arm and leg- lean masses. Thereafter, linear regression was used to model the 
relationship between ALM on height and fat mass. Residuals of the regression were used to 
identify those with lower ALM than predicted for their fat mass. Participants with a negative 
residual value were considered relatively sarcopenic, and those with a positive residual value 
were considered as relatively muscular. The equation was as follows:  
ALM=-14.69+(0.25*percentage fat mass)+(16.08*height)  
Sarcopenia was set at the 20th%ile of the distribution of the residuals as suggested by 
Newman et al in 2003 and Figueirdo et al in 2014 (146-147).  
 
Statistical Analysis: 
Statistical analysis was carried out using Statistica version 12. All data are presented as 
mean(SD) (except where otherwise stated), and a p value 0.05 was considered significant. 
Student’s unpaired t-tests and Mann Whitney U tests were used to compare physical activity, 
patient characteristics, and RA disease activity data between low and normal bone mass 
groups.  A Fishers exact test was used to determine differences in prevalence of sarcopenia 
between groups. Pearson’s correlation was used to determine associations between known 
confounders of BMD in patients with RA. Thereafter, an ANCOVA was used to assess 
differences in physical activity patterns between the low and normal bone mass groups. The 
strongest univariate correlates of total hip BMD, that were also found to be different between 
the two groups (excluding collinear variables), were used as covariates i.e.: disease duration, 
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body mass, height and mHAQ. Power analysis indicated a 99% chance of detecting a 
difference between the two groups in average activity counts per day as significant at the 5% 
level (two tail). 
 
Results: 
Thirty one patients with established RA completed this study. Two patients were excluded 
from the analysis due to invalid activity data. Of the remaining patients, eight were classified 
as having low bone mass according to peak BMD reference values at the total hip, and the 
remaining 21 were considered to have normal bone mass. Patient characteristics are shown in 
Table 2.6. There was no significant difference in age between the two groups, however RA 
disease duration was almost twice as high in the low bone mass group (although not 
significant). Patients with low bone mass also had a lower BMI (p=0.03), as well as smaller 
waist and hip circumferences (p=0.01 and p=0.02 respectively), and a trend towards lower 
leg girth (p=0.06). Waist:hip ratio was, however, not significantly different between the two 
groups (0.83(0.06) vs. 0.80(0.05), for the normal bone mass and low bone mass groups 
respectively, p=0.25). Furthermore, patients with low bone mass had significantly less body 
fat (p=0.02), and significantly lower ALM (p<0.01). 
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Table 2.6. Participant characteristics of low and normal bone mass groups. Data are 
mean(SD). 
 
 Normal Bone Mass 
(n=21) 
Low Bone Mass 
(n=8) 
p-value 
Age (years) 51(10) 57(12) 0.19 
Disease Duration (years) 9.6(8.5) 16.5(10.6) 0.08 
Height (m) 1.59(0.07) 1.52(0.07) 0.03* 
Body mass (kg) 88.85(21.30) 63.51(11.57) <0.01* 
BMI (kg/m2) 35.30(7.63) 28.20(7.82) 0.03* 
Waist circumference (cm) 101.19(15.25) 85.00(10.46) 0.01* 
Hip circumference (cm) 122.21(16.65) 106.06(11.79) 0.02* 
Leg girth (cm) 64.86(8.98) 57.50(8.62) 0.06 
Fat mass (kg) 37.18(11.87) 24.90(9.59) 0.02* 
ALM (kg) 20.29(3.69) 15.47(1.95) <0.01* 
LBM(kg) 44.20(12.42) 36.18(2.83) 0.09 
Sarcopenic (%) 14 25 0.59 
Negative residual value (%) 57 63 0.23 
*p≤0.05 
BMI – body mass index, ALM – appendicular lean mass, LBM – total lean body mass. 
 
 
Rheumatoid arthritis disease activity was more severe in the low bone mass group (Table 
2.7). Disability as assessed by the mHAQ, was higher in patients with low bone mass 
(p=0.05). Tender 3(3) vs. (1(1), p=0.03) and swollen 4(4) vs. (2(2), p=0.05) joint counts were 
significantly higher in the low bone mass group than in the normal bone mass group 
respectively. Similarly, CDAI was worse (approaching significance) in the low bone mass 
group (p=0.07). Pain levels, duration of morning stiffness, and fatigue levels were not 
different between the two groups (p>0.05). 
Table 2.7. Disease activity data for low and normal bone mass groups. Data are 
mean(SD). 
 
mHAQ – modified health assessment questionnaire, CDAI – Compound disease activity index. 
 Normal Bone Mass 
(n=21) 
Low Bone Mass 
(n=8) 
p-value 
mHAQ (/3) 1.0(0.7) 1.6(0.7) 0.05* 
CDAI  7.7(6.1) 13.8(10.9) 0.07 
Pain (/5) 4.2(2.6) 2.8(2.5) 0.22 
Stiffness (minutes) 22(45) 31(61) 0.68 
Fatigue (/5) 3.4(2.7) 4.7(3.1) 0.28 
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Anthropometric and disease activity variables that have previously been shown to confound 
BMD in patients with RA (148) were correlated with total hip BMD. Total hip BMD was 
positively associated with ALM (p<0.01, r=0.79), height (p=0.01, r=0.49), body mass 
(p<0.01, r=0.74), waist and hip circumference (p<0.01, r=0.66 and p<0.01, r=0.60 
respectively), and leg girth (p=0.01, r=0.48). Total hip BMD was negatively associated with 
disease duration (p=0.05, r=-0.38) and HAQ-DI (p<0.01, r=-0.55). Trends towards significant 
correlations were seen for age (p=0.07, r=-0.34), and CDAI (p=0.09, r=-0.33).  
 
By study design hip BMD was significantly lower in the low bone mass group 
(0.75(0.07)g/cm2) than the normal bone mass group (1.06(0.11)g/cm2), p<0.01. In 
conjunction with having lower hip BMD, lumbar spine (0.72(0.07)g/cm2 vs. 0.98(0.11)g/cm2, 
p<0.01) and whole body  BMD (0.93(0.06)g/cm2 vs. 1.12(0.08)g/cm2, p<0.01) were also 
lower in the low bone mass group compared to the normal bone mass group. There was no 
significant difference in number of days that the participants wore the accelerometers for 
(p=0.60), (Table 2.8). Patients with low bone mass also had significantly fewer breaks in 
sedentary activity per day than the normal bone mass group (p=0.03), however did not 
exhibit less activity bouts per day than the normal bone mass group (p=0.36), (Table 2.8). 
Participants who achieved the recommended physical activity guidelines had significantly 
lower hip Z scores than patients who did not meet the guidelines for physical activity, 
(p=0.03), while hip T scores were not different between those who met the guidelines for 
physical activity and those who did not (p=0.12) (Figure 2.6). Furthermore, even after 
adjusting for RA disease duration, body mass, height and mHAQ; physical activity indices 
were significantly lower in the low bone mass group than the normal bone mass group. 
Figure 2.7 shows the significant differences between the two groups in adjusted percentage of 
time spent in sedentary (p<0.01), light (p<0.01), and moderate (p<0.01) thresholds of activity 
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per day. Furthermore, the low bone mass group had fewer average activity counts per day 
(5425(1222)), than did the normal bone mass group (8123(2164)), p<0.01).  
 
Table 2.8. Physical activity data and sedentary behaviour of the normal and the low 
bone mass group. Data are mean(SD). 
 
 Normal Bone mass 
(n=21) 
Low bone mass 
(n=8) 
P-Value 
Days worn 7(2) 7(3) 0.60 
Weartime (hours/day) 17(3) 16(3) 0.55 
Sedentary activity (min/hour) 39(6) 44(6) 0.05* 
Light activity (min/hour) 14(4) 11(5) 0.09 
Moderate activity (min/hour) 7(3) 5(2) 0.05* 
Vigorous activity (min/hour) 0(0) 0(0) 0.40 
Activity Bouts (number/day) 3(2) 2(1) 0.36 
Bout time (min/bout) 13(7) 13(6) 0.96 
Sedentary for 60 min (number/day) 7(3) 8(3) 0.55 
Sedentary Breaks (number/day) 72(21) 53(18) 0.03* 
Sedentary % 65(11) 74(10) 0.05* 
Light % 23(6) 18(8) 0.10 
Moderate % 12(6) 8(3) 0.06 
Vigorous % 0(0) 0(0) 0.40 
*p≤0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. T and Z scores between patients who met the guidelines for physical activity and those who did not. 
*p<0.05 
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Figure 2.7. Percentage of day spent in each threshold of activity between the normal bone mass and low bone 
mass groups. Data are adjusted for body mass, height, disease duration and modified health assessment 
questionnaire (mHAQ). Data are mean(SEM) 
** p≤0.01 
 
 
Discussion: 
We explored the association between varying habitual physical activity levels on bone health 
in a group of patients with RA. Patients who were classified as having low bone mass had 
significantly lower levels of habitual activity throughout the day than those who had normal 
bone mass, even after adjustment for RA disease duration and disease activity. Furthermore, 
patients with low bone mass spent significantly more time being sedentary, and less time in 
light, moderate, and vigorous activity, and had fewer breaks in sedentary time than those with 
normal bone mass. Our findings lend support to the possibility that higher levels of habitual 
 101 
physical activity (even in a population that remains highly sedentary), and more frequent 
breaks in sedentary activity are associated with higher BMD in patients with RA. 
 
In the present study, we found significant differences between the two groups for time spent 
in each threshold of physical activity (sedentary, light, moderate and vigorous). The greatest 
differences were evident in time spent in sedentary and light activity. Recently, literature has 
focussed on the effects of a sedentary lifestyle on metabolic health, and studies have shown 
that breaking up sedentary time with light activities more frequently during the day can have 
protective effects on metabolic health, regardless of time spent in moderate and vigorous 
activity (117). In our study, participants with low bone mass spent over two hours more per 
day being sedentary than the normal bone mass group. Our normal bone mass group spent 
over an hour more per day in light activity, and just under an hour more in moderate activity 
compared to the low bone mass group. Furthermore, the normal bone mass group broke up 
their sedentary time approximately 30% more frequently than did the low bone mass group, 
even though their cumulative sedentary time was lower. The evidence of greater amounts of 
time spent engaging in light and moderate physical activity in our normal bone mass group 
may indicate that increased physical activity, even if only to break up sedentary time more 
frequently, does offer some protection against RA related bone loss. These findings are 
important for patients with RA who have been shown to be more sedentary than their healthy 
counterparts (143).  
 
In our study, participants with normal bone mass had on average 150% greater physical 
activity counts per day than the low bone mass group. This disparity in activity between the 
two groups was independent of RA disease activity or disease duration, and suggests that 
even low levels of habitual physical activity levels in a very sedentary population may have a 
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significant impact on BMD. Results from studies conducted in healthy, postmenopausal 
women, show that women who perform two hours more moderate activity per week than 
their less active counterparts have significantly higher BMD at the hip (138). Hagberg and 
colleagues (2001) reported that increased physical activity levels (as assessed via 
questionnaire) in postmenopausal Caucasian women were associated with increased BMD at 
the trochanter, lumbar spine, and total body (149). Of interest, the authors found that women 
who had been moderately active throughout their lives had higher BMD than those who had 
been sedentary, or even very athletic. These findings mirror the present findings, in that 
simply being active (whether through engaging in light or moderate activity), may be 
protective of bone health; and that vigorous activity (which is likely to be unfeasible in an 
RA population) may not be the only necessary intensity of activity for maintaining BMD. 
Furthermore, compared to the normal bone mass group, patients with low bone mass had 
significantly lower total ALM, and a trend towards lower LBM; indicating a greater presence 
of sarcopenia in this group. The combination of sarcopenia and low bone mass increases the 
likelihood of incurring a fracture through increased susceptibility to falling. Physical activity 
has been recommended as a means to treat both sarcopenia (61), and osteoporosis (139) in 
RA. Excessive time spent in sedentary activity, however, appears to be detrimental to bone 
health and should be counteracted as much as possible. 
 
Guidelines for physical activity in a rheumatic population are varied in the current literature. 
The American College of Sports Medicine (ACSM) recommends that older adults, and 
people with clinically significant chronic conditions such as RA, follow similar, yet modified 
guidelines to those for a healthy population (30 minutes of moderate activity on most days of 
the week) (88). Patients with arthritis are specifically recommended to participate in low 
intensity activity (light to moderate), three to five times per week (150-151). Guidelines for a 
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healthy population recommend that periods of physical activity occur in bouts of at least 10 
continuous minutes each (4). In the present study, we defined the guidelines as spending 30 
minutes of activity accumulated in 10 minute bouts, at least three times per week. We found 
that those patients who met these guidelines had significantly lower Z scores than those who 
did not, yet T scores were not different between the two groups of patients. This is suggestive 
of increased levels of habitual physical activity being beneficial in attenuating loss in BMD 
not related to the normal aging process (i.e.: presumably related to the RA disease process) in 
patients with RA. Therefore, physical activity may be able to counteract disease related bone 
loss in patients with RA to a certain degree.  
 
In our study, participants with normal bone mass had an average BMI which classified them 
as severely obese (according to the WHO), and had significantly higher fat mass than the low 
bone mass group. Fat mass may offer a protective role for the maintenance of bone density; 
and women (whether healthy or diseased) with smaller stature and lower body mass have 
continuously been shown to be more predisposed to developing osteoporosis (152). It is 
interesting to note that in the present cohort, even patients with low bone mass had an 
average BMI which classified them as overweight; and lower physical activity levels were 
related to lower bone mass even in these obese patients. In healthy, postmenopausal female 
populations, physical inactivity has been associated with increased risk of hip fracture in 
every category of BMI (153). 
 
Low BMD has been also associated with more severe RA disease activity (48), and the 
present study corroborated these results. In our study, participants with low bone mass 
showed a trend towards higher CDAI scores, and had significantly more tender and swollen 
joints. Furthermore, participants with low bone mass exhibited higher mHAQ scores, 
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indicating a greater degree of functional impairment. Previous research has shown that 
greater functional impairment is associated with a greater risk of developing osteoporosis, 
specifically at the hip (47).  
 
Our study is limited by a small sample size, leading to small numbers in the low bone mass 
group. Furthermore, discord between classification criteria for defining osteoporosis must be 
considered. Although the most current WHO criteria (46), and the 2013 ISCD guidelines for 
classifying osteoporosis state that peak normative values for a Caucasian female should be 
used in all female cases regardless of race; it is still unknown whether fracture risk is the 
same in Black and Caucasian populations (133). Another limitation is the potential 
confounding effect of menopausal status on bone health, which was not assessed in this 
study. 
 
Notwithstanding the limitations of this study, we have used an objective measure of physical 
activity to show that increased habitual physical activity levels are associated with better 
bone mass in Black, female patients with RA, regardless of disease duration or severity. The 
results of the present study suggest that patients with RA should be encouraged to increase 
physical activity levels, and to avoid sedentary behaviour. Patients with normal bone mass 
were less sedentary, and engaged habitually in greater amounts of light and moderate 
activities, and patients who met recommended physical activity guidelines exhibited better 
BMD for their age. Physical activity is an important, non-pharmacological treatment for low 
BMD, and should be emphasised as an affordable, sustainable treatment option for patients 
with RA. 
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2.4. Study 3 – Positive Effects of a 12 week WBV Intervention on Bone 
Mineral Density and Fatigue are Sustained in a Population with 
Established RA1 
 
Trial Number: PACTR201405000823418 (19/05/2014) 
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Abstract 
 
Introduction: Rheumatoid arthritis (RA) predisposes patients to developing osteoporosis. 
We aimed to determine the effects of a whole body vibration (WBV) intervention on 
functional ability, and bone mineral density (BMD), as well as on RA disease activity, health 
related quality of life (HRQoL) and habitual physical activity profiles in participants with 
stable, established RA. Methods: Thirty one female participants with RA were randomly 
assigned to a control group (CON, n=15) or a WBV group (n=16). The CON group continued 
with their normal activities for three months, while the WBV group underwent a three month 
WBV intervention, consisting of 15 minutes of intermittent vibration, performed twice per 
week. Participants were assessed at baseline, as well as following the intervention period, and 
three months post intervention for functional ability using mHAQ; for BMD and body 
composition using DXA; for RA disease activity using CDAI and for physical activity 
profiles using accelerometry. Results: Participants in both groups were well matched for all 
variables at baseline. Following the intervention period, functional ability was significantly 
improved in the WBV group (1.22(0.19) to 0.92(0.19), p=0.02). Hip BMD was significantly 
reduced in the CON group (0.97(0.05) to 0.84(0.05) g.cm-2, p=0.01), while no significant loss 
was seen in the WBV group (1.01(0.05) to 0.94(0.05) g.cm-2, p=0.50). Furthermore fatigue 
levels were improved in the WBV group after three months (4.4(0.63) to 1.1(0.65), yet 
remained unchanged in the CON group at both follow ups (p=0.01). RA disease activity did 
not change in either group at either follow up. Ten minute bouts of light to moderate physical 
activity were significantly reduced in the CON group over the intervention period (2.8(0.61) 
to 1.8(0.64) bouts per day, p=0.01), and were preserved in the WBV group (3.1(0.59) to 
3.0(0.61) bouts per day, p=0.70). Conclusion: Intermittent WBV shows promise for 
sustained improvements in functional ability, for attenuating loss of bone mass at the hip, as 
well as for improving fatigue levels in patients with established RA. 
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Introduction: 
 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition resulting in 
severe pain, joint erosion, and decreased functional ability. RA also predisposes patients to 
developing osteoporosis. This may be as a result of the presence of circulating inflammatory 
cytokines inherent to the disease, the decreased mobility of RA patients, resulting in a 
sedentary lifestyle, or due to certain medications taken to treat the disease. Levels of mobility 
and functional ability have been shown to be related to BMD; as have age, stature, and sex, 
independently of RA disease (48-49). 
 
The health assessment questionnaire (HAQ), which is a disease specific measure of 
functional ability for patients with RA, is an increasingly widely used outcome measure for 
RA (33). A large qualitative study conducted in female patients with RA found that patients 
report pain and decreased functional ability as having the most widespread effect on their 
daily lives (154). Inability to perform normal daily activities not only decreases quality of 
life, but also further perpetuates a sedentary lifestyle. Moderate and vigorous habitual 
physical activities have known osteogenic effects (155). Conversely, increased time spent in 
sedentary behaviours has been independently associated with poor bone mass in healthy 
populations (156). Functional ability as assessed by the HAQ, has been shown to be 
improved following certain exercise interventions conducted on patients with RA (90), yet 
there is still no consensus on the most feasible type of exercise intervention for patients with 
chronic pain and , often, severe disability. 
 
Whole body vibration (WBV) comprises of a mechanical vibration platform that produces 
energy via forced oscillation. The vibratory waves are then transferred to an individual via 
propagation through the feet, legs, trunk and the head (93). WBV has been shown to increase 
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strength, balance, and to improve pain in various chronic conditions (97). Furthermore, 
studies conducted in postmenopausal women (99), as well as in younger healthy populations 
(96), and athletes with low BMD (100), have shown WBV  to improve BMD, particularly at 
the hip and spine (101-102). Although the exact mechanisms whereby WBV increases BMD 
are unclear, it is likely that there are multiple mechanisms at play. Whole body vibration has 
been shown to activate fluid flow in the caniliculi and lacunae of bone matrix in rats (103), in 
a manner proportional to loading frequency. This fluid flow creates shear stress on the plasma 
membrane of osteocytes, bone lining cells, and osteoblasts, which therefore respond 
accordingly (56). WBV thus activates mechanostransduction in bone and stimulates 
osteogenesis (103). Furthermore, muscle forces have been shown to exert the greatest 
osteogenic stimulus on bone, and the generation of these forces through vibration stimulus is 
likely a contributor to the skeletal adaptations that occur (94).  
 
Exercise interventions in RA are not always feasible, specifically bone loading exercises 
which need to be dynamic in order to increase bone mass (56). Whole body vibration is safe, 
requires minimal effort and movement, has positive effects on muscle strength, and 
stimulates bone loading. Further, WBV has been shown to decrease fatigue levels in patients 
with fibromyalgia (157), and to decrease pain levels in patients with knee osteoarthritis (158).  
WBV has not, to the best of our knowledge, been used as a form of exercise in patients with 
RA. Furthermore, of the studies which have used WBV in other populations, none have 
examined whether WBV induced effects are sustained following an intervention. The aims of 
our study were therefore to determine the effects of a WBV programme on functional ability 
in participants with established RA, as well as to determine any effects WBV may have on 
BMD, RA disease activity, health related quality of life (HRQoL) as assessed by fatigue and 
pain levels, physical activity profiles, and body composition. 
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Methods: 
 
Study Design: 
Thirty nine Black, female participants with stable and established RA were initially enrolled 
in this study, and were assigned (using an alternating method) into either a WBV group who 
underwent the WBV intervention, or a control (CON) group who continued with their normal 
daily activities. The study was conducted at one site (Chris Hani Baragwanath Academic 
hospital). All eligible participants were initially assessed at enrollment (baseline assessment). 
Participants then underwent the relevant intervention for a three month period, following 
which all participants returned for a follow up assessment (three month assessment) in order 
to determine the effects of the WBV intervention in comparison to the CON group. 
Thereafter, all participants continued with their normal activities for another three months, 
following which a three month post intervention assessment was conducted (six month 
assessment) in order to determine whether any WBV effects were sustained.  
 
Participants: 
Participants were recruited from the Rheumatology Clinic at the Chris Hani Baragwanath 
Academic Hospital in Soweto, South Africa. Consenting participants were included if they 
were older than 18 years, had been diagnosed with RA (according to the 1987 ACR criteria 
(123)) at least three years previously, were on stable drug therapy (prednisone <10mg/day), 
and had been for at least three months previously. Participants were excluded if they were 
HIV+, were using bisphosphonates or corticosteroid injections, had any co-morbidities that 
could potentially impact on physical activity levels, were using assistive walking devices, had 
previously had hip or knee joint replacement surgery, and if they were pregnant. Ethical 
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approval was obtained from the Human Research Ethics Committee of the University of the 
Witwatersrand (M130113) 
 
Outcome Assessments: 
Functional Ability assessment 
Participants were assessed for functional ability using the modified Health Assessment 
Questionnaire (mHAQ). The mHAQ is a well validated, self-administered, RA specific 
questionnaire that assesses functional ability in eight domains of daily activities where scores 
range from 0 (no disability) to 3 (severe disability) (29).  
 
BMD assessment 
Participants underwent a Dual X-Ray Absorptiometry (DXA) scan to assess Bone Mineral 
Density (BMD) and body composition. All participants were assessed for site specific areal 
BMD at the left hip, lumbar spine (L1-L4), and whole body. All scans were performed by the 
same qualified technician on the same machine (Hologic QDR 4500A, Hologic, Boston, 
USA). The DXA operator was not aware of the assignment of the participants to the WBV or 
CON group. The machine was routinely calibrated throughout the study, and a phantom spine 
was scanned daily to determine coefficients of variation of the machine. Coefficients of 
variation during the course of the study for spine BMD was 0.31%. Z scores were calculated 
based on the total hip BMD, and according to the reference values in the NHANES database 
(145).  
 
Disease Activity and HRQoL measurements 
All participants were assessed for disease activity using the Clinical Disease Activity Index 
(CDAI) by the same physician (MAM, who was blinded to the assignment of participants to 
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either the WBV group or CON group). Participants were also asked to assess their fatigue 
levels using a Lickert scale anchored at 0 (not tired at all) and 5 (the most tired I have ever 
felt), as well as their pain anchored at 0 (no pain) and 5 (unbearable pain).  
 
Physical Activity 
Participants were fitted with an Actical (Respironics Inc., Murrysville, PA, USA) 
accelerometer (for the assessment of habitual physical activity) worn on a Velcro belt on the 
right hip for a one week period at baseline (assessment 1), at the end of the intervention 
(assessment 2) and three months after that (assessment 3). Participants then returned the 
accelerometer to the clinic one week later. Participants were instructed to wear the 
accelerometer all day, and to remove the device only while sleeping, bathing or showering. 
Actical data were recorded in one minute epochs and data were reduced by removing only 
full days of non-wear time as observed by a full day of zero activity counts. Sleep time was 
removed by direct observation of the data (159), and only the remaining data were considered 
as wear time. Three days of wear time with a minimum of 10 hours of wear time per day was 
required for inclusion in the analysis (25).  
 
Activity Data 
 The Actical accelerometer records activity counts, which (based on the number of counts per 
epoch), are then classified by the inbuilt Actical software into thresholds of intensity; namely 
sedentary (0-100 counts), light activity (100-1485 counts), moderate activity (1486-5557 
counts), and vigorous activity (5558 counts). Data were thus considered “active” data if a 
minute epoch had an activity count that was greater than 100 (i.e.: light to moderate/vigorous 
activity). Activity bouts were then calculated as the number of times per day that at least 10 
consecutive minutes of “active data” were recorded (160). The number of times that 
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sedentary activity was “broken up” was calculated as the number of times per day that a 
sedentary minute epoch (<100 counts) was followed by at least one active minute epoch 
(>100 counts); and these data were thus considered as a break in sedentary time (144). Data 
were reported as average activity counts per day; percentage of time spent in sedentary, light, 
moderate and vigorous activity thresholds; average number of activity bouts per day, as well 
as average number of sedentary breaks per day. Participants wore the same Actical at both 
visits in order to minimise inter-device variability.  
 
Body Composition 
Height (measured to the nearest mm using a stadiometer (Holtaine, UK)), and body mass 
(measured to the nearest 100g using a standard digital scale (Dismed, USA) were measured. 
From these measurements Body Mass Index (BMI) was calculated. Total lean and fat mass 
measurements were obtained from the body composition component of the whole body DXA 
scan. Skeletal muscle index (SMI) was calculated by adding appendicular lean mass (left and 
right- arm and leg- lean masses), and dividing by height squared (147). 
 
Intervention: 
The WBV group performed two 15 minute session per week of supervised WBV, which 
consisted of ten repetitions standing on the vibration plate for 60 seconds, followed by a 30 
second rest period. This intermittent protocol was designed to increase osteogenic effects (53) 
and has previously been used successfully (Prioreschi et al, 2012). All WBV training was 
performed on the same vertical synchronous vibration plate (DKN XG 5.0, DKN 
Technology, California, USA), and vibration was set at 3mm amplitude and a frequency of 
30Hz in all instances. Participants were taught the correct posture while on the vibration plate 
in order to maximise the vibration effect and standardise procedure; and all sessions were 
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monitored by the primary investigator for compliance and accuracy. All participants in the 
WBV group completed the required 24 sessions of WBV training. The CON group was 
instructed to continue with their normal daily activities for the three month period, and 
compliance was assessed using accelerometry before and after the intervention period to 
ensure that activity levels did not change.   
 
Statistical Analysis: 
All analyses were conducted using Stata 12/IC 12.0 for Mac (StataCorp LP, College Station 
TX, USA). Student’s unpaired t-tests were used to compare HAQ, BMD, physical activity, 
patient characteristics, and RA disease activity data between the WBV group and CON group 
at baseline. Thereafter, to assess the effect of the intervention on the primary and secondary 
outcomes, individual linear mixed models were used for each dependent variable. Random 
intercepts were used to account for within person correlation of repeated measures. To test a 
priori hypothesis, the estimated mean scores at each time point (three- and six months post 
baseline) were contrasted with baseline values. Model fit was assessed using residual plots 
and diagnostics. The WBV was then divided into responders and non-responders using 
percentage change from baseline in whole body BMD and mHAQ. Various outcome 
variables were then compared in these two groups using student’s unpaired t-tests. All values 
are mean (SD) or mean (SEM), and a p value 0.05 was considered significant. A sample 
size calculation (ß=0.10) showed that at a 5% level (using an SD of 0.19) we would require a 
sample of 8 participants in each group in order to detect a minimum clinically important 
difference of 0.22 in HAQ score (161) with a power of 90%.  
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Results: 
Patient Characteristics: 
Following enrollment, there were eight dropouts due to participants not being able to attend 
the required assessments. These participants were not different from completers in terms of 
age, disease duration, or functional ability (p>0.05). Therefore, 31 participants allocated to 
the WBV group (n=16) or the CON group (n=15) completed the study. There were no 
participants lost to follow up after the three month intervention period, however at the six 
month assessment (3 month post intervention period), one patient in the WBV group and 
three participants in the CON group were lost to follow up due to no longer being interested 
in participating, or not being able to attend the required assessments (Figure 2.8).  
 
 
Figure 2.8. Number of study participants initially enrolled and followed up at each assessment time point.  
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Upon entry into the study, there were no differences between the WBV group and the CON 
group for any of the variables measured as shown in Table 2.9. There were no significant 
differences between the WBV and CON groups for BMD at any of the sites measured at 
baseline, specifically at the total hip (1.01(0.16)g.cm2 vs. 0.97(0.20)g.cm2 , p=0.50), lumbar 
spine (0.92(0.16)g.cm2  vs. 0.91(0.15)g.cm2, p=0.84), and whole body sites (1.09(0.12)g.cm2 
vs. 1.07(0.14)g.cm2, p=0.70). Furthermore, there were no significant differences between 
average physical activity levels (p=0.63, data shown in Table 2.10). 
 
Table 2.9. Patient characteristics at baseline in the WBV group and CON group. Data 
are mean(SD). 
* p<0.05 
 
Functional Ability 
Baseline, post intervention (three month)-, and six month follow up data for mHAQ, BMD, 
RA and physical activity variables are presented in Table 2.10. In the WBV group, mHAQ 
was significantly decreased (p=0.02) at the six month follow up as compared to baseline, 
while no changes were observed in the CON group at either the three or six month 
assessments (Figure 2.9).  
 WBV 
(n=16) 
CON 
(n=15) 
p value 
Age (years) 51(10) 52(12) 0.81 
Disease duration 
(years) 
10(11) 12(8) 0.54 
Height (m) 1.59(0.07) 1.55(0.08) 0.16 
Body mass (kg) 85.24(21.96) 80.76(23.63) 0.59 
Lean body mass (kg) 45.65(8.48) 42.11(7.96) 0.25 
% body fat 42(7) 41(6) 0.55 
CDAI 11(9) 8(6) 0.33 
mHAQ (max. of 5) 1.22(0.67) 1.13(0.86) 0.74 
Pain (max. of 3) 4(3) 4(3) 0.92 
Fatigue (max. of 5) 4(3) 3(3) 0.35 
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Table 2.10. Mixed model analysis between the WBV and CON groups at baseline, three- and six month assessments. Data are 
mean(SEM) 
 
  WBV  
Mean (SEM) 
CON 
Mean(SEM) 
Mixed models analysis 
(p value) 
Outcomes Variables Baseline 3 month 6 month Baseline 3 month 6 month group Time Group*time 
Functional 
Ability 
mHAQ 
(max. of 
3) 
1.22(0.19) 1.02(0.19) 0.92(0.19)* 1.13(0.20) 1.06(0.20) 1.17(0.20) 0.79 0.25 0.18 
Bone Whole 
Body 
BMD 
(g.cm2) 
1.09(0.03) 1.10(0.03)^ 1.10(0.03)* 1.07(0.03) 1.07(0.03) 1.05(0.03)* 0.47 0.15 <0.01 
Hip BMD 
(g.cm2) 
1.01(0.05) 0.96(0.05) 0.94(0.05) 0.97(0.05) 0.94(0.05) 0.84(0.05)* 0.37 0.01 0.50 
Spine 
BMD 
(g.cm2) 
0.92(0.04) 0.92(0.04) 0.92(0.04) 0.91(0.04) 0.91(0.04) 0.91(0.04) 0.87 0.84 0.74 
Z score 0.32(0.32) -0.14(0.32) -0.15(0.33) 0.10(0.34) -0.11(0.34) -0.82(0.38)* 0.38 0.02 0.50 
HRQoL and 
Disease 
activity 
Fatigue 
(/5) 
4.4(0.63) 1.1(0.65)* 3.7(0.67) 3.4(0.67) 3.7(0.75) 3.7(0.72) 0.40 0.04 0.01 
Pain (/5) 3.90(0.69) 3.07(0.71) 4.75(0.71) 4.00(0.71) 4.83(0.71) 4.75(0.78) 0.40 0.34 0.26 
CDAI 11.10(1.88) 9.59(1.88) 9.64(1.94) 8.20(1.94) 10.33(1.94) 8.80(1.94) 0.59 0.91 0.56 
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Physical 
activity 
Average 
AC (/day) 
7296(828) 7424(864) 7194(884) 6984(855) 6613(855) 6385(971) 0.53 0.85 0.88 
Sedentary 
(%/day) 
68(2.6) 68(2.8) 70(2.8) 69(2.7) 70(2.8) 71(3.2) 0.67 0.57 0.96 
Light 
(%/day) 
21(1.70) 21(1.80) 19(1.85) 20(1.75) 20(1.75) 20(2.08) 0.80 0.65 0.92 
Moderate 
(%/day) 
11(1.27) 11(1.32) 10(1.35) 11(1.31) 10(1.31) 9(1.47) 0.59 0.50 0.91 
Vigorous 
(%/day) 
0.02(0.01) 0.02(0.01) 0.01(0.01) 0.01(0.01) 0.01(0.01) 0.00(0.01) 0.31 0.75 0.91 
Breaks 
sedentary 
time 
(#/day) 
61(3.3) 63(3.5) 63(3.6) 67(3.4) 60(3.4)* 61(4.0) 0.90 0.59 0.14 
Activity 
bouts 
(#/day) 
3.1(0.59) 3.4(0.60) 3.0(0.61) 2.8(0.61) 2.1(0.61)* 1.8(0.64)* 0.26 0.14 0.16 
Body 
Composition 
BMI 
(kg/m2) 
34(2.1) 34(2.1) 33(2.1)* 34(2.2) 34(2.2) 34(2.2) 0.84 0.58 0.05 
Fat mass 
(kg) 
37(3) 36(3) 35(3)*  31(3) 32(3) 35(3)* 0.43 0.44 <0.01 
Lean 
mass (kg) 
46(2) 46(2) 45(2) 42(2) 42(2) 40(2)* 0.13 <0.01 <0.01 
SMI 7.8(0.39) 8.0(0.39)^ 8.0(0.39)^ 7.7(0.40) 7.9(0.40) 7.4(0.41)* 0.64 0.02 <0.01 
Breaks in sedentary time are adjusted for % total sedentary time at each time point.  
mHAQ – modified health assessment questionnaire, BMD – bone mineral density, HRQoL – health related quality of life, CDAI – clinical disease activity score, AC – 
activity counts, BMI - body mass index, SMI – skeletal mass index. 
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* Significantly different from baseline (p<0.05) 
^ Trend towards significant difference from baseline (p<0.07) 
Shading refers to reference cell 
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Figure 2.9. Changes in functional ability as assessed by the modified Health Assessment Questionnaire (mHAQ) 
for the whole body vibration group (WBV) and the control group (CON) at baseline, post intervention (3 
months as well as at the 6 month follow up. Data are mean(SEM). 
* Significantly different from baseline (p<0.05) 
 
Bone mineral density 
A significant interaction for time and group was evident for whole body BMD (p<0.01), 
whereby there was a trend towards a significant (p=0.06) increase in whole body BMD for 
the WBV group after the intervention, and BMD was significantly increased at the six month 
follow up compared to baseline (p=0.05) (Table 2.10). In the CON group, whole body BMD 
was significantly decreased (p<0.01) at the six month follow up compared to baseline (Figure 
2.10). Hip BMD was significantly lower (p=0.01) in the CON group at the six month follow 
up compared to baseline. No changes were observed for the WBV group. There were no 
significant changes in spine BMD over the study period for either of the groups. There was a 
significant time effect (p=0.02) for Z scores (calculated at the hip site), in the CON group at 
the six month follow up from baseline (p=0.02). No significant changes were observed in the 
WBV group.  
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Figure 2.10. Changes in whole body bone mineral density (BMD) from baseline, post intervention (3 month 
assessment) as well as at the 6 month follow up in the whole body vibration group (WBV) and control group 
(CON). Data are mean(SEM). 
* Significantly different from baseline (p<0.05) 
^ Trend towards significant difference from baseline (p<0.07) 
 
HRQoL and Disease Activity 
Table 2.10 shows the significant time effect (p=0.04), as well as a significant group by time 
interaction (p=0.01) for fatigue levels, where fatigue was significantly decreased (p<0.01) in 
the WBV group at the three month follow up as compared to baseline, however this effect 
was not sustained at the six month follow up. No changes were observed in the CON group 
for fatigue levels over the study period. There were no significant changes in CDAI scores 
over the intervention period for either of the groups. There were no significant changes in 
pain levels over the study period for either of the groups.  
 
Physical activity  
No significant main effects, or group by time interactions were observed for physical activity 
levels (Table 2.10). No significant changes were evident in either group for average activity 
counts per day, or percentage of time spent in sedentary, light, moderate or vigorous activity 
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over the study period. However, in the CON group, the number of breaks in sedentary time 
(after adjusting for percentage of time in sedentary activity at each time point) were 
significantly decreased (p=0.05) at the three month follow up as compared to baseline. In the 
CON group, there was also a significant decrease (p=0.05) in number of activity bouts per 
day at the three month follow up as compared to baseline; and this effect was sustained at the 
six month follow up compared to baseline assessment (p=0.01). No changes were observed in 
the WBV group for number of breaks in sedentary time, or number of active bouts. 
 
Body composition  
Table 2.10 shows the significant group by time interaction effects for BMI (p=0.05) and fat 
mass (p<0.01), both were significantly decreased in the WBV group at the 6 month follow up 
as compared to baseline (p=0.02, p=0.01 respectively). In the CON group, fat mass was 
significantly increased (p<0.01) at the six month follow up from baseline. Lean mass and 
SMI showed significant time effects (p<0.01, and p=0.02 respectively), as well as significant 
(both p<0.01) group by time interactions. Lean mass was significantly (p<0.01) decreased in 
the CON group at the six month follow up as compared to baseline. SMI showed a trend 
towards significant increase (p=0.06) in the WBV group at the three month follow up from 
baseline, which was sustained at the 6 month follow up from baseline (p=0.08), while in the 
CON group SMI was significantly decreased (p<0.01) at the three month follow up from 
baseline, and the six month follow up from baseline (p=0.02).  
 
Effects of intervention on individual responses: 
Figure 2.11 shows the percentage change from baseline in whole body BMD for each 
participant. The WBV group showed significant increases in BMD (0.90(0.53)%) compared 
to the CON group who showed decreases in BMD (-0.66(0.52)%) over the intervention 
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period (p=0.04). In a sub-analysis, the WBV group was divided into responders (0% change 
from baseline) and non-responders (<0% change from baseline) according to percentage 
change in whole body BMD. Eleven out of the 16 participants were found to be responders 
(67%) within the WBV group. mHAQ improved significantly more in the responders 
(43(41)%) than in the non-responders, who experienced decreases in mHAQ over the three 
month intervention (-38(9.2)%), p=0.02. Furthermore, responders showed significantly 
greater increases in number of activity bouts per day (27(77)%) than the non-responders, who 
experienced decreases in activity bouts (-40(36)%), (p=0.08). No other significant differences 
were found between these two sub-groups for any of the other variables measured. The WBV 
group was then divided into responders and non-responders in a similar manner, but now 
according to change in mHAQ (Figure 2.12). Ten out of the 16 participants were found to be 
responders (63%). Here, responders showed significantly greater improvements in lean mass 
(1.4(1.7)%) then the non-responders who showed decreases in lean mass (-2.2(2.3)%), 
p<0.01. No other differerences were seen between responders and non-responders for 
mHAQ. 
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Figure 2.11. Percentage change in whole body bone mineral density (BMD) from baseline to post intervention 
(three month assessment) for each participant in the whole body vibration group (WBV) and the control group 
(CON). 
 
 
Figure 2.12. Percentage change in functional ability as assessed by the modified Health Assessment 
Questionnaire (mHAQ ) from baseline to post intervention (three month assessment) for each participant in the 
whole body vibration group (WBV) and the control group (CON).
   
 126 
 
Discussion: 
 
Our 12 week WBV intervention in participants with established, stable RA had positive effects on 
functional ability, BMD, HRQoL, physical activity profiles, and body composition in comparison to 
participants in the control group. Importantly, mHAQ scores started to decrease in these patients 
with established RA who underwent WBV, and were significantly improved at the six month follow 
up. Also of importance is the maintenance of increased whole body BMD observed in the WBV 
group after cessation of WBV, as well as the attenuation of loss of hip BMD in the WBV group in 
comparison to the losses of hip BMD observed in the control group. Our findings lend support to 
the possibility that WBV may be useful for improving certain HRQoL outcomes such as fatigue, 
which may in turn have contributed to the increase in functional ability observed; therefore having a 
protective effect on bone health in patients with RA. 
 
Participants in the WBV group became more likely to have normal daily function following the 
intervention, which is an important target for RA treatment (8). Improvements in HAQ have been 
shown in previous exercise interventions performed in groups of people with RA, which utilised 
either strength training (162-163), or aerobic exercise programmes (91). In the present study, 
changes in mHAQ were significantly higher for those who exhibited an osteogenic response to the 
WBV intervention than for those whose bone mass did not respond; implying that improvements in 
mHAQ may be related to improvements in BMD in this cohort.  
 
Various WBV interventions have produced promising results with regards to improving BMD. 
Versheuren et al in 2004 (102) and Rubin et al in 2004 (101) showed that WBV training for a six 
months and one year period respectively, was able to significantly increase hip BMD in a group of 
postmenopausal women. Rubin and colleagues further showed improvements in spine BMD in their 
cohort. Prioreschi et al in 2012 were also able to show increases in hip BMD and attenuated losses 
of spine BMD in a group of road cyclists who participated in 10 weeks of intermittent WBV (100). 
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In an RA population, where bone health is severely compromised and continuously deteriorating, 
maintenance of BMD is often the goal of treatment. The present study showed that participants who 
participated in a WBV exercise intervention experienced sustained improvements in whole body 
BMD, as well as preserved hip BMD levels, while the CON group experienced losses in BMD at 
both these sites. Hip BMD has been shown to be the best predictor of fracture risk at any site (132), 
and maintenance of these levels could therefore contribute to a decreased fracture risk. WBV was 
well tolerated by the present cohort, and could potentially be a feasible intervention for BMD in 
patients with RA that does not require the vigorous, high-impact movements that are usually 
required to increase BMD (yet are often not feasible in this population). 
  
Notwithstanding the stable disease activity that was maintained by the patients, fatigue levels were 
significantly improved following the WBV intervention (although these effects were not maintained 
at the six month follow up). Fatigue and ‘feeling well’ are important outcomes in RA, and two of 
the most relevant improvements to note following treatment interventions in RA (8, 164). The 
constant presence of fatigue greatly alters the ability to lead a functional life. The present effects on 
fatigue are similar to the effects observed in cohorts of patients with fibromyalgia and osteoarthritis 
following WBV – who experienced decreases in fatigue levels and pain levels respectively (157), 
(158). It is difficult to separate the true effects of WBV from the presence of a group intervention, 
however it is clear that our WBV intervention was able to modify patients’ sense of well-being, and 
their HRQoL even though disease activity was not significantly altered.  WBV in the present study 
has shown similar effects on well being as have been shown following aerobic and resistance 
exercise interventions in patients with RA (89-91). 
 
Previous research has shown that higher levels of habitual physical activity in patients with RA are 
correlated with improved fatigue levels, as well as functional ability (143).  Recent literature has 
focused on the beneficial effects of breaking up sedentary time (regardless of overall activity levels) 
on health (165), as well as the beneficial effects of being more active (often requiring activity to be 
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performed in 10 minute bouts) (4). Although overall physical activity remained unchanged before 
and after the intervention for both groups, there were important changes observed in the patterns of 
physical activity that should be considered. The CON group decreased the number of times they 
broke up their sedentary time and also had fewer bouts of activity following the intervention, yet 
these activity profiles were maintained in the WBV group. Furthermore, those who exhibited an 
osteogenic response to the WBV intervention had significantly greater increases in activity bouts 
after the intervention compared to non-responders. Limiting sedentary time has been shown to have 
beneficial effects on bone health (156). It is possible that the WBV intervention, by means of 
decreasing fatigue levels, allowed patients to modify their habitual physical activity profiles and to 
start engaging in less sedentary behaviors, thereby becoming more functional.  
 
Participants who underwent WBV also lost a significant amount of body mass (specifically body 
fat) during the intervention period, and experienced a significant increase in lean mass. This is 
likely due to the ability of WBV to increase oxygen consumption, energy expenditure, and 
neuromuscular performance (166) through continuously effecting eccentric and concentric muscular 
contractions (167). Sarcopenia, in combination with osteoporosis, greatly increases the risk of 
obtaining a fracture (168). Participants in the WBV group maintained their lean muscle mass, and 
showed a trend towards improving SMI (an indicator of sarcopenia), while both SMI and lean mass 
were decreased in the CON group. Participants who showed an improvement in functional ability 
after undergoing WBV intervention also had significantly greater increases in lean mass than non-
responders. This is likely also related to improved physical activity profiles. Whole body vibration 
has previously been shown to decrease BMI, as well as body fat (as measured by DXA) in obese 
women (167), and has been shown to slow fat acquisition in rodent models (169). In both of these 
studies a decrease in fat mass following WBV was accompanied by an increase in BMD or bone 
mineral content, which was not observed in the relevant control group. Although lower body mass 
is a known risk factor for low bone mass (48), and it is therefore assumed that higher body mass is 
protective of BMD, recent studies have suggested that obesity may have an inverse relationship 
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with BMD (170), and that fractures that occur in obese populations should be considered ‘fragility 
fractures’ (171). Potentially, obesity is distinct from ‘high body mass’ in terms of the effect it has 
on bone health; and should still be avoided in patients with RA, as is recommended in the general 
population. Our results suggest that WBV therapy may be useful in decreasing body mass, as well 
as increasing lean muscle mass in patients with RA. 
 
Our study has strengths and limitations. The intervention was implemented by a multidisciplinary 
team of community practitioners and has potential to be disseminated for a wider reach. 
Additionally, all assessments were repeated after the completion of the intervention, and we have 
thus demonstrated that some of the benefits of WBV in participants with RA can be sustained for at 
least three months. Furthermore, our attrition rates were very low and the program was well 
tolerated within this population. Unfortunately we did not make qualitative assessments of the 
intervention and thus cannot negate the possibility that group participation had an effect on various 
outcomes, as opposed to the WBV itself. Furthermore, the short duration of the intervention, as well 
as the limited sample size (although significantly powered) limits the conclusions that can be 
drawn.  Lastly, since the intervention ran over a year period with staggered recruitment, the effects 
of the colder temperatures in winter may have altered various pain and well-being outcomes; 
however participants were recruited in an alternating manner, which would limit the potential 
differences between groups.    
 
In conclusion, participants with stable and established RA, who underwent a WBV intervention 
showed improvements in functional ability, and preservation of bone mass at the hip and whole 
body, and preservation of lean muscle mass. Participants who participated in the WBV intervention 
also had improved fatigue levels, yet no changes in RA disease activity were observed. 
Furthermore, participants in the WBV group maintained their habitual physical activity profiles 
throughout the assessment period. WBV offers a useful and affordable adjunct therapy with 
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sustained effects in patients with established RA for the improvement of functional ability and 
attenuation of bone loss, as well as improvement of fatigue. 
 
Competing Interests: 
The authors declare that they have no competing interests. 
 
Author Contributions: 
AP conceived the study, collected all data, drafted the manuscript and analysed the data. MAM was 
the primary physician involved in assessing all patients. MT was involved in conceptualisation of 
the study design. JAM was involved in conceptualisation of the study as well as analysis of the data. 
All authors read and approved the final manuscript. 
 
Acknowledgements: 
 
The authors would like to acknowledge and thank Professor Duncan Mitchell for his advice, the 
DPHRU for the generous use of their facilities, as well as Thabile Sibiya and Vinodha Murugan for 
performing and analysing the DXA scans.
   
 131 
Chapter 3. Discussion and Conclusions 
 
The most exciting phrase to hear in science, the one that heralds new discoveries, is not Eureka (I 
found it!) but rather, “hmmm… that’s funny…” 
 
-Isaac Asimov 
 
3.1 Introduction 
 
This thesis aimed to examine three main objectives. Firstly, to determine whether accelerometry can 
be used as an objective measurement of habitual physical activity levels in patients with RA, 
secondly to determine the associations between habitual physical activity levels and RA disease, 
and the factors contributing to this relationship, and thirdly, to determine whether WBV therapy can 
be used as an effective intervention for increasing functional ability and BMD, as well as for 
improving other disease outcomes in patients with RA. These objectives were addressed in more 
detail in Chapter 1, where after the results of the studies that were conducted in order to assess these 
objectives were presented in Chapter 2. Each study was also individually discussed with reference 
to the current literature in Chapter 2. This chapter will briefly discuss and summarise the results of 
this thesis as a whole, and will conclude with the main findings, as well as the contribution that the 
thesis hopes to make to the current literature.  
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3.2 Objectives and Results Summary 
 
Table 3.1. Summary of objectives and corresponding results of the thesis 
 
Objective Location Findings 
1 
To objectively quantify habitual physical activity levels 
in patients with RA in comparison to a healthy 
population 
 
Study 1 
 
Accelerometry was identified as a feasible means to objectively 
measure habitual physical activity levels in a group of female patients 
with RA and was used in all subsequent studies. 
 
Patients with RA were found to be significantly more sedentary and 
to undertake significantly less light activity than their healthy 
counterparts. Diurnal differences in daily activity were also found, 
most likely due to late afternoon fatigue and early morning joint 
stiffness. 
 
2 
To ascertain any associations between habitual physical 
activity levels and disease activity in patients with RA 
Study 1 
 
Habitual physical activity levels were found to be positively 
associated with functional ability as assessed by HAQ. Furthermore, 
patients who were more physically active had better HRQoL, 
(specifically fatigue levels), than the less physically active patients. 
Associations were evident between habitual physical activity levels 
and disease activity in these patients i.e.: increased physical activity 
was associated with better RA disease outcomes 
3 
To determine changes in habitual physical activity 
levels in patients newly diagnosed with RA in response 
to commencement of DMARD therapy 
Study 2 
 
Habitual physical activity levels were significantly improved 
following DMARD therapy. Diurnal differences in daily activity were 
no longer evident between the RA patients and healthy counterparts 
following DMARD therapy 
 
4 
To determine predictive factors causing the changes 
seem in disease activity in response to commencement 
of DMARD therapy in patients with RA 
 
Study 2 
 
Changes in CRP and joint stiffness were predictive of changes in 
habitual physical activity levels in patients with RA 
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5 
To determine the associations between habitual 
physical activity levels and bone health in patients with 
RA 
Study 3 
 
Higher levels of habitual physical activity were found in patients with 
normal bone mass in comparison with those with low bone mass, 
highlighting the relationship between increased habitual physical 
activity and bone mass in patients with RA 
6 
To determine the effects of a WBV therapy intervention 
on functional ability and bone health, as well as on 
disease activity and habitual physical activity levels in 
patients with RA 
Study 3 
 
Patients who participated in a WBV therapy intervention experienced 
increased functional ability, as well as increased whole body BMD; 
maintained their hip BMD, and reported having a improved fatigue 
levels following the intervention in comparison to a control group of 
RA patients who continued with their normal activities for three 
months 
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3.3 Summary of contributions to the field: 
 
The literature review presented in Chapter 1 identified several gaps in the literature, broadly: The 
lack of a clear outcome measure for physical activity in RA, the lack of understanding of the 
associations between physical activity and disease activity in RA, the lack of data regarding 
habitual activity levels in RA, as well as the inconclusive evidence and prescriptions for exercise 
interventions in RA. The results of the studies conducted in this thesis have given novel insights 
into the habitual activity levels of patients with RA, as well as the benefits of being more physically 
active for this population; using accelerometry as an effective outcome measure for physical 
activity in RA.  Increased levels of physical activity have repeatedly shown beneficial effects on 
fatigue, functional ability and well being. This is important for physicians and patients alike, as 
these results indicate that a vigorous exercise intervention is not necessarily needed to experience 
improvements in HRQoL. Patients should be encouraged to be more habitually active i.e.: breaking 
up their sedentary time more frequently by standing up more often and incorporating light walking 
into their daily routines. Patients should spend less time sitting and should aim to move around as 
much as possible. While enforced exercise is also important, most patients are not able, or unwilling 
to participate in exercise programmes. Increasing habitual activity levels may be a means to 
counteract this problem, while still conferring beneficial effects on well being. The beneficial 
effects of increased habitual activity levels were also evident on bone health in patients with RA. 
However, increased habitual activity is most likely not enough to increase BMD, or attenuate BMD 
loss to any large degree in patients with RA, who progressively lose BMD throughout the course of 
their disease. A bone loading intervention is required, and WBV proved to be effective in 
attenuating loss of BMD at the hip (as well as improving HRQoL and functional ability). WBV 
therapy does not require conventional ‘exercising’, and is therefore a very feasible option for these 
patients. These data provide a therapeutic option for these patients, that is effective and provided 
sustained improvements in BMD. These findings will be discussed in more detail in the next 
section. 
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3.4 Discussion: 
 
The results presented in this thesis contribute to the current understanding of the effects of physical 
activity in RA. Overall this thesis has provided evidence as to the beneficial effects of greater levels 
of physical activity on RA disease activity, as well as on other important RA outcomes such as 
HRQoL, functional ability, and bone health. These findings are in agreement with numerous other 
studies that have found physical activity to have beneficial effects for patients with RA. The work 
presented in this thesis provides novel objective assessments of physical activity, which allowed for 
in depth analyses of activity patterns in these patients, as well as in the first evidence of WBV 
therapy as an intervention for patients with RA. 
 
3.4.1 Methodological themes emanating from this thesis: 
 
The main methodological theme emanating from this thesis was objective measurement of physical 
activity in RA. It is well known that patients with RA are forced into a sedentary lifestyle due to the 
pain and deformities that are common characteristics of their disease. Previous studies assessing 
physical activity levels in RA have generally made use of subjective physical activity 
questionnaires, which have downfalls with regards to their accuracy, as well as language barriers 
that my exist. In the first study presented in this thesis, accelerometry was used as an objective 
measure of physical activity, and whether or not these measurements could be translated into 
clinical practice was investigated. A better understanding of patterns and detailed information about 
patterns of physical activity may be valuable information for consideration in the design of 
successful interventions that target certain physical activity behaviours or times of day (172-173). 
The use of accelerometry allowed for the extent of the sedentary lifestyles of patients with RA to be 
objectively characterised for the first time in comparison to a healthy control group. Furthermore, 
this study established the use of accelerometry as a feasible, well tolerated measure of habitual 
physical activity levels in this group of patients, and was thus used throughout the subsequent 
studies that emanated from this thesis.  
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Additionally, accelerometry was able to identify distinct periods of lower physical activity levels 
during the day (in the early morning, as well as the late afternoon) in patients with RA that were not 
evident in control participants. These were attributed to two common symptoms of RA: early 
morning joint stiffness and late afternoon fatigue, which have long been described by clinicians, but 
had not until this point been empirically shown as periods of lower physical activity. Previously, 
people with osteoarthritis have been shown to have a stronger association between fatigue and 
objectively measured physical activity (using the Actical) than with pain and physical activity 
(174), yet these associations had not, until this research, been shown in populations with RA. This 
further highlights the ability of accelerometry to capture activity patterns and provide a thorough 
understanding of daily habitual activities in this cohort.  
 
In Study three, we were also able to use accelerometry to assess patterns of physical activity in 
patients with RA, by monitoring the number of times that patients were breaking up their sedentary 
time, as well as the number of ten minute bouts of light to moderate activity that were being 
undertaken per day. These assessments are extremely novel in RA, and allow for an in depth 
understanding of how physical activity levels are affected by the disease, as well as how they can be 
modified. With the growing interest into understanding sedentary behaviour as an independent 
contributor to negative health outcomes, these novel assessments are now proving to be crucial in 
the understanding of physical activity and inactivity in healthy, as well as diseased populations. 
Increased time spent being sedentary is associated with many health problems, such as metabolic 
and cardiovascular disorders, and this risk may be greater than the risk of not meeting the required 
guidelines of physical activity (117, 165). Patients with RA are already at greater risk of 
cardiovascular morbidity (75, 79), emphasising the importance of breaking up time spent in 
sedentary activity with light and moderate activities such as walking at various intensities. 
Prolonged periods of sedentary behaviour means unbroken periods of muscular unloading and 
therefore loss of contractile stimulation (117), which is compounded by the decreased strength and 
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muscular atrophy that occurs in patients with RA. This research provides novel insights in to the 
benefits of using accelerometry as an objective measure of physical activity in RA, as well as the 
techniques that can be employed to determine detailed patterns of physical activity in these patients. 
This work has clinical, as well as practical applications for physicians, researchers, and patients 
alike. 
 
3.4.2 Empirical themes emanating from this thesis: 
 
The first empirical theme emanating from this research was the beneficial effects of higher levels of 
habitual physical activity for patients with RA. The first study of this thesis showed that patients 
with RA are very sedentary, spending almost three quarters of their awake day being sedentary. 
Once able to objectively measure the sedentary lifestyles of these patients to such an extent, it 
became interesting to try and identify associations between physical activity levels and other 
routinely measured disease activity outcomes. All three studies make inroads towards showing that 
patients who were more habitually active fare better on other RA outcomes, specifically their 
functional ability, and their fatigue levels. Increased physical activity has been shown to reduce 
pain and improve function (84, 122), decrease swollen and tender joint counts (71), decrease 
morning stiffness and fatigue using a graded aerobic exercise programme (72), as well as to 
improve self impression (175). Similarly to previously conducted studies (however now making use 
of an objective measurement of physical activity), we were able to show that improved functional 
ability is positively correlated with increased physical activity levels, as is an improved sense of 
well being.  
 
In Study 2, the relationship between improved disease activity and improved habitual physical 
activity levels, with no actual exercise intervention or verbal promotion of physical activity taking 
place could mean that in addition to the improvements seen in disease activity measures after 
commencing drug therapy, patients spontaneously alter their habitual physical activity. Increasing 
habitual physical activity levels, which is potentially more sustainable than an exercise intervention 
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in an arthritic population, could lead to improved functional ability, allowing for a more vigorous 
exercise intervention to be implemented at a later stage.  
 
Furthermore, although the associations between physical activity and bone health have been shown 
in multiple previous studies (138, 149), Study 3 was able to objectively monitor these physical 
activity levels, and thus to objectively explore the relationships between different intensities of 
physical activity on bone health for the first time. Furthermore, we were able for the first time to 
determine the effects of not meeting recommended physical activity guidelines on bone health, and 
showed that patients who were classified as meeting the required physical activity guidelines also 
had significantly better Z scores than those who did not, implying less bone loss due to the disease 
process rather than normal aging. Once again, the link between being habitually active and having 
better disease outcomes was clear in this population. These findings are important for patients with 
RA who have been shown to be more sedentary than their healthy counterparts (143).  
 
These three studies contributed to the understanding of the beneficial effects of physical activity for 
patients with RA, and make it clear that higher levels of habitual physical activity need to be 
prescribed for patients with RA. From these studies, better recommendations can start being made 
regarding the intensity and duration of physical activity that is required for beneficial effects to be 
seen. Specifically and most importantly, patients should aim to be less sedentary. Further evidence 
examining the effects of enforcing such prescriptions in more varied cohorts of patients still needs 
to be obtained.  
 
The next empirical theme emanating from this thesis was the use of WBV therapy as an exercise 
intervention for patients with RA. Upon reading the multiple studies that have been conducted 
examining the effects of various exercise interventions in RA (summarised in Chapter 1, Section 
1.10), a clear gap in the literature was discovered. Very few studies have designed exercise 
interventions aimed specifically at increasing, or attenuating the loss of BMD; even though 
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osteoporosis is a major problem for patients with RA. Furthermore, many of the exercise 
interventions that have been conducted in this population are not necessarily feasible in a South 
African context, nor for patients who are disabled and have chronic pain.  
 
Since WBV therapy is easy to use, does not require much movement or impact, and is feasible in a 
South African context, it could possibly be a means to allow patients with RA to exercise safely and 
regularly. Whole body vibration had not previously been used as an intervention for RA, yet 
previous studies have shown the beneficial effects of WBV on HRQoL in diseases such as 
fibromyalgia and osteoarthritis (157-158). Furthermore various WBV interventions have produced 
promising results with regards to improving BMD (100-102). 
 
Patients who participated in WBV therapy experienced significant decreases in fatigue levels and 
improvements in the functional ability. They also had increases in their muscle mass, and decreases 
in their fat mass, which were not evident in the control group. Patients in control group also had 
decreases in their habitual physical activity levels, which were preserved in the group who 
participated in WBV therapy. Whole body vibration therapy was able to elicit similar benefits to 
previous exercise intervention studies, without requiring strenuous exercising. This study also 
showed that WBV was able to maintain physical activity patterns, while they decreased in the 
participants who did not partake in WBV. The beneficial effects of higher levels of physical activity 
and lower levels of sedentary activity have been shown in the previous studies in this thesis, as well 
as in the current literature, and the importance of maintaining these levels in patients with RA is 
thus clear.  
 
Furthermore, patients who had participated in the WBV intervention experienced improvements, or 
attenuations in the loss of their bone health. These findings are similar to what has been shown in 
healthy, as well as postmenopausal populations. Versheuren et al in 2004 (102) and Rubin et al in 
2004 (101) showed that WBV training for a six month and one year period respectively, was able to 
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significantly increase hip BMD in a group of postmenopausal women. Rubin and colleagues further 
showed improvements in spine BMD in their cohort. Prioreschi et al in 2012 were also able to show 
increases in hip BMD and attenuated losses of spine BMD in a group of road cyclists who 
participated in 10 weeks of intermittent WBV (100). These findings have not previously been 
shown in populations with RA. We were further able to show for the first time that there were 
associations between improved bone health and improved functional ability in this population, 
likely alluding to the mechanisms behind the increases seen in bone mass. Whole body vibration 
was well tolerated and safe, and could therefore be implement in routine care for these patients. 
 
This research makes inroads towards understanding the potential uses of WBV in RA, yet more 
research is required to fully understand the mechanisms, effects, and optimal duration and 
frequency of this kind of intervention. However, the potential implications of such a simple, 
feasible intervention are great, for South Africa, as well as for other low to middle or high income 
countries. These needs to be further explored so that better exercise recommendations can be made. 
 
The results of the studies conducted in this thesis provide novel insights into the relationship 
between physical activity and health in RA. We have assessed novel techniques for objectively 
measuring physical activity in RA, and through this have contributed to the understanding of how 
physical activity levels affect various outcomes in RA. We have also provided evidence for a novel 
form of exercise therapy that could be used in RA, which is affordable, sustainable, effective, and 
feasible in this population. Sedentary behavior is a global problem, but more so in a population 
where the effects of a sedentary lifestyle are amplified by the disease process. This thesis helps in 
the understanding of these associations, as well as in providing solutions to improve the problems 
that exist in the treatment of RA. 
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3.5 Limitations: 
 
There were various limitations to this research, the details of which were discussed in relation to 
each specific study (Chapter 2).  This research was focused only on females, and therefore the 
results presented cannot necessarily be extrapolated to males. However the incidence of RA is 
known to be much higher in females than in males (26), thus this research maintains far reaching 
implications for the population. The lack of data with regards to occupation or employment status 
could be considered a limitation of the first two studies. Furthermore, throughout these studies we 
excluded patients who were severely disabled or using assistive walking devices, which limits the 
extrapolations we can make to RA patients needing to make use of such devices. However these 
patients would most likely not be able to make use of WBV therapy, nor partake in standard 
physical activity, and further research would need to be done into feasible interventions for such 
patients.  
 
The placement of the Actical on the hip could be considered a limitation of our studies. The hip 
placement meant that only lower limb movement could be measured, however the manufacturer 
recommends hip placement for accuracy of detection of movements in multiple planes. Our studies 
were particularly focused on habitual, ambulatory physical activity, and thus hip placement was the 
most sensible option.  
 
Another limitation is the potential confounding effect of menopausal status on bone health, which 
was not assessed in this study. The short duration of the WBV intervention may have had an impact 
on the size of the effect seen, and future studies should examine the effects of a long term WBV 
intervention. Lastly, the limited sample sizes within the various studies could be considered a 
limitation, however each study was significantly powered for the primary outcome of that study. 
Study 3 could have benefitted from a larger sample size that would have ensured more participants 
in each bone mass group, yet a power analysis conducted retrospectively showed that the study was, 
in fact, significantly powered. The WBV intervention could have benefitted from a larger sample 
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size in order to ensure significant power of the mixed model analysis, yet was significantly powered 
in order to detect univariate changes from baseline.   
 
Upon retrospective evaluation of the intervention process, it became evident that it was unfortunate 
that I had not made any qualitative assessments of the WBV intervention, which limited the 
conclusions that can be made with regards to the possibility of group participation having an effect 
on various outcomes, as opposed to the WBV itself. This should be considered in future research. 
3.6 Future Research and Direction: 
 
The results presented in this study open up new questions that remain to be considered as well as 
new ideas as to the direction that should be taken in dealing with physical activity behaviours and 
interventions for patients with RA.  Firstly, the interactions that have been made evident between 
habitual physical activity levels and HRQoL (including fatigue and pain), as well as disease 
activity, functional ability, and even bone health; allude to the importance of incorporating an 
objective measure of physical activity, such as accelerometry, into the routinely measured clinical 
outcomes assessments of RA. In doing so, clinicians would be better equipped to understand the 
extent to which patients are limited by their disease, as well as to monitor improvements more 
robustly. Since the ability to be functional has such weighting in the lifestyle of the patient, being 
able to objectively assess this would add hugely to understanding of individualised responses to the 
disease. Furthermore, the ability of accelerometry to detect periods of fatigue and early morning 
joint stiffness provides an even more comprehensive assessment of the patients’ well being. 
 
Secondly, this research points to the importance of promoting physical activity as a means to 
improve various symptoms of RA, as discussed throughout this thesis. It is evident that, although 
exercise interventions have been shown to have great benefits on disease activity in RA; simply 
increasing habitual physical activity levels can lead to significant improvements. This means that 
patients should, before even considering enforced exercise programmes, be encouraged to start 
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being more active. This includes breaking up sedentary time more frequently by standing up from 
sitting or lying down as often as possible, as well as light walking, and finally incorporating small 
bouts of moderate activity such as a walk around the block every day (although this does not seem 
to impart as much benefit as simply being less sedentary). These guidelines are simple, easy to 
explain, and most importantly, easy to incorporate into daily life even when faced with a chronic 
pain condition. Importantly, although simplistic, the effects of such changes seem to be great. 
Thereafter, targeted interventions can be included, such as a WBV intervention. These interventions 
need to be designed for people who cannot properly exercise, and as such, WBV seems to be ideal.  
 
Future research should also aim to better understand the effects of different intensities of exercise 
on RA. It is clear that breaking up sedentary time is important for health, and that bouts of activity 
seem to have greater effects than sporadic activity. Furthermore it seems that decreased sedentary 
activity and increased light activity have greater effects on certain outcomes than increased 
moderate activity in patients with RA. This needs to be further explored in the context of RA so that 
better exercise prescriptions can be made.  
 
Lastly, the importance of a qualitative assessment on the effects of an exercise intervention should 
not be overlooked. It is possible that some of the effects on well being that were achieved can be 
attributed to participating in a monitored programme, being ‘looked after’ twice weekly, and having 
a ‘support group’ of sorts to talk to and befriend. Furthermore, having a reason to get up and leave 
the house twice a week surely has an impact on feelings of well being, as well as habitual activity 
levels (many patients reported that, when not at their sessions with me or at their doctors 
appointments, they would stay in bed or at home all day- having no reason or motivation to do 
otherwise). Patients self reported during informal discussions with myself that they appreciated 
having me care for them and being aware of the pain they felt on a daily basis. Certain patients 
would come to sessions that were not their own, simply to visit and chat to their friends who were 
exercising, and most patients stayed long after their session was finished just to socialise. These 
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effects and lifestyle modifications cannot be ignored. These ideas should be explored in a well 
designed, qualitative analysis, and should be included in the designs of future interventions in order 
to allow for cumulative effects.  
 
Given all of these findings and the limitations of the studies that have already been conducted, there 
are two main branches of research I would like to examine in more detail in future studies. Firstly, I 
would like to design a more long term, targeted WBV intervention designed at improving bone 
mass, and to examine the effects of such an intervention on sub groups of patients with varying 
levels of bone health in comparison to the standard drug therapy for bone health within each sub 
group. Secondly, I would like to design a habitual physical activity intervention, aimed at educating 
patients about the benefit of being more physically active, and specifically designed to break up 
sedentary time. Both of these studies would require quantitative analysis in order to determine the 
impact of the group participation and individualised care, over and above the intervention itself. 
 
3.7 Conclusion: 
 
The results of these studies have given novel insights into the habitual activity levels of patients 
with RA, as well as evidence as to the benefits of being more physically active for this population. 
In conclusion, this thesis provides results that should encourage patients with RA to become more 
habitually active, and should encourage physicians to incorporate these ideas, as well as objective 
measurement of these outcomes, into standard treatment of RA. If patients cannot, or will not 
exercise; WBV therapy should be offered as a therapeutic tool. Ultimately, awareness of these 
associations, and the benefits that can be achieved through simple means, could vastly improve the 
quality of life for patients afflicted with a painful, chronic condition where any small improvement 
to their symptoms could greatly change their lifestyles. 
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Appendix 1 – Study 1 Subject Information Sheet and Informed Consent 
 
 
 
INFORMATION SHEET 
 
Objective measures of physical activity in patients with rheumatoid arthritis 
 
 
Hello. My colleagues (Dr Joanne McVeigh, Dr Ingrid Avidon) and I, Alessandra Prioreschi, are 
doing research on physical activity in patients with rheumatoid arthritis (RA). In this study we want 
to learn whether we can monitor physical activity levels in patients with RA and whether these 
physical activity levels change in response to rheumatoid medication.  This study involves research 
only and does not provide routine care or treatment for your disease. The study is being conducted 
to learn more about the effects of rheumatoid arthritis on physical activity and quality of life in 
patients on RA medication, which could help with future treatment of RA patients. 
 
If you are already enrolled in either the GREAT or CHERISH study at the Rheumatology clinic 
(Chris Hani Baragwanath Hospital) we would like to invite you to participate in our research study. 
If you agree to participate in our study, you will be asked to do the following as described below: 
 
1. When you visit the clinic for your routine GREAT or CHERISH study visit, you will once 
again complete the routine set of questionnaires for the GREAT or CHERISH study as you 
have done on a previous visit. This set of questionnaires will take approximately 40 minutes 
to complete. An investigator or a nurse will be available to help you complete the 
questionnaire if you require assistance. At this visit, you will be given an activity data logger 
(a small, match-box size device) that you will be asked to wear on a belt on your hip during 
the day and on your wrist at night. The logger is small and light and will not cause any 
discomfort. The logger will measure your physical activity (how much you are moving) 
during the day and during the night.  You will be asked to begin wearing the logger the next 
day and will wear the logger for two weeks (during the day on your hip and at night on your 
wrist). The logger cannot be worn when you swim, shower or bath and should be removed 
at these times. After the two week period you will be asked to return the logger to the clinic. 
 
2. In addition, for the full two weeks, you will be asked to complete a simple pain 
questionnaire at night before going to bed which will ask about your pain during the day and 
will take one minute to complete. In the morning when you wake up you will be asked to 
complete a questionnaire about your sleep and pain during the night (how well you slept and 
whether your sleep was disturbed by pain). This questionnaire will take two minutes to 
complete.  
 
3. After the two weeks, when you return the activity data logger as well as the pain and sleep 
questionnaire to the clinic, you will be asked to complete a physical activity questionnaire. 
The questionnaire asks questions about your physical activity over the previous two weeks 
Previously diagnosed 
patients 
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and will take approximately 15 minutes to complete. As before, an investigator or a nurse 
will be available to help you complete the questionnaire if you require assistance. 
   
 
The details of your involvement are given below: 
 
Visit 1 to clinic 
  Complete the routine GREAT or CHERISH questionnaires 
 Receive the activity data logger 
 
During the two weeks 
 Wear the data logger on your waist during the day and on your wrist at night. 
 Remove the logger when you bath or shower or swim.  
 Complete the pain questionnaire at night and sleep and pain questionnaire in the morning. 
 
Visit 2 to clinic (after two weeks) 
 Return data logger to the clinic. 
 Return pain and sleep questionnaires 
 Complete physical activity questionnaire  
 
Please note that all participation is voluntary and you will be free to leave the trial at any time. You 
participation in this study, as well as any personal information is strictly confidential. You will 
receive a code and all your records and information will be filed under this code. If you wish, your 
individual results will be made available to you. We have obtained approval for this study from the 
Committee for Research on Human Subjects of the University of the Witwatersrand. If, after 
reading this information, you decide against participating in the study please be assured that this 
will not impact on you negatively in any way. If you have any further questions please ask me 
(Alessandra, 0741887545) or one of my colleagues at the clinic.  
 
You will not be paid to participate in this study, but your transport and, where necessary, 
refreshment costs will be reimbursed adequately according to the Medicines Control Council of 
South Africa. We would like to invite you to participate in this study and to confirm your 
willingness to do so by signing the consent form overleaf. If you agree to participate, you are 
allowing us to use any information obtained from the questionnaires filled out in the GREAT or 
CHERISH studies, as well as allowing us access to your medical records as needed. 
 
Sincerely, 
 
Alessandra Prioreschi, Ingrid Avidon, Joanne McVeigh 
 
If you require any information regarding your rights as a research participant you may contact Prof. Cleaton-Jones, 
Chairperson of the University of the Witwatersrand, Human Research ethics Committee (HREC), which is an 
independent committee established to protect the rights of research participants at (011) 7172301 
 
Contact details of researcher: Alessandra Prioreschi (011) 7172115 
 
If you have questions about this trial you should first discuss them with your doctor or the ethics committee (contact 
details as provided on this form). After you have consulted your doctor or the ethics committee and if they have not 
provided you with answers to your satisfaction, you should write to the Medicines Control Council (MCC) South Africa 
at: 
 
The Registrar 
Medicines Control Council SA 
Department of Health 
Private Bag X828 
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             PRETORIA, 0001 
INFORMED CONSENT: 
 
 
                                         
 I hereby confirm that I, ___________________________________, have been informed by 
the study co-ordinator about the nature, conduct, benefits and risks of the study: “Objective 
measures of physical activity in patients with rheumatoid arthritis”. 
 I have also received, read and understood the above written information sheet regarding the 
study. 
 I am aware that the results of the study, including personal details regarding my sex, age, 
date of birth, initials and diagnosis will be anonymously processed into a study report. 
 In view of the requirements of research, I agree that the data collected during this study, as 
well as data from the ORBIT/GREAT/CHERISH studies can be processed in a 
computerised system by the University of the Witwatersrand, School of Physiology, or on 
their behalf.  
 I may, at any stage, without prejudice, withdraw my consent and participation in the study. 
 I have had sufficient opportunity to ask questions and (of my own free will) declare myself 
prepared to participate in the study.  
 
PARTICIPANT: 
 
 
Printed Name     Signature   Date and Time 
 
 
I, ________________________________, herewith confirm that the above participant has been 
fully informed about the nature, conduct and risks of the above study. 
STUDY CO-ORDINATOR: 
 
 
Printed Name          Signature     Date  
 
TRANSLATOR 
 
 
Printed Name           Signature                    Date
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Appendix 2 – Study 2 Subject Information Sheet and Informed Consent 
 
 
 
INFORMATION SHEET 
 
Objective measures of physical activity in patients with rheumatoid arthritis 
 
 
Hello. My colleagues (Dr Joanne McVeigh, Dr Ingrid Avidon) and I, Alessandra Prioreschi, are 
doing research on physical activity in patients with rheumatoid arthritis (RA). In this study we want 
to learn whether we can monitor physical activity levels in patients with RA and whether these 
physical activity levels change in response to rheumatoid medication.  This study involves research 
only and does not provide routine care or treatment for your disease. The study is being conducted 
to learn more about the effects of rheumatoid arthritis on physical activity and quality of life in 
patients on RA medication, which could help with future treatment of RA patients. 
 
If you are already enrolled in the ORBIT study at the Rheumatology clinic (Chris Hani 
Baragwanath Hospital) we would like to invite you to participate in our research study. If you agree 
to participate in our study, you will be asked to do the following as described below: 
 
4. When you visit the clinic for your routine ORBIT study visit, you will be asked to complete 
the routine set of questionnaires for the ORBIT study. This set of questionnaires will take 
approximately 40 minutes to complete and asks questions about your health, use of 
medication, pain, functional ability and mood. An investigator or a nurse will be available to 
help you complete the questionnaire if you require assistance. At this visit, you will be given 
an activity data logger (a small, match-box size device) that you will be asked to wear on a 
belt on your hip during the day and on your wrist at night. The logger is small and light and 
will not cause any discomfort. The logger will measure your physical activity (how much 
you are moving) during the day and during the night.  You will be asked to begin wearing 
the logger the next day and will be asked to wear the logger until you receive your 
prescribed medication which should be one-to-two weeks later. When you do start to take 
your medication please do not wear the logger and return it to the clinic. The logger cannot 
be worn when you swim, shower or bath and should be removed at these times. 
 
5. In addition, for the full one-or-two weeks when you wear the logger, you will be asked to 
complete a simple pain questionnaire at night before going to bed which will ask about your 
pain during the day and will take one minute to complete. In the morning when you wake up 
you will be asked to complete a questionnaire about your sleep and pain during the night 
(how well you slept and whether your sleep was disturbed by pain). This questionnaire will 
take two minutes to complete.  
 
6. After the one-to-two weeks, when you return the activity data logger as well as the pain and 
sleep questionnaire to the clinic, you will be asked to complete a physical activity 
Newly diagnosed 
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questionnaire. The questionnaire asks questions about your physical activity over the 
previous one-to-two weeks and will take approximately 15 minutes to complete. As before, 
an investigator or a nurse will be available to help you complete the questionnaire if you 
require assistance.  
 
7. Three months later, when you return to the clinic for your routine visit as part of the ORBIT 
study, we will ask that you to once again complete the set of questionnaires for the ORBIT 
study, wear the activity data logger for a full two weeks, complete the pain and sleep 
questionnaires during the two weeks and complete the physical activity questionnaire when 
you return the data logger after the two weeks.  
 
 
The details of your involvement are given below: 
 
Visit 1 to clinic 
  Complete the routine ORBIT questionnaires 
 Receive the activity data logger 
 
During the one-t0-two weeks 
 Wear the data logger on your waist during the day and on your wrist at night. 
 Remove the logger when you bath or shower or swim.  
 Complete the pain questionnaire at night and sleep and pain questionnaire in the morning. 
 
Visit 2 to clinic (after one-to-two weeks) 
 Return data logger to the clinic. 
 Return pain and sleep questionnaires 
 Complete physical activity questionnaire  
 
 
Visit 3 to clinic (three months later) 
 Complete the routine ORBIT questionnaires 
 Receive the activity data logger 
 
During the two weeks 
 Wear the data logger on your waist during the day and on your wrist at night. 
 Remove the logger when you bath or shower or swim.  
 Complete the pain questionnaire at night and sleep and pain questionnaire in the morning. 
 
Visit 4 to clinic (after the two weeks) 
 Return data logger to the clinic. 
 Return pain and sleep questionnaires 
 Complete physical activity questionnaire  
 
 
Please note that all participation is voluntary and you will be free to leave the trial at any time. You 
participation in this study, as well as any personal information is strictly confidential. You will 
receive a code and all your records and information will be filed under this code. If you wish, your 
individual results will be made available to you. We have obtained approval for this study from the 
Committee for Research on Human Subjects of the University of the Witwatersrand. If, after 
reading this information, you decide against participating in the study please be assured that this 
will not impact on you negatively in any way. If you have any further questions please ask me 
(Alessandra, 0741887545) or one of my colleagues at the clinic.  
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You will not be paid to participate in this study, but your transport and, where necessary, 
refreshment costs will be reimbursed adequately according to the Medicines Control Council of 
South Africa.  
 
We would like to invite you to participate in this study and to confirm your willingness to do so by 
signing the consent form overleaf. If you agree to participate, you are allowing us to use any 
information obtained from the questionnaires filled out in the ORBIT study, as well as allowing us 
access to your medical records as needed. 
 
Sincerely, 
 
Alessandra Prioreschi, Ingrid Avidon, Joanne McVeigh 
 
 
If you require any information regarding your rights as a research participant you may contact Prof. Cleaton-Jones, 
Chairperson of the University of the Witwatersrand, Human Research ethics Committee (HREC), which is an 
independent committee established to protect the rights of research participants at (011) 7172301 
 
Contact details of researcher: Alessandra Prioreschi (011) 7172115 
 
If you have questions about this trial you should first discuss them with your doctor or the ethics committee (contact 
details as provided on this form). After you have consulted your doctor or the ethics committee and if they have not 
provided you with answers to your satisfaction, you should write to the Medicines Control Council (MCC) South Africa 
at: 
 
The Registrar 
Medicines Control Council SA 
Department of Health 
Private Bag X828 
             PRETORIA, 0001 
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INFORMED CONSENT: 
 
       
  
 I hereby confirm that I, ___________________________________, have been informed by 
the study co-ordinator about the nature, conduct, benefits and risks of the study: “Objective 
measures of physical activity in patients with rheumatoid arthritis”. 
 I have also received, read and understood the above written information sheet regarding the 
study. 
 I am aware that the results of the study, including personal details regarding my sex, age, 
date of birth, initials and diagnosis will be anonymously processed into a study report. 
 In view of the requirements of research, I agree that the data collected during this study, as 
well as data from the ORBIT/GREAT/CHERISH studies can be processed in a 
computerised system by the University of the Witwatersrand, School of Physiology, or on 
their behalf.  
 I may, at any stage, without prejudice, withdraw my consent and participation in the study. 
 I have had sufficient opportunity to ask questions and (of my own free will) declare myself 
prepared to participate in the study.  
 
PARTICIPANT: 
 
 
Printed Name     Signature   Date and Time 
 
 
I, ________________________________, herewith confirm that the above participant has been 
fully informed about the nature, conduct and risks of the above study. 
STUDY CO-ORDINATOR: 
 
 
Printed Name              Signature     Date 
 
TRANSLATOR 
 
 
Printed Name    Signature                     Date 
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Appendix 3 – Study 3 Information Sheet and Informed Consent 
 
 
INFORMATION SHEET 
 
Whole Body Vibration therapy in patients with Rheumatoid Arthritis 
 
 
Hello, my name is Alessandra Prioreschi. My colleagues (Dr Joanne McVeigh and Dr Mohammed 
Tikly) and I are doing research on whole body vibration therapy and resistance training in patients 
with rheumatoid arthritis (RA). This research will form part of my PhD degree at the University of 
the Witwatersrand. In this study we want to learn whether we can use whole body vibration therapy 
to help improve your bone and muscle strength, and to maybe help your pain as well.  This study 
involves research only and does not provide routine care or treatment for your disease. The study is 
being conducted to learn more about the effects of whole body vibration on rheumatoid arthritis 
disease, osteoporosis and physical activity in patients on RA medication, which could help with 
future treatment of RA patients. 
 
We would like to invite you to participate in our research study. If you agree to participate in our 
study, you will be assigned into one of two groups: a Whole Body Vibration group, or a Control 
group. The details of your involvement are described below depending on the group you are in: 
 
8. You will first be asked to visit the clinic for an assessment. You will be asked to complete a 
set of questionnaires used routinely in RA diagnosis and therapy. This set of questionnaires 
will take approximately 20 minutes to complete and asks questions about your health, use of 
medication, pain, functional ability and mood. An investigator or a nurse will be available to 
help you complete the questionnaire if you require assistance. You will also have some 
measurements taken including height and weight, flexibility and balance, strength 
measurements and cardiovascular health. We will also measure your bone mineral density 
using the same DXA scan that was used to diagnose your osteoporosis. In this scan you need 
to lie still for approximately 15 minutes while a qualified technician operates the machine. 
The measurements will not hurt or be uncomfortable. A DXA scan exposes you to very 
small amounts of radiation (less than a normal X-Ray), and is considered safe for adults. 
Lastly, you will be given an activity data logger (a small, match-box size device) that you 
will be asked to wear on a belt on your hip during the day. The logger is small and light and 
will not cause any discomfort. The logger will measure your physical activity (how much 
you are moving) during the day.  You will be asked to begin wearing the logger the same 
day and will be asked to wear the logger for one full week until you return to the clinic for 
your next visit. The logger cannot be worn when you swim, shower or bath and should be 
removed at these times. The first assessment will last approximately 2 hours. 
 
9. If you are in the Whole Body Vibration group: 
One week after your first assessment, you will start with your whole body vibration sessions 
at the clinic. Whole body vibration is a type of therapy that is used to increase your bone 
density, and improve your osteoporosis. Whole body vibration therapy may also improve 
your pain and tiredness. All you need to do in these sessions is stand on the vibration plate 
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for 10 sets of one minute sessions. The total session will last 15 minutes. I will be with you 
for each session to show you how to use the plate and in case you need help. The vibration 
therapy does not cause any pain, and if you feel uncomfortable at any point you are free to 
stop and a doctor will be available if you need one. You will need to come for these sessions 
twice a week for 12 weeks which will total 24 sessions of vibration therapy. We will either 
organize transport for you, or reimburse you per kilometer for your travel expenses on each 
day of travel. 
 
 
If you are in the Control group: 
One week after your first assessment, you will return the data logger to the clinic. For the 
following 12 weeks you will not be required to do anything except to carry on with your 
normal daily routine. You should continue to take your medication as usual and you should 
not change your normal daily activities (including exercising) for the 12 weeks period.  
 
Following the 12 weeks of whole body vibration, or your normal routine (depending on which 
group you are assigned to), you will be asked to come to the clinic to repeat all the 
measurements that were done at the first assessment, including completing the questionnaires, 
and the DXA scan. You will also be asked to wear the data logger on your hip for another one 
week. Therefater you will continue with your normal activities for another 12 week period, no 
matter which group you are in. We will then call you in for a final assessment were all the same 
measurements that were done at the first assessment will be repeated, including completing the 
questionnaires, and the DXA scan. You will also be asked to wear the data logger on your hip 
for another one week 
 
Once you return the data logger after the one week period of wearing it, your involvement in 
this study will be complete. The results of your measurements and scans will be available to you 
at your request. 
 
The details of your involvement are given below: 
 
Visit 1 to clinic 
 Complete the routine questionnaires 
 Receive the activity data logger 
 Undergo measurements 
 DXA scan 
 
During the first week 
 Wear the data logger on your waist during the day for one week. 
 Remove the logger when you bath or shower or swim.  
 
During the six weeks (Whole Body Vibration group) 
 Come to the clinic two to three times a week for whole body vibration therapy 
 
This image shows you how you will be asked to stand 
on the vibration plate 
   
 161 
During the six weeks (Control group) 
 Continue with your normal daily routine 
 Continue taking your medication as normal 
 Do not change your daily activities during this time 
 
Visit 2 to the clinic 
 Complete the routine questionnaires 
 Receive the activity data logger 
 Undergo measurements 
 DXA scan 
 
During the six weeks (Whole Body Vibration group) 
 Continue with your normal daily routine 
 Continue taking your medication as normal 
 Do not change your daily activities during this time 
 
During the six weeks (Control group) 
 Continue with your normal daily routine 
 Continue taking your medication as normal 
 Do not change your daily activities during this time 
 
Final visit to the clinic 
 Complete the routine questionnaires 
 Receive the activity data logger 
 Undergo measurements 
 DXA scan 
 
Please note that all participation is voluntary and you will be free to leave the trial at any time. You 
participation in this study, as well as any personal information is strictly confidential. You will 
receive a code and all your records and information will be filed under this code. If you wish, your 
individual results will be made available to you. We have obtained approval for this study from the 
Committee for Research on Human Subjects of the University of the Witwatersrand. If, after 
reading this information, you decide against participating in the study please be assured that this 
will not impact on you negatively in any way. If you have any further questions please ask me 
(Alessandra, 0741887545) or one of my colleagues at the clinic.  
 
You will not be paid to participate in this study, but your transport and, where necessary, 
refreshment costs will be reimbursed adequately according to the Medicines Control Council of 
South Africa.  
 
We would like to invite you to participate in this study and to confirm your willingness to do so by 
signing the consent form overleaf. If you agree to participate, you are allowing us to use any 
information obtained from the questionnaires filled out in the ORBIT study, as well as allowing us 
access to your medical records as needed. 
 
Sincerely, 
 
Alessandra Prioreschi, Mohammed Tikly, Joanne McVeigh 
 
 
If you require any information regarding your rights as a research participant you may contact Prof. Cleaton-Jones, 
Chairperson of the University of the Witwatersrand, Human Research ethics Committee (HREC), which is an 
independent committee established to protect the rights of research participants at (011) 7172301 
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Contact details of researcher: Alessandra Prioreschi (011) 7172140 
 
If you have questions about this trial you should first discuss them with your doctor or the ethics committee (contact 
details as provided on this form). After you have consulted your doctor or the ethics committee and if they have not 
provided you with answers to your satisfaction, you should write to the Medicines Control Council (MCC) South Africa 
at: 
 
The Registrar 
Medicines Control Council SA 
Department of Health 
Private Bag X828 
             PRETORIA, 0001 
                                     
INFORMED CONSENT: 
 
 I hereby confirm that I, ___________________________________, have been informed by 
the study co-ordinator about the nature, conduct, benefits and risks of the study: “Whole 
body vibration therapy in patients with rheumatoid arthritis”. 
 I have also received, read and understood the above written information sheet regarding the 
study. 
 I am aware that the results of the study, including personal details regarding my sex, age, 
date of birth, initials and diagnosis will be anonymously processed into a study report. 
 In view of the requirements of research, I agree that the data collected during this study can 
be processed in a computerised system by the University of the Witwatersrand, School of 
Physiology, or on their behalf.  
 I may, at any stage, without prejudice, withdraw my consent and participation in the study. 
 I have had sufficient opportunity to ask questions and (of my own free will) declare myself 
prepared to participate in the study.  
 
PARTICIPANT: 
 
 
Printed Name     Signature   Date and Time 
 
 
I, ________________________________, herewith confirm that the above participant has been 
fully informed about the nature, conduct and risks of the above study. 
STUDY CO-ORDINATOR: 
 
 
Printed Name             Signature     Date 
 
TRANSLATOR 
 
 
Printed Name   Signature                     Date
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Appendix 4 – Subject Reimbursement Letter for Study 1 and Study 2 
 
 
School of Physiology, Faculty of Health Sciences, University of the 
Witwatersrand, York Road Parktown, Johannesburg, South Africa, 
2193 
 Tel: +27 11 717 2363, Fax: +27 11 643 2765 
 
 
 
Objective Measures of Physical Activity in Patients with Rheumatoid 
Arthritis 
 
 
 
This letter is to certify that ______________________________________________ 
(volunteer) received compensation of travel expenses to the sum of R75 for travel to 
the Chris Hani Baragwanath Hospital for participation in the abovementioned study 
on the following dates ____________________________________ 
 
 
Volunteer sign: ________________________________________ 
Investigator sign: ________________________________________ 
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Appendix 5 – Subject Reimbursement Letter for Study 3 
 
 
School of Physiology, Faculty of Health Sciences, University of the 
Witwatersrand, York Road Parktown, Johannesburg, South Africa, 
2193 
 Tel: +27 11 717 2363, Fax: +27 11 643 2765 
 
 
 
Physical Activity in Patients with Rheumatoid Arthritis 
 
 
 
This letter is to certify that ______________________________________________ 
(volunteer) received compensation of travel expenses to the sum of R200 for travel to 
the Chris Hani Baragwanath Hospital for participation in the abovementioned study 
(8 visits) for the month of  ____________________________________ 
 
 
Volunteer sign: ________________________________________ 
Investigator sign: ________________________________________ 
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Appendix 6 – Health Assessment Questionnaire 
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Appendix 7 – Short Form-36 Questionnaire and Fatigue 
 
 
 
INSTRUCTIONS: THIS QUESTIONNAIRE ASKS FOR YOUR VIEWS ABOUT YOUR HEALTH. THIS INFORMATION 
WILL HELP KEEP TRACK OF HOW YOU FEEL AND HOW WELL YOU ARE ABLE TO DO YOUR USUAL ACTIVITIES. 
PLEASE BE SURE TO ANSWER EACH QUESTION BY CIRCLING ONE OF THE RESPONSES PROVIDED. IF YOU ARE 
UNSURE ABOUT HOW TO ANSWER A QUESTION, GIVE THE BEST ANSWER YOU CAN. 
 
1. IN GENERAL, WOULD YOU SAY YOUR HEALTH IS: 
 EXCELLENT  1 VERY GOOD  2 GOOD  3 FAIR  4 POOR  5 
 
2.  COMPARED TO ONE YEAR AGO, HOW WOULD YOU RATE YOUR HEALTH IN GENERAL NOW? 
MUCH BETTER NOW THAN ONE YEAR AGO   1 
SOMEWHAT BETTER NOW THAN ONE YEAR AGO   2 
ABOUT THE SAME AS A YEAR AGO   3 
SOMEWHAT WORSE NOW THAN ONE YEAR AGO   4 
MUCH WORSE NOW THAN ONE YEAR AGO   5 
 
 
3. THE FOLLOWING ITEMS ARE ABOUT ACTIVITIES YOU MIGHT DO DURING A TYPICAL DAY.  DOES YOUR 
HEALTH NOW LIMIT YOU IN THESE ACTIVITIES?  IF SO, HOW MUCH? 
ACTIVITIES YES, LIMITED YES, LIMITED
 NO, NOT 
 A LOT A LITTLE LIMITED AT ALL 
A. VIGOROUS ACTIVITIES, SUCH AS RUNNING, LIFTING HEAVY 
OBJECTS, PARTICIPATING IN STRENUOUS SPORTS 1 2 3 
 
B. MODERATE ACTIVITIES, SUCH AS MOVING A TABLE, PUSHING 
A VACUUM CLEANER, BOWLING OR PLAYING GOLF 1 2 3 
 
C. LIFTING OR CARRYING GROCERIES 1 2 3 
 
D. CLIMBING SEVERAL FLIGHTS OF STAIRS 1 2 3 
 
E. CLIMBING ONE FLIGHT OF STAIRS 1 2 3 
 
F. BENDING, KNEELING OR STOOPING 1 2 3 
 
G. WALKING MORE THAN A MILE 1 2 3 
 
H. WALKING SEVERAL BLOCKS 1 2 3 
 
I. WALKING ONE BLOCK 1 2 3 
 
J. BATHING OR DRESSING YOURSELF 1 2 3 
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4. DURING THE PAST 4 WEEKS, HAVE YOU HAD ANY OF THE FOLLOWING PROBLEMS WITH YOUR WORK OR OTHER REGULAR 
DAILY ACTIVITIES AS A RESULT OF YOUR PHYSICAL HEALTH? 
  YES NO 
A. CUT DOWN THE AMOUNT OF TIME YOU SPENT ON WORK OR OTHER  1 2 
 ACTIVITIES 
 
B. ACCOMPLISHED LESS THAN YOU WOULD LIKE 1 2 
 
C. WERE LIMITED IN THE KIND OF WORK OR OTHER ACTIVITIES 1 2 
 
D. HAD DIFFICULTY PERFORMING THE WORK OR OTHER ACTIVITIES 1 2 
 (E.G., IT TOOK EXTRA EFFORT) 
 
 
5. DURING THE PAST 4 WEEKS, HAVE YOU HAD ANY OF THE FOLLOWING PROBLEMS WITH YOUR WORK OR OTHER REGULAR 
DAILY ACTIVITIES AS A RESULT OF EMOTIONAL PROBLEMS (SUCH AS FEELING DEPRESSED OR ANXIOUS)? 
  YES NO 
A. CUT DOWN THE AMOUNT OF TIME YOU SPENT ON WORK OR OTHER  1 2 
 ACTIVITIES 
 
B. ACCOMPLISHED LESS THAN YOU WOULD LIKE 1 2 
 
C. DIDN’T DO WORK OR OTHER ACTIVITIES AS CAREFULLY AS USUAL 1 2 
 
 
6. DURING THE PAST 4 WEEKS, TO WHAT EXTENT HAS YOUR PHYSICAL HEALTH OR EMOTIONAL PROBLEMS INTERFERED 
WITH YOUR NORMAL SOCIAL ACTIVITIES WITH FAMILY, FRIENDS, NEIGHBORS, OR GROUPS? 
 
  NOT AT ALL  1 SLIGHTLY  2 MODERATELY  3 QUITE A BIT  4 EXTREMELY  5 
 
 
7. HOW MUCH BODILY PAIN HAVE YOU HAD DURING THE PAST 4 WEEKS? 
 
  NONE  1 VERY MILD  2 MILD  3 MODERATE  4 SEVERE  5 VERY SEVERE  6 
 
 
8. DURING THE PAST 4 WEEKS, HOW MUCH DID PAIN INTERFERE WITH YOUR NORMAL WORK (INCLUDING BOTH WORK 
OUTSIDE THE HOME AND HOUSEWORK)? 
 
  NOT AT ALL  1 A LITTLE BIT  2 MODERATELY  3 QUITE A BIT  4 EXTREMELY  5 
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9. THE FOLLOWING QUESTIONS ASK HOW YOU FEEL AND HOW THINGS HAVE BEEN WITH YOU DURING THE PAST 4 WEEKS.  
FOR EACH QUESTION, PLEASE GIVE THE ONE ANSWER THAT COMES CLOSEST TO THE WAY YOU HAVE BEEN FEELING.  
 HOW MUCH OF THE TIME DURING THE PAST 4 WEEKS 
 
  ALL OF MOST OF A GOOD BIT SOME OF A LITTLE OF NONE OF 
  THE TIME THE TIME OF THE TIME THE TIME THE TIME THE TIME 
 
A. DID YOU FEEL FULL OF PEP? 1 2 3 4 5 6 
 
B. HAVE YOU BEEN A VERY  
NERVOUS PERSON?  1 2 3 4 5 6 
 
C. HAVE YOU FELT SO DOWN IN 
THE DUMPS THAT NOTHING 
COULD CHEER YOU UP?  1 2 3 4 5 6 
 
D. HAVE YOU FELT CALM 
AND PEACEFUL? 1 2 3 4 5 6 
 
E. DID YOU HAVE A LOT 
OF ENERGY?  1 2 3 4 5 6 
 
F. HAVE YOU FELT 
DOWNHEARTED AND BLUE?  1 2 3 4 5 6 
 
G. DID YOU FEEL WORN OUT?  1 2 3 4 5 6 
 
H. HAVE YOU BEEN A HAPPY  
PERSON?  1 2 3 4 5 6 
 
I. DID YOU FEEL TIRED?  1 2 3 4 5 6 
 
 
10. DURING THE PAST 4 WEEKS, HOW MUCH OF THE TIME HAS YOUR PHYSICAL HEALTH OR EMOTIONAL PROBLEMS 
INTERFERED WITH YOUR SOCIAL ACTIVITIES (LIKE VISITING WITH FRIENDS, RELATIVES, ETC.)?  
 
  ALL OF MOST OF SOME OF A LITTLE OF NONE OF 
  THE TIME THE TIME THE TIME THE TIME THE TIME 
 
  1 2 3 4 5 
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11. HOW TRUE OR FALSE IS EACH OF THE FOLLOWING STATEMENTS FOR YOU.  
 
 DEFINITELY MOSTLY DON’T MOSTLY DEFINITELY 
 TRUE TRUE KNOW FALSE FALSE 
 
A. I SEEM TO GET SICK A LITTLE 
EASIER THAN OTHER PEOPLE 1 2 3 4 5 
 
B. I AM HEALTHY AS ANYBODY I KNOW 1 2 3 4 5 
 
C. I EXPECT MY HEALTH TO GET WORSE 1 2 3 4 5 
 
D. MY HEALTH IS EXCELLENT 1 2 3 4 5
  
 
 
 
 
 
Fatigue Assessment 
 
How Tired have you felt over the last week? 
 
No at all tired  
A little tired  
Moderately tired  
Very tired  
The most tired ever felt  
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Appendix 8 – SDAI and CDAI Index Form 
 
TJC    Shoulder    
 right     Elbow   left  
      Wrist     
5 4 3 2 1   MCP 1 2 3 4 5 
        PIP      
      Knee     
  
TOTAL TJC______ 
 
 
SJC    Shoulder    
 right     Elbow   left  
      Wrist     
5 4 3 2 1   MCP 1 2 3 4 5 
        PIP      
      Knee     
       
TOTAL SJC______ 
 
PHYSICIAN GLOBAL ASSESSMENT 
 
Excellent  
0 
Good  
25 
 Fair  
50 
Poor  
75 
Very poor  
100 
 
 
EARLY MORNING STIFFNESS How long were your joints stiff this morning? (minutes) _______ 
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PATIENT PAIN ASSESSMENT 
 
How bad has your pain over the last week? 
 
No pain  
Mild pain  
Moderate pain  
Severe pain  
Unbearable pain  
 
 
PATIENT GLOBAL ASSESSMENT 
 
How has your arthritis been over last week? 
 
Excellent  
0 
Good  
25 
Fair  
50 
Poor  
75 
Very poor  
100 
 
 
SDAI/CDAI 
 
TJC SJC CRP patient 
global 
physician 
global 
SCORE  
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Appendix 9 – WBV Instructions to Patients 
 
How to use the Vibration Plate: 
 
1. Switch on plate at the bottom 
 
2. Stand on the plate like this: 
 
 
 
 
3. Press “Manual” 
 
4. Press “Time ” so that it says: 1:00 on the screen 
 
 
5. Press “Start/Stop” 
 
6. The plate will shake for 1 minute then you have 30 seconds rest on the screen 
 
 
7. Before the time reaches 0:00, press “Start/Stop” again 
 
8. Repeat 10 times 
No vibrations to your 
head, lean forward on 
your toes 
Hold onto the handle 
bars 
Bend your knees a 
little 
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Appendix 10- Human Research Ethics Committee Approval Certificates 
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                       Radiation and Health Physics Unit
  
 
Radiation and Health Physics Unit, Wits East Campus, Empire Road, Johannesburg Telephone: +27 (0)11 717 6931/29 Fax:+27 (0)11  717 
6937 
Private Bag 3, Wits 2050 South Africa:  E-mail: james.larkin@wits.ac.za 
 
 
 
18th December 2012, 
 
To: Prof Cleaton – Jones, 
Chairman, Human Research Ethics Committee. 
 
Re: The effect of a whole body vibration therapy intervention on disease activity and 
bone mineral density in patients with Rheumatoid Arthritis. 
Student:  Alessandra Prioreschi   Student Number: 0700859D 
 
Dear Sir, 
  I have reviewed the research proposal submitted by Mr. A. Prioreschi, and am 
satisfied that this research proposal can go forward unmodified. 
 
Kindest regards, 
 
 
James Larkin, 
Director, Radiation and Health Physics Unit 
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Appendix 11 – Study 1 
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Appendix 12 – Study 2 
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Appendix 13 – Protocol Paper  
(Under review at BMC Musculoskeletal disorders) 
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Appendix 14 – Author Contributions and Acquiescence 
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